Description

[0001] The present invention is related to an SDF-1 binding nucleic acid molecule, the nucleic acid molecule for use in a method of treating a disease, the nucleic acid molecule for use in inhibiting angiogenesis, neovascularization, inflammation and metastasis, a pharmaceutical composition comprising the nucleic acid molecule, the use of the nucleic acid molecule for the manufacture of a medicament, the use of the nucleic acid molecule for the manufacture of a diagnostic means, a complex comprising the nucleic acid molecule, the use of the nucleic acid molecule for the detection of SDF-1, and a kit comprising the nucleic acid molecule.

[0002] The chemokines are a family of structurally related, heparin-binding basic small proteins of 8-14 kDa. Functionally, they can be classified as proinflammatory, homeostatic, or dual function (Moser, Wolf et al. 2004). Inflammatory chemokines are induced by pathogens, cytokines, or growth factors and recruit effector leukocytes to sites of infection, inflammation, tissue injury, and tumor. Such chemokines regulate the recruitment, activation, and proliferation of white blood cells (leukocytes) (Schall and Bacon 1994; Springer 1995; Baggiolini 1998). Chemokines selectively induce chemotaxis of neutrophils, eosinophils, basophils, monocytes, macrophages, mast cells, T and B cells. In addition to their chemotactic effect, they can selectively exert other effects in responsive cells like changes in cell shape, transient increase in the concentration of free intracellular calcium ions, degranulation, upregulation of integrins, formation of bioactive lipids (leukotrienes, prostaglandins, thromboxans), or respiratory burst (release of reactive oxygen species for destruction of pathogenic organisms or tumor cells). Thus, by provoking the release of further proinflammatory mediators, chemotaxis and extravasation of leukocytes towards sites of infection or inflammation, chemokines trigger escalation of the inflammatory response. Homeostatic chemokines, on the other hand, are expressed predominantly in bone marrow and lymphoid tissues and are involved in hematopoiesis, immune surveillance, and adaptive immune responses (Godessart 2005).

[0003] Based on the arrangement of the first two of four conserved cystein residues, the chemokines are divided into four classes: CC or β-chemokines (e.g.) in which the cysteins are in tandem, CXC or α-chemokines, where they are separated by one additional amino acid residue, XC or γ chemokines (lymphotactin/XCL1 as only representant to date) that possess only one disulfide bridge, and CX3C-chemokines which feature three amino acid residues between the cysteins (membrane-bound fractalkin as only class member; (Bazan, Bacon et al. 1997)).

[0004] The CXC chemokines act primarily on neutrophils, in particular those CXC chemokines that carry the amino acid sequence ELR on their amino terminus. Examples of CXC chemokines that are active on neutrophils are IL-8/CXCL8, GROα/CXCL1, GROβ/CXCL2, and GROγ/CXCL3, NAP-2/CXCL7, ENA-78/CXCL5, SDF-1/CXCL12 and GCP-2/CXCL6. The CC chemokines act on a larger variety of leukocytes, such as monocytes, macrophages, eosinophils, basophils, as well as T and B lymphocytes (Oppenheim, Zachariae et al. 1991; Miller and Krangel 1992; Baggiolini, Dewald et al. 1994; Jose, Griffiths-Johnson et al. 1994; Ponath, Qin et al. 1996). Examples of these are I-309/CCL1; MCP-1/CCL2, MCP-2/CCL8, MCP-3/CCL7, MCP-4/CCL13, MIP-1α/CCL3 and MIP-1β/CCL4, RANTES/CCL5, and eotaxin/CCL11.

[0005] Chemokines act through receptors that belong to a superfamily of seven transmembrane-spanning G protein-coupled receptors (GPCRs; (Murphy, Baggiolini et al. 2000)). Generally speaking, chemokine and chemokine receptor interactions tend to be promiscuous in that one chemokine can bind many chemokine receptors and conversely a single chemokine receptor can interact with several chemokines. Some known receptors for the CXC chemokines include CXCR1, which binds GROα, GCP-2, and IL-8; CXCR2, which binds chemokines including GROα, GROβ, GROγ, ENA-78, and IL-8; CXCR3, which binds chemokines including PF4, MIG, IP-10, and I-TAC; CXCR4 which thus far has been found only to signal in response to SDF-1, and CXCR5, which has been shown to signal in response to BCA-1 (Godessart 2005).

[0006] SDF-1 (stromal-cell derived factor-1; synonyms, CXCL12; PBSF [pre-B-cell growth-stimulating factor]; TPAR-1 [TPA repressed gene 1]; SCYB12; TLSF [thymic lymphoma cell stimulating factor]; hIRH [human intercrine reduced in hepatomas]) is an angiogenic CXC chemokine that does not contain the ELR motif typical of the IL-8-like chemokines (Salcedo, Wasserman et al. 1999; Salcedo and Oppenheim 2003) that binds and activates the G-protein coupled receptor CXCR4. The chemokine was discovered by three groups independently, either by cloning cDNAs that carry N-terminal signal sequences (Tashiro, Tada et al. 1993), by virtue of its ability to stimulate early B cell progenitors when expressed by the stromal cell line PA6 (Nagasawa, Kikutani et al. 1994), or by isolation from a cDNA library constructed from mouse embryo fibroblasts treated with the protein kinase C-activator tetra dodecanoyl phorbol acetate (TPA) (Jiang, Zhou et al. 1994).
As a result of alternative splicing, there are two forms of SDF-1, SDF-1α (68 AA) and SDF-1β, which carries four additional residues at the C-terminus (Shirozu, Nakano et al. 1995). The biological significance of these two splice variants is not completely understood.

[0007] The sequence conservation between SDF-1 from different species is remarkable: human SDF-1α (SEQ.ID. 1) and murine SDF-1α (SEQ.ID. 2) are virtually identical. There is a only a single conservative change of V to I at position 18 (Shirozu, Nakano et al. 1995). Another unusual feature that distinguishes SDF-1 from most other chemokines is its selectivity. In fact, SDF-1 and the receptor CXCR4 seem to comprise a monogamous receptor-ligand pair.

EP 2 041 282 B1

[0008] An NMR structure model exists (PDB access, 1SDF) for SDF-1 [8-68]. SDF-1 was found to be a monomer with a disordered N-terminal region. Differences to other chemokines are found mainly in the packing of the hydrophobic core and surface charge distribution (Crump, Gong et al. 1997).

[0009] Physiological activities of SDF-1: Since the SDF-1 receptor CXCR4 is widely expressed on leukocytes, mature dendritic cells, endothelial cells, brain cells, and megakaryocytes, the activities of SDF-1 are pleiotropic. This chemokine, more than any other identified thus far, exhibits the widest range of biological functions, especially outside of the immune system. The most significant functional effects of SDF-1 are:

> *Homing and attachment* of epithelial cells to neovascular sites in the choroid portion of the retina. SDF-1 has been shown to be involved in homing of epithelial cells to the choroid during neovascularization in eye tissue. The exact role of these cells is still under investigation but the published hypothesis is that epithelial cells are involved in the formation of aberrant blood vessels (Sengupta, Caballero et al. 2005).

[0010] *Hematopoiesis.* SDF-1 is required to maintain hematopoietic progenitor (CD34+) cells in the bone marrow of the adult. AMD3100, a selective CXCR4 antagonist, can be used to mobilize CD34+ cells for hematopoietic stem cell transplantation. CD34+ cells migrate *in vitro* and *in vivo* towards a gradient of SDF-1 produced by stromal cells (Aiuti, Webb et al. 1997).

[0011] *B cell development and chemotaxis.* SDF-1 supports proliferation of pre-B cells and augments the growth of bone marrow B cell progenitors (Nagasawa, Kikutani et al. 1994); it induces specific migration of pre- and pro-B cells, while not acting as a significant chemoattractant for mature B cells (D'Apuzzo, Rolink et al. 1997; Bleul, Schultze et al. 1998). Presumably, SDF-1 is important for the positioning of B cells within secondary lymphoid tissue.

[0012] *T cell chemotaxis.* SDF-1 is one of the most efficacious T cell chemoattractants; CXCR4 is present on many T cell subsets (Bleul, Farzan et al. 1996).

[0013] *Embryonic development.* SDF-1 and its receptor CXCR4 is essential for embryonic development. SDF-1 and CXCR4 knockout mice die perinatally; they exhibit cardiac ventricular septal defects or abnormal cerebellar development in addition to reduced numbers of B cell and myeloid progenitors (Nagasawa, Hirota et al. 1996; Ma, Jones et al. 1998; Zou, Kottmann et al. 1998). SDF-1 is also required for normal ontogeny of blood development during embryogenesis (Juarez and Bendall 2004).

[0014] *HIV infection.* SDF-1 is able to inhibit T-tropic HIV-1 entry into CXCR4-bearing cell lines, and SDF-1 expression may have an important bearing on AIDS pathogenesis, since a polymorphism in the human SDF-1 gene affects the onset of AIDS (Bleul, Farzan et al. 1996).

[0015] Altered expression levels of SDF-1 or its receptor CXCR4 or altered responses towards those molecules are associated with many human diseases, such as retinopathy (Brooks, Caballero et al. 2004; Butler, Guthrie et al. 2005; Meleth, Agron et al. 2005); cancer of breast (Muller, Homey et al. 2001; Cabioglu, Sahin et al. 2005), ovaries (Scotton, Wilson et al. 2002), pancreas (Koshiba, Hosotani et al. 2000), thyroid (Hwang, Chung et al. 2003), nasopharynx (Wang, Wu et al. 2005); glioma (Zhou, Larsen et al. 2002); neuroblastoma (Geminder, Sagi-Assif et al. 2001); B cell chronic lymphocytic leukemia (Burger, Tsukada et al. 2000); WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis) (Gulino, Moratto et al. 2004; Balabanian, Lagane et al. 2005; Kawai, Choi et al. 2005); immunologic deficiency syndromes (Arya, Ginsberg et al. 1999; Marechal, Arenzana-Seisdedos et al. 1999; Soriano, Martinez et al. 2002); pathologic neovascularization (Salvucci, Yao et al. 2002; Yamaguchi, Kusano et al. 2003; Grunewald, Avraham et al. 2006); inflammation (Murdoch 2000; Fedyk, Jones et al. 2001; Wang, Guan et al. 2001); multiple sclerosis (Krumbholz, Theil et al. 2006); rheumatoid arthritis / osteoarthritis (Buckley, Amft et al. 2000; Kanbe, Takagishi et al. 2002; Grassi, Cristino et al. 2004).

[0016] In experimental animal settings, antagonists of SDF-1 or its receptor have proved efficient for blocking growth and/or metastatic spreading of human cancer cells from different origin such as pancreas (Guleng, Tateishi et al. 2005; Saur, Seidler et al. 2005), colon (Zeelenberg, Ruuls-Van Stalle et al. 2003; Guleng, Tateishi et al. 2005), breast (Muller, Homey et al. 2001; Lapteva, Yang et al. 2005), lung (Phillips, Burdick et al. 2003), glioblastoma / medulloblastoma (Rubin, Kung et al. 2003), prostate (Sun, Schneider et al. 2005), osteosarcoma (Perissinotto, Cavalloni et al. 2005), melanoma (Takenaga, Tamamura et al. 2004), stomach (Yasumoto, Koizumi et al. 2006), multiple myeloma (Menu, Asosingh et al. 2006).

[0017] In addition, anti-SDF-1 therapy was beneficial in animal models in preventing retinal neovascularization (Butler, Guthrie et al. 2005), nephritis (Balabanian, Couderc et al. 2003) and arthritis (Matthys, Hatse et al. 2001; Tamamura, Fujisawa et al. 2004; De Klerck, Geboes et al. 2005).

[0018] SDF-1 is a player in the pathology of diseases of the back of the eye such as diabetic retinopathy (DR) (Fong, Aiello et al. 2004) and age-related macular degeneration (AMD) (Ambati, Anand et al. 2003). Both of these diseases damage the eye and lead to gradual loss of vision culminating in blindness. The damage occurs due to the inappropriate growth of blood vessels in the back of the eye, a process known as choroidal neovascularization (CNV).

[0019] During CNV, new blood vessels that originate from the choroid migrate through a break in the Bruch membrane

into the sub-retinal pigment epithelium (sub-RPE) or subretinal space. The abnormal vessels can bleed (intraretinal hemorrhage) or leak fluid under the retina. This can leave scars and can elevate the macula, which distorts vision.

[0020]   SDF-1 is thought to play a role in CNV via recruitment of endothelial precursor cells (EPCs) to the eye. These precursor cells then become key structural components in the aberrant blood vessels.

[0021]   Diabetic retinopathy is a major sequel to diabetes, occuring frequently in patients with both type 1 and type 2 diabetes. There are approximately 16 million diabetics in the U.S., with nearly 8 million having some form of diabetic retinopathy. When proliferative diabetic retinopathy (PDR) is left untreated, about 60% of patients become blind in one or both eyes within 5 years. With the alarming rise in the prevalence of diabetes in North America, Europe and many emerging countries, the patient population is growing quickly. For instance, the incidence of blindness is 25 times higher in patients with diabetes than in the general population. Furthermore, diabetic retinopathy (DR) is the most common cause of blindness in middle-aged subjects, accounting for at least 12 percent of all new cases in the United States each year. Screening programs are in place so that the vision of diabetes patients can be monitored and treatment, such as is available, can be delivered in time.

[0022]   The direct causes of diabetic retinopathy are poorly understood, but the disease is thought to have its origins in a combination of sources: impaired auto-regulation of retinal blood flow; accumulation of sorbitol inside retinal cells; and accumulation of advanced glycosylation end products in the extracellular fluid. All of these factors are related directly or indirectly to hyperglycemia, the abundance of sugar in the bloodstream.

[0023]   The symptoms of DR are similar to those of AMD. Patients lose cells in the retina and microaneurysms (blood flows) occur in the basement membrane of the retina. In addition, VEGF, IGF-1 and other blood-borne factors, possibly including SDF-1, attract new vascular cells and encourage the formation of damaging blood vessels.

[0024]   Age-related macular degeneration (AMD) destroys a person's central vision. The early stages of the disease may not even be noticeable, because symptoms vary among patients. Sometimes a patient is affected only in one eye. Or vision may be impaired in both eyes but not significantly. The disease causes distortion or faulty color perception. There is often a dark spot in the center of the visual field.

[0025]   The etiology (course) of the disease is poorly understood. AMD is often thought of as the aging of the outermost layer of the retina. The physical alterations occur in the center of the retina, also known as the macula, which is the part of the retina relied upon for the most acute vision.

[0026]   Wet AMD begins as a sequel to the dry form of the disease. Some 90% of patients suffer from the dry form of AMD, which results in the thinning of macular tissues and disturbances in its pigmentation. The rest have the wet form, which involves the bleeding described above.

[0027]   The wet form of AMD represents an ideal market for a novel therapeutic: already the most common cause of blindness in people over the age of 55, AMD afflicts an estimated 4% to 5% of the United States population aged 65-74 and nearly 10% of those 75 years of age or older. There are already 5 million people in the United States alone over the age of 80 who have this disease and another 5 million people are expected to be affected by 2020.

[0028]   Tumors are not just masses of cancer cells: infiltration of tumors with immune-cells is a characteristic of cancer. Many human cancers have a complex chemokine network that influences the extent and phenotype of this infiltrate, as well as tumor growth, survival and migration, and angiogenesis. Most solid tumors contain many non-malignant stromal cells. Indeed, stromal cells sometimes outnumber cancer cells. The predominant stromal cells that are found in cancers are macrophages, lymphocytes, endothelial cells and fibroblasts.

[0029]   Malignant cells from different cancer types have different profiles of chemokine-receptor expression, but the SDF-1 receptor CXCR4 is most commonly found in mouse and man: tumor cells from at least 23 different types of human cancers of epithelial, mesenchymal, and haematopoietic origin express CXCR4 (Balkwill 2004). SDF-1 is the only known ligand for CXCR4. Apart from the bone marrow and secondary lymphoid tissue, where it is constitutively expressed, SDF-1 is found in primary tumor sites in lymphoma (Corcione, Ottonello et al. 2000) and brain tumors of both neuronal and astrocytic lineage. Furthermore, it is present at high levels in ovarian (Scotton, Wilson et al. 2002) and pancreatic cancer (Koshiba, Hosotani et al. 2000) as well as at sites of metastasis in breast (Muller, Homey et al. 2001) and thyroid cancer (Hwang, Chung et al. 2003), neuroblastoma and haematological malignancies (Geminder, Sagi-Assif et al. 2001). In contrast, CXCR4 expression is low or absent on normal breast (Muller, Homey et al. 2001), ovarian (Scotton, Wilson et al. 2002) and prostate epithelia (Sun, Schneider et al. 2005). CXCR4 expression thus seems to be a general characteristic of the malignant epithelial cell and not its normal counterpart.

[0030]   Inhibiting chemokine-receptor signalling on tumor cells has the potential to induce growth arrest or apoptosis, and prevent invasion and metastasis *in vivo:*

CXCR4 knockdown by siRNA abrogated breast tumor growth (Lapteva, Yang et al. 2005); T-hybridoma cells which were transfected with a construct that prevents surface expression of CXCR4 could no longer metastasize to distant organs when injected intravenously into mice (Zeelenberg, Ruuls-Van Stalle et al. 2001); in similar experiments with colorectal cancer cells, lung and liver metastases were greatly reduced (Zeelenberg, Ruuls-Van Stalle et al. 2003); anti-CXCR4 antibodies inhibited the spread of breast cancer xenografts to the lymph nodes (Muller, Homey et al.

2001); treatment of lymphoblastoid cells with anti-CXCR4 or anti-SDF-1 antibodies delayed tumor growth in (NOD)/SCID mice (Bertolini, Dell'Agnola et al. 2002); anti-SDF-1 antibodies inhibited development of organ metastases of non-small-cell lung cancer (NSCLC) cells (Phillips, Burdick et al. 2003); systemic administration of the CXCR4 antagonist AMD3100 (AnorMED) inhibited the growth of intracranial glioblastoma and medulloblastoma xenografts, and increased tumor cell apoptosis within 24 hours (Rubin, Kung et al. 2003); anti-SDF-1 antibodies inhibited growth of MCF-7 breast cancer cells admixed with carcinoma-associated fibroblasts (Orimo, Gupta et al. 2005); neutralization of CXCR4 with antibodies blocked prostate cancer metastasis and growth in osseous sites (Sun, Schneider et al. 2005); development of lung metastasis after injection of osteosarcoma cells was prevented by administration of the peptidic CXCR4 antagonist T134 (Perissinotto, Cavalloni et al. 2005).

[0031]   Different authors come to the conclusion that targeting the SDF-1 / CXCR4 axis may provide new therapeutic options for cancer patients:

Human ovarian tumors strongly express SDF-1 plus, on a lower level, VEGF. Both proteins are triggered by hypoxia in the tumor. Pathologic concentrations of any of the proteins alone were not sufficient to induce in vivo angiogenesis, but together, SDF-1 and VEGF in pathologic concentrations efficiently and synergistically induced neovascularization. Thus, interrupting this synergistic axis, rather than VEGF alone, can be a novel efficient antiangiogenesis strategy to treat cancer (Kryczek, Lange et al. 2005);

Breast cancer cell lines, when equipped with the autocrine SDF-1 / CXCR4 signalling pathway, display aggressive behavior. This includes an increase in invasiveness and migration together with faster growth. The SDF-1 / CXCR4 axis may thus provide important information for predicting the aggressive nature and constitute important therapeutic targets in human breast cancer (Kang, Watkins et al. 2005);

Migration and metastasis of small-cell lung cancer (SCLC) cells - which express high levels of CXCR4 - is regulated by SDF-1. Activation of CXCR4 promotes adhesion to accessory cells (such as stromal cells) and extracellular matrix molecules within the tumor microenvironment. These adhesive interactions result in an increased resistance of SCLC cells to chemotherapy. As such, inhibitors of the SDF-1 / CXCR4 axis may increase the chemosensitivity of SCLC cells and lead to new therapeutic avenues for patients with SCLC (Hartmann, Burger et al. 2004);

The SDF-1 / CXCR4 axis emerges as a pivotal regulator of trafficking of various types of stem cells in the body. Since most if not all malignancies originate in the stem/progenitor cell compartment, cancer stem cells also express CXCR4 on their surface and, as a result, the SDF-1 / CXCR4 axis is involved in directing their trafficking/metastasis to organs that express SDF-1 (e.g. lymph nodes, lungs, liver, bones). In consequence, strategies aimed at modulating the SDF-1 / CXCR4 axis could have important clinical applications both in regenerative medicine to deliver normal stem cells to the tissues and in clinical oncology to inhibit metastasis of cancer stem cells (Kucia, Reca et al. 2005).

[0032]   International patent application WO 02/101350 is related to a modified cell migration assay allowing for identification of chemokine receptor antagonists from non-specific blockers.
[0033]   The problem underlying the present invention is to provide a specific antagonist to SDF-1. A further aspect of the problem underlying the present invention is to provide a compound for the treatment of diseases and disorders involving SDF-1 and the CXCR4 receptor, respectively.
[0034]   A another problem underlying the present invention is to provide methods for the specific detection of SDF-1.
[0035]   The problem underlying the present invention is solved by the subject matter of the independent claims. Preferred embodiments may be taken from the dependent claims.
[0036]   The problem underlying the present invention is solved in a first aspect by a nucleic acid molecule, binding to SDF-1, comprising in 5'->3' direction a first stretch of nucleotides, a core nucleotide sequence and a second stretch of nucleotides, or a second stretch of nucleotides, a core nucleotide sequence and a first stretch of nucleotides,
whereby the length of the nucleic acid molecule is 20 to 50 nucleotides,
whereby the nucleic acid molecule is selected from the group consisting of type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID.No. 142, SEQ.ID.No. 143 and SEQ.ID.No. 144;
whereby the type A nucleic acid molecules comprise the following core nucleotide sequence:

5' AAAGYRACAHGUMAAX$_A$UGAAAGGUARC 3' (SEQ.ID. 19)

whereby X$_A$ is either absent or is A, and
whereby the first stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5'

6

X_1X_2NNBV 3' (SEQ.ID.No. 44) and the second stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5' BNBNX$_3$X$_4$ 3' (SEQ.ID.No. 45),
whereby X_1 is either absent or R, X_2 is S, X_3 is S and X_4 is either absent or Y, or
X_1 is absent, X_2 is either absent or S, X_3 is either absent or S and X_4 is absent;
whereby the type B nucleic acid molecules comprise the following core nucleotide sequence:

5' GUGUGAUCUAGAUGUADWGGCUGWUCCUAGUYAGG 3' (SEQ.ID.No. 57), and

whereby the first stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' X_1X_2SVNS 3' (SEQ.ID.No. 77) and the second stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' BVBSX$_3$X$_4$ 3' (SEQ.ID.No. 78), whereby
X_1 is either absent or is A, X_2 is G, X_3 is C and X_4 is either absent or is U,
or
X_1 is absent, X_2 is either absent or is G, X_3 is either absent or is C and X_4 is absent;
whereby the type C nucleic acid molecules comprise a core nucleotide sequence of

GGUYAGGGCUHRXA$_A$GUCGG (SEQ.ID.No. 90),

whereby X_A is either absent or is A, and
whereby the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' RKSBUSNVGR 3' (SEQ.ID.No. 120) and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' YYNRCASSMY 3' (SEQ.ID.No. 121),
or
whereby the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' X_SSSSV 3' (SEQ.ID.No. 124) and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' BSSSX$_S$ 3' (SEQ.ID.No. 125), whereby X_s is either absent or is S,
or
whereby the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' UGAGAUAGG 3' and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' CUGAUUCUCA 3',
or
whereby the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' GAGAUAGG 3' and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' CUGAUUCUC 3'.

[0037]   In an embodiment of the first aspect, the type A nucleic acid molecules comprise a core nucleotide sequence selected from the group comprising

5' AAAGYRACAHGUMAAUGAAAGGUARC 3' (SEQ.ID.No. 20),
5' AAAGYRACAHGUMAAAUGAAAGGUARC 3' (SEQ.ID.No. 21), and
5' AAAGYAACAHGUCAAUGAAAGGUARC 3' (SEQ.ID.No. 22), preferably the core nucleotide sequence comprises
5' AAAGYAACAHGUCAAUGAAAGGUARC 3' (SEQ. ID. No. 22).

[0038]   In an embodiment of the first aspect, said first and said second stretch of nucleotides of the type A nucleic acid molecules optionally hybridize with each other, whereby upon hybridization a double-stranded structure is formed.
[0039]   In an embodiment of the first aspect, the double-stranded structure consists of four to six base pairs, preferably five base pairs.
[0040]   In an embodiment of the first aspect, the first stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5' X_2BBBS 3' (SEQ.ID.No. 42) and the second stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5' SBBVX$_3$ 3' (SEQ.ID.No. 43),
whereby X_2 is either absent or is S and X_3 is either absent or is S;
preferably the first stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5' CUGUG 3' and the second stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5' CGCAG 3';
or the first stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5' GCGUG 3'and the second stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5' CGCGC 3'.
[0041]   In an embodiment of the first aspect, the type A nucleic acid molecule has a nucleic acid sequence according to any of SEQ.ID.Nos. 5 to 18, 25 to 41, 133, 137 and 139 to 141.

[0042] In an embodiment of the first aspect, the type B nucleic acid molecules comprise a core nucleotide sequence of GUGUGAUCUAGAUGUADUGGCUGAUCCUAGUCAGG (SEQ.ID.No. 58).

[0043] In an embodiment of the first aspect, said first and said second stretch of nucleotides of the type B nucleic acid molecules optionally hybridize with each other, whereby upon hybridization a double-stranded structure is formed.

[0044] In an embodiment of the first aspect, the double-stranded structure consists of four to six base pairs, preferably five base pairs.

[0045] In an embodiment of the first aspect, the first stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' X_2SSBS 3' (SEQ.ID.No. 73) and the second stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' BVSSX$_3$ 3' (SEQ.ID.No. 74),

whereby X_2 is either absent or G, and X_3 is either absent or C,

preferably the first stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' GCGUG 3' and the second stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' UACGC 3'.

[0046] In an embodiment of the first aspect, the nucleic type B acid molecule has a nucleic acid sequence according to any of SEQ.ID.Nos. 46 to 56, 61 to 72 and 132.

[0047] In an embodiment of the first aspect, the type C nucleic acid molecules comprise a core nucleotide sequence selected from the group comprising

5' GGUYAGGGCUHRAAGUCGG 3' (SEQ.ID.No. 91),
5' GGUYAGGGCUHRAGUCGG 3' (SEQ.ID.No. 92), and
5' GGUUAGGGCUHGAAGUCGG 3' (SEQ.ID.No. 93), preferably the core nucleotide sequence comprises 5' GG-UUAGGGCUHGAAGUCGG 3' (SEQ. ID. No. 93).

[0048] In an embodiment of the first aspect, at least a part of said first stretch and at least a part of said second stretch of nucleotides of the type C nucleic acid molecules optionally hybridize with each other, whereby upon hybridization a double-stranded structure is formed.

[0049] In an embodiment of the first aspect, the double-stranded structure comprises 4 to 10 base pairs, preferably 4 to 6 base pairs, more preferably 5 base pairs.

[0050] In an embodiment of the first aspect, the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' RKSBUGSVGR 3' (SEQ.ID.No. 122) and

the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' YCN-RCASSMY 3' (SEQ.ID.No. 123).

[0051] In an embodiment of the first aspect, the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' SSSSR 3' (SEQ.ID.No. 130) and the second stretch of nucleotides of the type C nucleic acid molecules comprise a nucleotide sequence of 5' YSBSS 3' (SEQ.ID.No. 131).

[0052] In an embodiment of the first aspect, the type C nucleic acid molecule has a nucleic acid sequence according to any of SEQ.ID.Nos. 79 to 89, 94 to 119 and 134 to 136.

[0053] In an embodiment of the first aspect, the nucleic acid molecule has a nucleic acid sequence according to any of SEQ.ID.Nos. 142 to 144.

[0054] In an embodiment of the first aspect, the nucleic acid molecule is an antagonist to SDF-1.

[0055] In an embodiment of the first aspect, the nucleic acid molecule is an antagonist of the SDF-1 receptor system, whereby preferably the SDF-1 receptor of the SDF-1 receptor system is the CXCR4 receptor.

[0056] In an embodiment of the first aspect, the SDF-1 is a human SDF-1, whereby preferably SDF-1 comprises an amino acid sequence according to SEQ ID No. 1.

[0057] In an embodiment of the first aspect, the nucleic acid molecule comprises a modification, preferably the mod-ification is selected from the group comprising a HES moiety and a PEG moiety.

[0058] In an embodiment of the first aspect, the nucleotides of the nucleic acid molecule are L-nucleotides, preferably the nucleotides of the sequences according to any of SEQ.ID.No. 19, 20, 21, 22, 57, 58, 90, 91, 92 and 93.

[0059] The problem underlying the present invention is solved in a second aspect by the nucleic acid molecule according to the first aspect including any embodiment thereof, for use in a method of treating a disease.

[0060] The problem underlying the present invention is solved in a third aspect by a pharmaceutical composition comprising a nucleic acid molecule according to the first aspect including any embodiment thereof, and optionally a further constituent, whereby the further constituent is selected from the group comprising pharmaceutically acceptable excipients and pharmaceutically active agents.

[0061] The problem underlying the present invention is solved in a fourth aspect by the use of a nucleic acid molecule according to the first aspect including any embodiment thereof, for the manufacture of a medicament.

[0062] In an embodiment of the second aspect, the disease is mediated by SDF-1, preferably such disease or disorder is selected from the group comprising back-of-the-eye diseases like diabetic retinopathy and age-related macular de-

generation; cancer of breast, ovaries, prostate, pancreas, thyroid, nasopharynx, colon, lung, and stomach; osteosarcoma; melanoma; glioma; medullo- and neuroblastoma; leukemia; WHIM syndrome; immunologic deficiency syndromes; pathologic neovascularization; inflammation; multiple sclerosis; rheumatoid arthritis / osteoarthritis and nephritis.

[0063]   The problem underlying the present invention is solved in a fifth aspect by the nucleic acid molecule according to the first aspect including any embodiment thereof, whereby the nucleic acid molecule is for use in inhibiting angiogenesis, neovascularizytion, inflammation and metastasis.

[0064]   The problem underlying the present invention is solved in a sixth aspect by the use of a nucleic acid molecule according to the first aspect including any embodiment thereof, for the manufacture of a diagnostic means.

[0065]   In an embodiment of the sixth aspect, the diagnostic means is for the diagnosis of a disease, whereby the disease is mediated by SDF-1, preferably such disease is selected from the group comprising back-of-the-eye diseases like diabetic retinopathy and age-related macular degeneration; cancer of breast, ovaries, prostate, pancreas, thyroid, nasopharynx, colon, lung, and stomach; osteosarcoma; melanoma; glioma; medullo- and neuroblastoma; leukemia; WHIM syndrome; immunologic deficiency syndromes; pathologic neovascularization; inflammation; multiple sclerosis; rheumatoid arthritis / osteoarthritis and nephritis.

[0066]   In an embodiment of the sixth aspect, the diagnostic means is for diagnosing angiogenesis, neovascularization, inflammation and/or metastasis.

[0067]   The problem underlying the present invention is solved in a seventh aspect by a complex comprising SDF-1 and a nucleic acid molecule according to the first aspect including any embodiment thereof, whereby preferably theh complex is a crystalline complex.

[0068]   The problem underlying the present invention is solved in an eighth aspect by the use of a nucleic acid molecule according to the first aspect including any embodiment thereof, for the detection of SDF-1.

[0069]   The problem underlying the present invention is solved in an eighth aspect by a kit for the detection of SDF-1, comprising a nucleic acid molecule according to the first aspect including any embodiment thereof.

[0070]   In an embodiment the first stretch of nucleotides of the type A nucleic acid molecules comprise a nucleotide sequence of 5' X_1X_2NNBV 3' (SEQ.ID.No. 44) and the second stretch of nucleotides of the type A nucleic acid molecule comprises a nucleotide sequence of 5' BNBNX_3X_4 3' (SEQ.ID.No. 45)
whereby X_1 is either absent or R, X_2 is S, X_3 is S and X_4 is either absent or Y;
or
X_1 is absent, X_2 is either absent or S, X_3 is either absent or S and X_4 is absent.

[0071]   In an embodiment the first stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5' RSHRYR 3' (SEQ.ID.No. 23) and the second stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5' YRYDSY 3'(SEQ.ID.No. 24),
preferably the first stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5' GCUGUG 3' and the second stretch of nucleotides of the type A nucleic acid molecules comprises a nucleotide sequence of 5' CGCAGC 3'.

[0072]   In an embodiment the first stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' X_1X_2SVNS 3' (SEQ.ID.No. 77) and the second stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' BVBSX_3X_4 3' (SEQ.ID.No. 78), whereby
X_1 is either absent or is A, X_2 is G, X_3 is C and X_4 is either absent or is U;
or
X_1 is absent, X_2 is either absent or is G, X_3 is either absent or is C and X_4 is absent.

[0073]   In an embodiment the first stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' X_1GCRWG 3' (SEQ.ID.No. 59) and the second stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' KRYSCX_4 3'(SEQ.ID.No. 60),
whereby X_1 is either absent or A, and X_4 is either absent or U.

[0074]   In an embodiment the first stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' X_1GCGUG 3' (SEQ.ID.No. 75) and the second stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' UACGCX_4 3' (SEQ.ID.No. 76),
whereby X_1 is either absent or A, and X_4 is either absent or U,
preferably the first stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' AGCGUG 3' and the second stretch of nucleotides of the type B nucleic acid molecules comprises a nucleotide sequence of 5' UACGCU 3'.

[0075]   In an embodiment the length of the first stretch of the type C nucleic acid molecules and the length of the second stretch of the type C nucleic acid molecules is individually and independently 0 to 17 nucleotides, preferably 4 to 10 nucleotides and more preferably 4 to 6 nucleotides.

[0076]   In an embodiment the double-stranded structure of the type C nucleic acid molecules comprises 4 to 10 base pairs, preferably 4 to 6 base pairs, more preferably 5 base pairs.

[0077]   In a preferred embodiment the double-stranded structure of the type C nucleic acid molecules comprises 4 to

10 consecutive base pairs, preferably 4 to 6 consecutive base pairs, more preferably 5 consecutive base pairs.

[0078] In an embodiment the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' RKSBUSNVGR 3' (SEQ.ID.No. 120) and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' YYNRCASSMY 3' (SEQ.ID.No. 121).

[0079] In an embodiment the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' X_SSSSV 3' (SEQ.ID.No. 124) and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' BSSSX$_S$ 3' (SEQ.ID.No. 125), whereby X_s is either absent or is S.

[0080] Preferably, the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' SGGSR 3' (SEQ.ID.No. 126) and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' YSCCS 3' (SEQ.ID.No. 127).

[0081] In an embodiment the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' GCSGG 3' (SEQ.ID.No. 128) and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' CCKGC 3' (SEQ.ID.No. 129), preferably the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' GCCGG 3' and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' CCGGC 3'.

[0082] In an embodiment the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' CGUGCGCUUGAGAUAGG 3' and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' CUGAUUCUCACG 3'.

[0083] In an embodiment the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5'UGAGAUAGG 3' and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' CUGAUUCUCA 3'.

[0084] In an embodiment the first stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' GAGAUAGG 3' and the second stretch of nucleotides of the type C nucleic acid molecules comprises a nucleotide sequence of 5' CUGAUUCUC 3'.

[0085] In an embodiment of the first aspect the SDF-1 is a human SDF-1 and/or the SDF-1 receptor is a human SDF-1 receptor.

[0086] In an embodiment of the first aspect SDF-1 comprises an amino acid sequence according to SEQ ID No. 1.

[0087] In a preferred embodiment of the first aspect the modification is a PEG moiety consisting of a straight or branched PEG, whereby the molecular weight of the PEG moiety is preferably from about 2 to 180 kD, more preferably from about 60 to 140 kD and most preferably about 40 kD.

[0088] In an embodiment of the first aspect the modification is a HES moiety, whereby preferably the molecular weight of the HES moiety is from about 10 to 130 kD, more preferably from about 30 to 130 kD and most preferably about 100 kD.

[0089] In an embodiment of the fourth aspect the medicament is for inhibiting angiogenesis, neovascularizytion, inflammation and metastasis.

[0090] Also disclosed is a method for the screening of a SDF-1 antagonist or a SDF-1 agonist comprising the following steps:

- providing a candidate SDF-1 antagonist and/or a candidate SDF-1 agonist,

- providing a nucleic acid according to the first aspect,

- providing a test system which provides a signal in the presence of a SDF-1 antagonist and/or a SDF-1 agonist, and

- determining whether the candidate SDF-1 antagonist is a SDF-1 antagonist and/or whether the candidate SDF-1 agonist is a SDF-1 agonist.

[0091] Also disclosed is a method for the screening of a SDF-1 agonist and/or a SDF-1 antagonist comprises the following steps:

- providing SDF-1 immobilised to a phase, preferably a solid phase,

- providing a nucleic acid according to the first aspect, preferably a nucleic acid according to the first aspect which is labelled,

- adding a candidate SDF-1 agonist and/or a candidate SDF-1 antagonist, and

- determining whether the candidate SDF-1 agonist is a SDF-1 agonist and/or whether the candidate SDF-1 antagonist

is a SDF-1 antagonist.

[0092] The method may be carried out such that it is assessed whether the nucleic acid is replaced by the candidate SDF-1 agonist or by a candidate SDF-1 antagonist.

5 **[0093]** Also disclosed is an SDF-1 antagonist obtainable by the method according to the seventh aspect or the eighth aspect.

[0094] The present invention is based on the surprising finding that it is possible to generate nucleic acids binding specifically and with high affinity to SDF-1.

[0095] SDF-1 is a basic peptide having the amino acid sequence according to SEQ. ID. No. 1. The calculated pI of

10 SDF-1 is 9.70. As used herein the term SDF-1 refers to any SDF-1 including, but not limited to, mammalian SDF-1. Preferably, the mammalian SDF-1 is selected from the group comprising mice, rat, rabbit, hamster, monkey and human SDF-1. Most preferably the SDF-1 is human SDF-1 (SEQ.ID. 1).

[0096] The finding that high affinity binding nucleic acids to SDF-1 could be identified, is insofar surprising as Eaton et al. (Eaton, Gold et al. 1997) observed that the generation of aptamers, i.e. D-nucleic acids binding to a target molecule,

15 directed to a basic protein is in general very difficult because this kind of target produces a high but non-specific signal-to-noise ratio. This high signal-to-noise ratio results from the high non-specific affinity shown by nucleic acids for basic targets such as SDF-1.

[0097] The features of the nucleic acid according to the present invention as described herein can be realised in any aspect of the present invention where the nucleic acid is used, either alone or in any combination.

20 **[0098]** Without wishing to be bound by any theory, the present inventors assume that the observed specificity of the SDF-1 binding nucleic acids according to the present invention share some structural features and in particular one of the nucleotide sequences which are also referred to therein as core sequences which shall be discussed in more detail in the following, whereby reference is made to Figs. 1 to 8 and to Example 1. However, it is to be understood that said Figs. and to Example 1 incorporates several of said structural features which do not have to be necessarily realized in

25 each and any of the nucleic acids according to the present invention.

[0099] As outlined in more detail in the claims and example 1, the various human SDF-1 binding nucleic acid molecules can be categorised based on said Boxes and some structural features and elements, respectively. The various categories thus defined are also referred to herein as types and more specifically as Type A, Type B and Type C.

[0100] In a preferred embodiment the nucleic acid according to the present invention is a single nucleic acid molecule.

30 In a further embodiment, the single nucleic acid molecule is present as a multitude of the single nucleic acid molecule. Preferably, the terms nucleic acid and nucleic acid molecule are used in an interchangeable manner herein if not indicated to the contrary.

[0101] It will be acknowledged by the ones skilled in the art that the nucleic acid molecule in accordance with the invention preferably consists of nucleotides which are covalently linked to each other, preferably through phosphodiester

35 links or linkages.

[0102] The nucleic acids according to the present invention shall also comprise nucleic acids which are essentially homologous to the particular sequences disclosed herein. The term substantially homologous shall be understood such as the homology is at least 75%, preferably 85%, more preferably 90% and most preferably more that 95 %, 96 %, 97 %, 98 % or 99%.

40 **[0103]** The actual percentage of homologous nucleotides present in the nucleic acid according to the present invention will depend on the total number of nucleotides present in the nucleic acid. The percent modification can be based upon the total number of nucleotides present in the nucleic acid.

[0104] The homology can be determined as known to the person skilled in the art. More specifically, a sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference

45 sequence, based on the designated program parameters. The test sequence is preferably the sequence or nucleic acid molecule which is said to be or to be tested whether it is homologous, and if so, to what extent, to another nucleic acid molecule, whereby such another nucleic acid molecule is also referred to as the reference sequence. In an embodiment, the reference sequence is a nucleic acid molecule as described herein, more preferably a nucleic acid molecule having a sequence according to any of SEQ. ID. NOs. 5 to 144. Optimal alignment of sequences for comparison can be

50 conducted, e.g., by the local homology algorithm of Smith & Waterman (Smith & Waterman, 1981) by the homology alignment algorithm of Needleman & Wunsch (Needleman & Wunsch, 1970) by the search for similarity method of Pearson & Lipman (Pearson & Lipman, 1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection.

55 **[0105]** One example of an algorithm that is suitable for determining percent sequence identity is the algorithm used in the basic local alignment search tool (hereinafter "BLAST "), see, e.g. Altschul et al (Altschul et al. 1990 and Altschul et al, 1997). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (hereinafter "NCBI"). The default parameters used in determining sequence identity using the software

available from NCBI, e.g., BLASTN (for nucleotide sequences) and BLASTP (for amino acid sequences) are described in McGinnis et al (McGinnis et al, 2004).

[0106] The term inventive nucleic acid or nucleic acid according to the present invention shall also comprise those nucleic acids comprising the nucleic acids sequences disclosed herein or part thereof, preferably to the extent that the nucleic acids or said parts are involved in the binding to SDF-1. Such a nucleic acid may be derived from the ones disclosed herein, e.g., by truncation. Truncation may be related to either or both of the ends of the nucleic acids as disclosed herein. Also, truncation may be related to the inner sequence of nucleotides, i.e. it may be related to the nucleotide(s) between the 5' and the 3' terminal nucleotide, respectively. Moreover, truncation shall comprise the deletion of as little as a single nucleotide from the sequence of the nucleic acids disclosed herein. Truncation may also be related to more than one stretch of the inventive nucleic acid(s), whereby the stretch can be as little as one nucleotide long. The binding of a nucleic acid according to the present invention can be determined by the ones skilled in the art using routine experiments or by using or adopting a method as described herein, preferably as described herein in the example part.

[0107] The nucleic acids according to the present invention may be either D-nucleic acids or L-nucleic acids. Preferably, the inventive nucleic acids are L-nucleic acids. In addition it is possible that one or several parts of the nucleic acid are present as D-nucleic acids or at least one or several parts of the nucleic acids are L-nucleic acids. The term "part" of the nucleic acids shall mean as little as one nucleotide. Such nucleic acids are generally referred to herein as D- and L-nucleic acids, respectively. Therefore, in a particularly preferred embodiment, the nucleic acids according to the present invention consist of L-nucleotides and comprise at least one D-nucleotide. Such D-nucleotide is preferably attached to a part different from the stretches defining the nucleic acids according to the present invention, preferably those parts thereof, where an interaction with other parts of the nucleic acid is involved. Preferably, such D-nucleotide is attached at a terminus of any of the stretches and of any nucleic acid according to the present invention, respectively. In a further preferred embodiment, such D-nucleotides may act as a spacer or a linker, preferably attaching modifications such as PEG and HES to the nucleic acids according to the present invention.

[0108] It is also within the present invention that each and any of the nucleic acid molecules described herein in their entirety in terms of their nucleic acid sequence(s) are limited to the particular nucleotide sequence(s). In other words, the terms "comprising" or "comprise(s)" shall be interpreted in such embodiment in the meaning of containing or consisting of.

[0109] It is also within the present invention that the nucleic acids according to the present invention are part of a longer nucleic acid whereby this longer nucleic acid comprises several parts whereby at least one such part is a nucleic acid, or a part thereof, according to the present invention. The other part(s) of these longer nucleic acids can be either one or several D-nucleic acid(s) or L-nucleic acid(s). Any combination may be used in connection with the present invention. These other part(s) of the longer nucleic acid can exhibit a function which is different from binding, preferably from binding to SDF-1. One possible function is to allow interaction with other molecules, whereby such other molecules preferably are different from SDF-1, such as, e.g., for immobilization, cross-linking, detection or amplification. In a further embodiment of the present invention the nucleic acids according to the invention comprise, as individual or combined moieties, several of the nucleic acids of the present invention. Such nucleic acid comprising several of the nucleic acids of the present invention is also encompassed by the term longer nucleic acid.

[0110] L-nucleic acids as used herein are nucleic acids consisting of L-nucleotides, preferably consisting completely of L-nucleotides.

[0111] D-nucleic acids as used herein are nucleic acids consisting of D-nucleotides, preferably consisting completely of D-nucleotides.

[0112] The terms nucleic acid and nucleic acid molecule are used herein in an interchangeable manner if not explicitly indicated to the contrary.

[0113] Also, if not indicated to the contrary, any nucleotide sequence is set forth herein in 5' → 3' direction.

[0114] Irrespective of whether the inventive nucleic acid consists of D-nucleotides, L-nucleotides or a combination of both with the combination being e.g. a random combination or a defined sequence of stretches consisting of at least one L-nucleotide and at least one D-nucleotide, the nucleic acid may consist of desoxyribonucleotide(s), ribonucle-otide(s) or combinations thereof.

[0115] Designing the inventive nucleic acids as L-nucleic acid is advantageous for several reasons. L-nucleic acids are enantiomers of naturally occurring nucleic acids. D-nucleic acids, however, are not very stable in aqueous solutions and particularly in biological systems or biological samples due to the widespread presence of nucleases. Naturally occurring nucleases, particularly nucleases from animal cells are not capable of degrading L-nucleic acids. Because of this the biological half-life of the L-nucleic acid is significantly increased in such a system, including the animal and human body. Due to the lacking degradability of L-nucleic acid no nuclease degradation products are generated and thus no side effects arising therefrom observed. This aspect delimits the L-nucleic acid of factually all other compounds which are used in the therapy of diseases and/or disorders involving the presence of SDF-1. L-nucleic acids which specifically bind to a target molecule through a mechanism different from Watson Crick base pairing, or aptamers which consists partially or completely of L-nucleotides, particularly with those parts of the aptamer being involved in the binding

of the aptamer to the target molecule, are also called spiegelmers.

[0116]   It is within the present invention that the first and the second stretch of nucleotides flanking the core nucleotide sequence can, in principle, hybridise with each other. Upon such hybridisation a double-stranded structure is formed. It will be acknowledged by the one skilled in the art that such hybridisation may or may not occur, particularly under *in vitro* and/or *in vivo* conditions. Also, in case of such hybridisation, it is not necessarily the case that the hybridisation occurs over the entire length of the two stretches where, at least based on the rules for base pairing, such hybridisation and thus formation of a double-stranded structure may occur. As preferably used herein, a double-stranded structure is a part of a molecule or a structure formed by two or more separate strands, whereby at least one, preferably two or more base pairs exist which are base pairing preferably in accordance with the Watson-Crick base pairing rules. It will also be acknowledged by the one skilled in the art that other base pairing such as Hoogsten base pairing may exist in or form such double-stranded structure.

[0117]   It is also within the present invention that the inventive nucleic acids, regardless whether they are present as D-nucleic acids, L-nucleic acids or D,L-nucleic acids or whether they are DNA or RNA, may be present as single stranded or double stranded nucleic acids. Typically, the inventive nucleic acids are single stranded nucleic acids which exhibit defined secondary structures due to the primary sequence and may thus also form tertiary structures. The inventive nucleic acids, however, may also be double stranded in the meaning that two strands which are complementary or partially complementary to each other are hybridised to each other. This confers stability to the nucleic acid which, in particular, will be advantageous if the nucleic acid is present in the naturally occurring D-form rather than the L-form.

[0118]   The inventive nucleic acids may be modified. Such modifications may be related to the single nucleotide of the nucleic acid and are well known in the art. Examples for such modification are described by, among others, Venkatesan et al. (Venkatesan, Kim et al. 2003) and Kusser (Kusser 2000). Such modification can be a H atom, a F atom or $O-CH_3$ group or NH_2-group at the 2' position of the individual nucleotide of which the nucleic acid consists. Also, the nucleic acid according to the present invention can comprises at least one LNA nucleotide. In an embodiment the nucleic acid according to the present invention consists of LNA nucleotides.

[0119]   In an embodiment, the nucleic acids according to the present invention may be a multipartite nucleic acid. A multipartite nucleic acid as used herein, is a nucleic acid which consists of at least two nucleic acid strands. These at least two nucleic acid strands form a functional unit whereby the functional unit is a ligand to a target molecule. The at least two nucleic acid strands may be derived from any of the inventive nucleic acids by either cleaving the nucleic acid to generate two strands or by synthesising one nucleic acid corresponding to a first part of the inventive, i.e. overall nucleic acid and another nucleic acid corresponding to the second part of the overall nucleic acid. It is to be acknowledged that both the cleavage and the synthesis may be applied to generate a multipartite nucleic acid where there are more than two strands as exemplified above. In other words, the at least two nucleic acid strands are typically different from two strands being complementary and hybridising to each other although a certain extent of complementarity between the various nucleic acid parts may exist.

[0120]   Finally it is also within the present invention that a fully closed, i.e. circular structure for the nucleic acids according to the present invention is realized, i.e. that the nucleic acids according to the present invention are closed, preferably through a covalent linkage, whereby more preferably such covalent linkage is made between the 5' end and the 3' end of the nucleic acid sequences as disclosed herein.

[0121]   The present inventors have discovered that the nucleic acids according to the present invention exhibit a very favourable Kd value range.

[0122]   A possibility to determine the binding constant is surface plasmon resonance measurement by the use of the so called Biacore device (Biacore AB, Uppsala, Sweden), which is also known to the one skilled in the art. Affinity as preferably used herein was also measured by the use of "pull-down binding assay" as described in the examples. An appropriate measure in order to express the intensity of the binding between the nucleic acid and the target which is in the present case SDF-1, is the so-called Kd value which as such as well as the method for its determination are known to the one skilled in the art.

[0123]   The nucleic acids according to the present invention are characterized by a certain Kd value. Preferably, the Kd value shown by the nucleic acids according to the present invention is below 1 μM. A Kd value of about 1 μM is said to be characteristic for a non-specific binding of a nucleic acid to a target. As will be acknowledged by the ones in the art, the Kd value of a group of compounds such as the nucleic acids according to the present invention are within a certain range. The above-mentioned Kd of about 1 μM is a preferred upper limit for the Kd value. The preferred lower limit for the Kd of target binding nucleic acids can be about 10 picomolar or higher. It is within the present invention that the Kd values of individual nucleic acids binding to ghrelin is preferably within this range. Preferred ranges can be defined by choosing any first number within this range and any second number within this range.

[0124]   Preferred upper values are 250 nM an 100 nM, preferred lower values are 50 nM, 10 nM, 1 nM, 100 pM and 10 pM.

[0125]   The nucleic acid molecules according to the present invention may have any length provided that they are still able to bind to the target molecule. It will be acknowledged in the art that there are preferred lengths of the nucleic acids according to the present inventions. Typically, the length is between 15 and 120 nucleotides. It will be acknowledged

by the ones skilled in the art that any integer between 15 and 120 is a possible length for the nucleic acids according to the present invention. More preferred ranges for the length of the nucleic acids according to the present invention are lengths of about 20 to 100 nucleotides, about 20 to 80 nucleotides, about 20 to 60 nucleotides, about 20 to 50 nucleotides and about 20 to 40 nucleotides.

[0126]   It is within the present invention that the nucleic acids disclosed herein comprise a moiety which preferably is a high molecular weight moiety and/or which preferably allows to modify the characteristics of the nucleic acid in terms of, among others, residence time in the animal body, preferably the human body. A particularly preferred embodiment of such modification is PEGylation and HESylation of the nucleic acids according to the present invention. As used herein PEG stands for poly(ethylene glycole) and HES for hydroxyethyl starch. PEGylation as preferably used herein is the modification of a nucleic acid according to the present invention whereby such modification consists of a PEG moiety which is attached to a nucleic acid according to the present invention. HESylation as preferably used herein is the modification of a nucleic acid according to the present invention whereby such modification consists of a HES moiety which is attached to a nucleic acid according to the present invention. These modifications as well as the process of modifying a nucleic acid using such modifications, is described in European patent application EP 1 306 382.

[0127]   Preferably, the molecular weight of a modification consisting of or comprising a high molecular weight moiety is about from 2,000 to 200,000 Da, preferably 40,000 to 120,000 Da, particularly in case of PEG being such high molecular weight moiety, and is preferably about from 3,000 to 180,000 Da, more preferably from 60,000 to 140,000 Da, particularly in case of HES being such high molecular weight moiety. The process of HES modification is, e.g., described in German patent application DE 1 2004 006 249.8.

[0128]   It is within the present invention that either of PEG and HES may be used as either a linear or branched from as further described in the patent applications WO2005074993 and PCT/EP02/11950. Such modification can, in principle, be made to the nucleic acid molecules of the present invention at any position thereof. Preferably such modification is made either to the 5' -terminal nucleotide, the 3'-terminal nucleotide and/or any nucleotide between the 5' nucleotide and the 3' nucleotide of the nucleic acid molecule.

[0129]   The modification and preferably the PEG and/or HES moiety can be attached to the nucleic acid molecule of the present invention either directly or through a linker. It is also within the present invention that the nucleic acid molecule according to the present invention comprises one or more modifications, preferably one or more PEG and/or HES moiety. In an embodiment the individual linker molecule attaches more than one PEG moiety or HES moiety to a nucleic acid molecule according to the present invention. The linker used in connection with the present invention can itself be either linear or branched. This kind of linkers are known to the ones skilled in the art and are further described in the patent applications WO2005074993 and PCT/EP02/11950.

[0130]   Without wishing to be bound by any theory, it seems that by modifying the nucleic acids according to the present invention with high molecular weight moiety such as a polymer and more particularly the polymers disclosed herein, which are preferably physiologically acceptable, the excretion kinetic is changed. More particularly, it seems that due to the increased molecular weight of such modified inventive nucleic acids and due to the nucleic acids not being subject to metabolism particularly when in the L form, excretion from an animal body, preferably from a mammalian body and more preferably from a human body is decreased. As excretion typically occurs via the kidneys, the present inventors assume that the glomerular filtration rate of the thus modified nucleic acid is significantly reduced compared to the nucleic acids not having this kind of high molecular weight modification which results in an increase in the residence time in the body. In connection therewith it is particularly noteworthy that, despite such high molecular weight modification the specificity of the nucleic acid according to the present invention is not affected in a detrimental manner. Insofar, the nucleic acids according to the present invention have surprising characteristics - which normally cannot be expected from pharmaceutically active compounds - such that a pharmaceutical formulation providing for a sustained release is not necessarily required to provide for a sustained release. Rather the nucleic acids according to the present invention in their modified form comprising a high molecular weight moiety, can as such already be used as a sustained release-formulation. Insofar, the modification(s) of the nucleic acid molecules as disclosed herein and the thus modified nucleic acid molecules and any composition comprising the same may provide for a distinct, preferably controlled pharmacokinetics and biodistribution thereof. This also includes residence time in circulation and distribution to tissues. Such modifications are further described in the patent application PCT/EP02/11950.

[0131]   However, it is also within the present invention that the nucleic acids disclosed herein do not comprise any modification and particularly no high molecular weight modification such as PEGylation or HESylation. Such embodiment is particularly preferred when a fast clearance of the nucleic acids from the body after administration is desired. Such fast clearance might be desired in case of in vivo imaging or specific therapeutic dosing requirements using the nucleic acids or medicaments comprising the same, according to the present invention.

[0132]   The inventive nucleic acids, which are also referred to herein as the nucleic acids according to the present invention, and/or the antagonists according to the present invention may be used for the generation or manufacture of a medicament. Such medicament contains at least one of the inventive nucleic acids, optionally together with further pharmaceutically active compounds, whereby the inventive nucleic acid preferably acts as pharmaceutically active

compound itself. Such medicaments comprise in preferred embodiments at least a pharmaceutically acceptable carrier. Such carrier may be, e. g., water, buffer, PBS, glucose solution, sucrose solution, mannose solution, preferably a 5% sucrose balanced solution, starch, sugar, gelatine or any other acceptable carrier substance. Such carriers are generally known to the one skilled in the art. It will be acknowledged by the person skilled in the art that any embodiments, use and aspects of or related to the medicament of the present invention is also applicable to the pharmaceutical composition of the present invention and vice versa.

[0133] The indication, diseases and disorders for the treatment and/or prevention of which the nucleic acids, the pharmaceutical compositions and medicaments in accordance with or prepared in accordance with the present invention result from the involvement, either direct or indirect, of SDF-1 in the respective pathogenetic mechanism.

[0134] Of course, because the SDF-1 binding nucleic acids according to the present invention interact with or bind to human or murine SDF-1, a skilled person will generally understand that the SDF-1 binding nucleic acids according to the present invention can easily be used for the treatment, prevention and/or diagnosis of any disease as described herein of humans and animals.

[0135] Disease and/or disorders and/or diseased conditions for the treatment and/or prevention of which such medicament may be used include, but are not limited to back-of-the-eye diseases like retinopathy, diabetic retinopathy and age-related macular degeneration, both dry and wet form; cancer; cancer of breast, ovaries, prostate, pancreas, thyroid, nasopharynx, colon, lung, and stomach; osteosarcoma; melanoma; glioma; medullo- and neuroblastoma; leukemia; B cell chronic lymphocytic leukaemia; multiple myoloma; lymphoma; WHIM syndrome; immunologic deficiency syndromes; pathologic neovascularization; inflammation; multiple sclerosis; arthritis, rheumatoid arthritis, osteoarthritis and nephritis.

[0136] In a further embodiment, the medicament comprises a further pharmaceutically active agent. Such further pharmaceutically active compounds can be those known to the ones skilled in the art and are preferably selected from the group comprising chemokine or cytokine antagonists, corticosteroids, and the like. It will be understood by the one skilled in the art that given the various indications which can be addressed in accordance with the present invention by the nucleic acids according to the present invention, said further pharmaceutically active agent(s) may be any one which in principle is suitable for the treatment and/or prevention of such diseases. The nucleic acid molecules according to the present invention, particularly if present or used as a medicament, are preferably combined with VEGF-inhibitors such as Macugen (Pegatanib) from Pfizer Ophthalmics, Lucentis (Ranitizumab) from Novartis Ophthalmics, Avastin (Bevacizumab) from Roche (off-label use); or with photodynamic therapy such as Visudyne (Verteporfing) from Novartis Ophthalmics and intravitreally injectable cortisone derivative such as Retaane (Anecortave acetate) from Alcon Inc.

[0137] Alternatively, or additionally, such further pharmaceutically active agent is a further nucleic acid according to the present invention. Alternatively, the medicament comprises at least one more nucleic acid which binds to a target molecule different from SDF-1 or exhibits a function which is different from the one of the nucleic acids according to the present invention.

[0138] As will be acknowledged by the ones of the art the inventive nucleic acids may factually be used in any disease where an antagonist to SDF-1 can be administered to a patient in need of such antagonist and such antagonist is suitable to eliminate the cause of the disease or the disorder or at least to reduce the effects from the disease or the disorder. Such effect includes, but is not limited to pathologic neovascularization, inflammation and metastasis. The applicability of the nucleic acids according to the present invention in connection with these and other diseases or disorders results, among others, from the involvement of SDF-1 as outlined in the introductory part of the present specification which is incorporated herein by reference so as to avoid any unnecessary repetition.

[0139] It is within the present invention that the medicament is alternatively or additionally used, in principle, for the prevention of any of the diseases disclosed in connection with the use of the medicament for the treatment of said diseases. Respective markers therefore, i.e. for the respective diseases are known to the ones skilled in the art. Preferably, the respective marker is SDF-1. Alternatively and/or additionally, the respective marker is selected from the group of oxidative stress markers, comprising transmembrane reductase of ferricyanide (TMR), increased activity of the sorbitol pathway which includes after accumulation of sorbitol, increased cytosolic NADH/NAD ratio, depletion of NADPH and accumulation of fructose with the resulting non enzymatic production of advanced glycation end products (AGES) and consequent activation of protein kinase C, nitrosative and oxidative stress mediated downstream events such as MAP kinase activation; inflammatory markers, comprising ICAM-1, VCAM-1, RANTES, haptoglobin, or C-reactive protein; and pro-angiogenic markers like erythropoetin or VEGF. In view of this, said markers can be used to determine whether or not a subject or a patient can be treated with any of the nucleic acid molecules in accordance with the present invention. Therefore, in a further aspect, the present invention is related to such method, whereby the presence or absence and more specifically the concentration of the respective marker(s) is/are determined. Methods for the detection of said markers and optionally their quantification, as well as the range within which the respective marker shall be present or absent so as to decide whether or not the subject or patient is suffering from any of said diseases or is a risk to develop such diseases, and, accordingly, may thus be treated in accordance with the present invention, are known to the ones skilled in the art.

[0140] In one embodiment of the medicament of the present invention, such medicament is for use in combination

with other treatments for any of the diseases disclosed herein, particularly those for which the medicament of the present invention is to be used.

[0141] "Combination therapy" (or "co-therapy") includes the administration of a medicament of the invention and at least a second agent as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents, i. e. the medicament of the present invention and said second agent. The beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents. Administration of these therapeutic agents in combination typically is carried out over a defined time period (usually minutes, hours, days or weeks depending upon the combination selected).

[0142] "Combination therapy" may, but generally is not, intended to encompass the administration of two or more of these therapeutic agents as part of separate monotherapy regimens that incidentally and arbitrarily result in the combinations of the present invention. "Combination therapy" is intended to embrace administration of these therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to a subject a single capsule having a fixed ratio of each therapeutic agent or in multiple, single capsules for each of the therapeutic agents.

[0143] Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, topical routes, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by injection while the other therapeutic agents of the combination may be administered topically.

[0144] Alternatively, for example, all therapeutic agents may be administered topically or all therapeutic agents may be administered by injection. The sequence in which the therapeutic agents are administered is not narrowly critical unless noted otherwise. "Combination therapy" also can embrace the administration of the therapeutic agents as described above in further combination with other biologically active ingredients. Where the combination therapy further comprises a non-drug treatment, the non-drug treatment may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and non-drug treatment is achieved. For example, in appropriate cases, the beneficial effect is still achieved when the non-drug treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.

[0145] As outlined in general terms above, the medicament according to the present invention can be administered, in principle, in any form known to the ones skilled in the art. A preferred route of administration is systemic administration, more preferably by parenteral administration, preferably by injuction.. Alternatively, the medicament may be administered locally. Other routes of administration comprise intramuscular, intraperitoneal, and subcutaneous, per orum, intranasal, intratracheal or pulmonary with preference given to the route of administration that is the least invasive, while ensuring efficiancy.

[0146] Parenteral administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Additionally, one approach for parenteral administration employs the implantation of a slow-release or sustained-released systems, which assures that a constant level of dosage is maintained, that are well known to the ordinary skill in the art.

[0147] Furthermore, preferred medicaments of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, inhalants, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. Other preferred topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of active ingredient would typically range from 0.01% to 15%, w/w or w/v.

[0148] The medicament of the present invention will generally comprise an effective amount of the active component(s) of the therapy, including, but not limited to, a nucleic acid molecule of the present invention, dissolved or dispersed in a pharmaceutically acceptable medium. Pharmaceutically acceptable media or carriers include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Supplementary active ingredients can also be incorporated into the medicament of the present invention.

[0149] In a further aspect the present invention is related to a pharmaceutical composition. Such pharmaceutical composition comprises at least one of the nucleic acids according to the present invention and preferably a pharmaceutically acceptable binder. Such binder can be any binder used and/or known in the art. More particularly such binder is any binder as discussed in connection with the manufacture of the medicament disclosed herein. In a further embodiment, the pharmaceutical composition comprises a further pharmaceutically active agent.

[0150] The preparation of a medicament and a pharmaceutical composition will be known to those of skill in the art in light of the present disclosure. Typically, such compositions may be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection; as tablets or other solids

for oral administration; as time release capsules; or in any other form currently used, including eye drops, creams, lotions, salves, inhalants and the like. The use of sterile formulations, such as saline-based washes, by surgeons, physicians or health care workers to treat a particular area in the operating field may also be particularly useful. Compositions may also be delivered via microdevice, microparticle or sponge.

[0151] Upon formulation, a medicament will be administered in a manner compatible with the dosage formulation, and in such amount as is pharmacologically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.

[0152] In this context, the quantity of active ingredient and volume of composition to be administered depends on the individual or the subject to be treated. Specific amounts of active compound required for administration depend on the judgment of the practitioner and are peculiar to each individual.

[0153] A minimal volume of a medicament required to disperse the active compounds is typically utilized. Suitable regimes for administration are also variable, but would be typified by initially administering the compound and monitoring the results and then giving further controlled doses at further intervals.

[0154] For instance, for oral administration in the form of a tablet or capsule (e.g., a gelatin capsule), the active drug component, i. e. a nucleic acid molecule of the present invention and/or any further pharmaceutically active agent, also referred to herein as therapeutic agent(s) or active compound(s) can be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum starches, agar, alginic acid or its sodium salt, or effervescent mixtures, and the like. Diluents, include, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine.

[0155] The medicament of the invention can also be administered in such oral dosage forms as timed release and sustained release tablets or capsules, pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions. Suppositories are advantageously prepared from fatty emulsions or suspensions.

[0156] The pharmaceutical composition or medicament may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. The compositions are prepared according to conventional mixing, granulating, or coating methods, and typically contain about 0.1% to 75%, preferably about 1% to 50%, of the active ingredient.

[0157] Liquid, particularly injectable compositions can, for example, be prepared by dissolving, dispersing, etc. The active compound is dissolved in or mixed with a pharmaceutically pure solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form the injectable solution or suspension. Additionally, solid forms suitable for dissolving in liquid prior to injection can be formulated.

[0158] For solid compositions, excipients include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. The active compound defined above, may be also formulated as suppositories, using for example, polyalkylene glycols, for example, propylene glycol, as the carrier. In some embodiments, suppositories are advantageously prepared from fatty emulsions or suspensions.

[0159] The medicaments and nucleic acid molecules, respectively, of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines. In some embodiments, a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, what is well known to the ordinary skill in the art. For example, the nucleic acid molecules described herein can be provided as a complex with a lipophilic compound or non-immunogenic, high molecular weight compound constructed using methods known in the art. Additionally, liposomes may bear such nucleic acid molecules on their surface for targeting and carrying cytotoxic agents internally to mediate cell killing. An example of nucleic-acid associated complexes is provided in U.S. Patent No. 6,011,020.

[0160] The medicaments and nucleic acid molecules, respectively, of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the medicaments and nucleic acid molecules, respectively, of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drag, for example, polylactic acid, polyepsilon capro lactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydro-

pyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

[0161] If desired, the pharmaceutical composition and medicament, respectively, to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and other substances such as for example, sodium acetate, and triethanolamine oleate.

[0162] The dosage regimen utilizing the nucleic acid molecules and medicaments, respectively, of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular aptamer or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

[0163] Effective plasma levels of the nucleic acid according to the present invention preferably range from 500 fM to 500 μM in the treatment of any of the diseases disclosed herein.

[0164] The nucleic acid molecules and medicaments, respectively, of the present invention may preferably be administered in a single daily dose, every second or third day, weekly, every second week, in a single monthly dose or every third month.

[0165] It is within the present invention that the medicament as described herein constitutes the pharmaceutical composition disclosed herein.

[0166] In a further aspect the present invention is related to a method for the treatment of a subject who is in need of such treatment, whereby the method comprises the administration of a pharmaceutically active amount of at least one of the nucleic acids according to the present invention. In an embodiment, the subject suffers from a disease or is in risk to develop such disease, whereby the disease is any of those disclosed herein, particularly any of those diseases disclosed in connection with the use of any of the nucleic acids according to the present invention for the manufacture of a medicament.

[0167] As preferably used herein a diagnostic or diagnostic agent or diagnostic means is suitable to detect, either directly or indirectly SDF-1 as described herein in connection with the various disorders and diseases described herein. The diagnostic is suitable for the detection and/or follow-up of any of the disorders and diseases, respectively, described herein. Such detection is possible through the binding of the nucleic acids according to the present invention to SDF-1. Such binding can be either directly or indirectly be detected. The respective methods and means are known to the ones skilled in the art. Among others, the nucleic acids according to the present invention may comprise a label which allows the detection of the nucleic acids according to the present invention, preferably the nucleic acid bound to SDF-1. Such a label is preferably selected from the group comprising radioactive, enzymatic and fluorescent labels. In principle, all known assays developed for antibodies can be adopted for the nucleic acids according to the present invention whereas the target-binding antibody is substituted to a target-binding nucleic acid. In antibody-assays using unlabeled target-binding antibodies the detection is preferably done by a secondary antibody which is modified with radioactive, enzymatic and fluorescent labels and bind to the target-binding antibody at its Fc-fragment. In the case of a nucleic acid, preferably a nucleic acid according to the present invention, the nucleic acid is modified with such a label, whereby preferably such a label is selected from the group comprising biotin, Cy-3 and Cy-5, and such label is detected by an antibody directed against such label, e.g. an anti-biotin antibody, an anti-Cy3 antibody or an anti-Cy5 antibody, or - in the case that the label is biotin - the label is detected by streptavidin or avidin which naturally bind to biotin. Such antibody, streptavidin or avidin in turn is preferably modified with a respective label, e.g. a radioactive, enzymatic or fluorescent label (like an secondary antibody).

[0168] In a further embodiment the nucleic acid molecules according to the invention are detected or analysed by a second detection means, wherein the said detection means is a molecular beacon. The methodology of molecular beacon is known to persons skilled in the art. In brief, nucleic acids probes which are also referred to as molecular beacons, are a reverse complement to the nucleic acids sample to be detected and hybridise because of this to a part of the nucleic acid sample to be detected. Upon binding to the nucleic acid sample the fluorophoric groups of the molecular beacon are separated which results in a change of the fluorescence signal, preferably a change in intensity. This change correlates with the amount of nucleic acids sample present.

[0169] It will be understood by the one skilled in the art that due to the relationship outlined herein between SDF-1 and its corresponding receptor, the diseases and conditions which can be diagnosed using the nucleic acid molecules of the present invention, are, in principle, the very same as described herein in connection with the use of said nucleic acid molecules for the treatment and/or prevention of said disease.

[0170] Apart from that, further uses of the nucleic acid molecules according to the present invention reside in a decrease in hematopoiesis, a decrease in invasion or metastasis, a decrease in B cell development and chemotaxis, a decrease in T cell chemoattraction and an induction of growth arrest and apoptosis.

[0171] In connection with the detection of SDF-1 a preferred method comprises the following steps:

(a) providing a sample which is to be tested for the presence of SDF-1,
(b) providing a nucleic acid according to the present invention,

(c) reacting the sample with the nucleic acid, preferably in a reaction vessel

whereby step (a) can be performed prior to step (b), or step (b) can be preformed prior to step (a).

[0172] In a preferred embodiment a further step d) is provided, which consists in the detection of the reaction of the sample with the nucleic acid. Preferably, the nucleic acid of step b) is immobilised to a surface. The surface may be the surface of a reaction vessel such as a reaction tube, a well of a plate, or the surface of a device contained in such reaction vessel such as, for example, a bead. The immobilisation of the nucleic acid to the surface can be made by any means known to the ones skilled in the art including, but not limited to, noncovalent or covalent linkages. Preferably, the linkage is established via a covalent chemical bond between the surface and the nucleic acid. However, it is also within the present invention that the nucleic acid is indirectly immobilised to a surface, whereby such indirect immobilisation involves the use of a further component or a pair of interaction partners. Such further component is preferably a compound which specifically interacts with the nucleic acid to be immobilised which is also referred to as interaction partner, and thus mediates the attachment of the nucleic acid to the surface. The interaction partner is preferably selected from the group comprising nucleic acids, polypeptides, proteins and antibodies. Preferably, the interaction partner is an antibody, more preferably a monoclonal antibody. Alternatively, the interaction partner is a nucleic acid, preferably a functional nucleic acid. More preferably such functional nucleic acid is selected from the group comprising aptamers, spiegelmers, and nucleic acids which are at least partially complementary to the nucleic acid. In a further alternative embodiment, the binding of the nucleic acid to the surface is mediated by a multi-partite interaction partner. Such multi-partite interaction partner is preferably a pair of interaction partners or an interaction partner consisting of a first member and a second member, whereby the first member is comprised by or attached to the nucleic acid and the second member is attached to or comprised by the surface. The multi-partite interaction partner is preferably selected from the group of pairs of interaction partners comprising biotin and avidin, biotin and streptavidin, and biotin and neutravidin. Preferably, the first member of the pair of interaction partners is biotin.

[0173] A preferred result of such method is the formation of an immobilised complex of SDF-1 and the nucleic acid, whereby more preferably said complex is detected. It is within an embodiment that from the complex the SDF-1 is detected.

[0174] The method for the detection of SDF-1 also comprises that the sample is removed from the reaction vessel which has preferably been used to perform step c).

[0175] The method comprises in a further embodiment also the step of immobilising an interaction partner of SDF-1 on a surface, preferably a surface as defined above, whereby the interaction partner is defined as herein and preferably as above in connection with the respective method and more preferably comprises nucleic acids, polypeptides, proteins and antibodies in their various embodiments. In this embodiment, a particularly preferred detection means is a nucleic acid according to the present invention, whereby such nucleic acid may preferably be labelled or non-labelled. In case such nucleic acid is labelled it can be directly or indirectly be detected. Such detection may also involve the use of a second detection means which is, preferably, also selected from the group comprising nucleic acids, polypeptides, proteins and embodiments in the various embodiments described herein. Such detection means are preferably specific for the nucleic acid according to the present invention. In a more preferred embodiment, the second detection means is a molecular beacon. Either the nucleic acid or the second detection means or both may comprise in a preferred embodiment a detection label. The detection label is preferably selected from the group comprising biotin, a bromo-desoxyuridine label, a digoxigenin label, a fluorescence label, a UV-label, a radio-label, and a chelator molecule. Alternatively, the second detection means interacts with the detection label which is preferably contained by, comprised by or attached to the nucleic acid. Particularly preferred combinations are as follows:

the detection label is biotin and the second detection means is an antibody directed against biotin, or wherein
the detection label is biotin and the second detection means is an avidin or an avidin carrrying molecule, or wherein
the detection label is biotin and the second detection means is a streptavidin or a stretavidin carrying molecule, or wherein
the detection label is biotin and the second detection means is a neutravidin or a neutravidin carrying molecule, or wherein the detection label is a bromo-desoxyuridine and the second detection means is an antibody directed against bromo-desoxyuridine, or wherein
the detection label is a digoxigenin and the second detection means is an antibody directed against digoxigenin, or

wherein the detection label is a chelator and the second detection means is a radio-nuclide, whereby it is preferred that said detection label is attached to the nucleic acid. It is to be acknowledged that this kind of combination is also applicable to the embodiment where the nucleic acid is attached to the surface. In such embodiment it is preferred that the detection label is attached to the interaction partner.

[0176] Finally, it is also within the present invention that the second detection means is detected using a third detection means, preferably the third detection means is an enzyme, more preferably showing an enzymatic reaction upon detection of the second detection means, or the third detection means is a means for detecting radiation, more preferably radiation

emitted by a radio-nuclide. Preferably, the third detection means is specifically detecting and/or interacting with the second detection means.

[0177] Also in the embodiment with an interaction partner of SDF-1 being immobilised on a surface and the nucleic acid according to the present invention is preferably added to the complex formed between the interaction partner and the SDF-1, the sample can be removed from the reaction, more preferably from the reaction vessel where step c) and/or d) are preformed.

[0178] In an embodiment the nucleic acid according to the present invention comprises a fluorescence moiety and whereby the fluorescence of the fluorescence moiety is different upon complex formation between the nucleic acid and SDF-1 and free SDF-1.

[0179] In a further embodiment the nucleic acid is a derivative of the nucleic acid according to the present invention, whereby the derivative of the nucleic acid comprises at least one fluorescent derivative of adenosine replacing adenosine. In a preferred embodiment the fluorescent derivative of adenosine is ethenoadenosine.

[0180] In a further embodiment the complex consisting of the derivative of the nucleic acid according to the present invention and the SDF-1 is detected using fluorescence.

[0181] In an embodiment of the method a signal is created in step (c) or step (d) and preferably the signal is correlated with the concentration of SDF-1 in the sample.

[0182] In a preferred aspect, the assays may be performed in 96-well plates, where components are immobilized in the reaction vessels as described above and the wells acting as reaction vessels.

[0183] The inventive nucleic acid may further be used as starting material for drug design. Basically there are two possible approaches. One approach is the screening of compound libraries whereas such compound libraries are preferably low molecular weight compound libraries. In an embodiment, the screening is a high throughput screening. Preferably, high throughput screening is the fast, efficient, trial-and-error evaluation of compounds in a target based assay. In best case the analysis are carried by a colormatic measurement. Libraries as used in connection therewith are known to the one skilled in the art.

[0184] Alternatively, the nucleic acid according to the present invention may be used for rational design of drugs. Preferably, rational drug design is the design of a pharmaceutical lead structure. Starting from the 3-dimensional structure of the target which is typically identified by methods such as X-ray crystallography or nuclear magnetic resonance spectroscopy, computer programs are used to search through databases containing structures of many different chemical compounds. The selection is done by a computer, the identified compounds can subsequently be tested in the laboratory.

[0185] The rational design of drugs may start from any of the nucleic acid according to the present invention and involves a structure, preferably a three dimensional structure, which is similar to the structure of the inventive nucleic acids or identical to the binding mediating parts of the structure of the inventive nucleic acids. In any case such structure still shows the same or a similar binding characteristic as the inventive nucleic acids. In either a further step or as an alternative step in the rational design of drugs the preferably three dimensional structure of those parts of the nucleic acids binding to the neurotransmitter are mimicked by chemical groups which are different from nucleotides and nucleic acids. By this mimicry a compound different from the nucleic acids can be designed. Such compound is preferably a small molecule or a peptide.

[0186] In case of screening of compound libraries, such as by using a competitive assay which are known to the one skilled in the arts, appropriate SDF-1 analogues, SDF-1 agonists or SDF-1 antagonists may be found. Such competitive assays may be set up as follows. The inventive nucleic acid, preferably a spiegelmer which is a target binding L-nucleic acid, is coupled to a solid phase. In order to identify SDF-1 analogues labelled SDF-1 may be added to the assay. A potential analogue would compete with the SDF-1 molecules binding to the spiegelmer which would go along with a decrease in the signal obtained by the respective label. Screening for agonists or antagonists may involve the use of a cell culture assay as known to the ones skilled in the art.

[0187] The kit according to the present invention may comprise at least one or several of the inventive nucleic acids. Additionally, the kit may comprise at least one or several positive or negative controls. A positive control may, for example, be SDF-1, particularly the one against which the inventive nucleic acid is selected or to which it binds, preferably, in liquid form. A negative control may, e.g., be a peptide which is defined in terms of biophysical properties similar to SDF-1, but which is not recognized by the inventive nucleic acids. Furthermore, said kit may comprise one or several buffers. The various ingredients may be contained in the kit in dried or lyophilised form or solved in a liquid. The kit may comprise one or several containers which in turn may contain one or several ingredients of the kit. In a further embodiment, the kit comprises an instruction or instruction leaflet which provides to the user information on how to use the kit and its various ingredients.

[0188] As preferably used herein, the term treatment comprises in a preferred embodiment additionally or alternatively prevention and/or follow-up.

[0189] The pharmaceutical and bioanalytical determination of the nucleic acid according to the present invention is elementarily for the assessment of its pharmacokinetic and biodynamic profile in several humours, tissues and organs of the human and non-human body. For such purpose, any of the detection methods disclosed herein or known to a

person skilled in the art may be used. In a further aspect of the present invention a sandwich hybridisation assay for the detection of the nucleic acid according to the present invention is provided. Within the detection assay a capture probe and a detection probe are used. The capture probe is complementary to the first part and the detection probe to the second part of the nucleic acid according to the present invention. Both, capture and detection probe, can be formed by DNA nucleotides, modified DNA nucleotides, modified RNA nucleotides, RNA nucleotides, LNA nucleotides and/or PNA nucleotides.

[0190] Hence, the capture probe comprise a sequence stretch complementary to the 5'-end of the nucleic acid according to the present invention and the detection probe comprise a sequence stretch complementary to the 3'-end of the nucleic acid according to the present invention. In this case the capture probe is immobilised to a surface or matrix via its 5'-end whereby the capture probe can be immobilised directly at its 5'-end or via a linker between of its 5'-end and the surface or matrix. However, in principle the linker can be linked to each nucleotide of the capture probe. The linker can be formed by hydrophilic linkers of skilled in the art or by D-DNA nucleotides, modified D-DNA nucleotides, D-RNA nucleotides, modified D-RNA nucleotides, D-LNA nucleotides, PNA nucleotides, L-RNA nucleotides, L-DNA nucleotides, modified L-RNA nucleotides, modified L-DNA nucleotides and/or L-LNA nucleotides.

[0191] Alternatively, the capture probe comprises a sequence stretch complementary to the 3'-end of the nucleic acid according to the present invention and the detection probe comprise a sequence stretch complementary to the 5'-end of the nucleic acid according to the present invention. In this case the capture probe is immobilised to a surface or matrix via its 3'-end whereby the capture probe can be immobilised directly at its 3'-end or via a linker between of its 3'-end and the surface or matrix. However, in principle, the linker can be linked to each nucleotide of the sequence stretch that is complementary to the nucleic acid according to the present invention. The linker can be formed by hydrophilic linkers of skilled in the art or by D-DNA nucleotides, modified D-DNA nucleotides, D-RNA nucleotides, modified D-RNA nucleotides, D-LNA nucleotides, PNA nucleotides, L-RNA nucleotides, L-DNA nucleotides, modified L-RNA nucleotides, modified L-DNA nucleotides and/or L-LNA nucleotides.

[0192] The number of nucleotides of the capture and detection probe that may hybridise to the nucleic acid according to the present invention is variable and can be dependant from the number of nucleotides of the capture and/or the detection probe and/or the nucleic acid according to the present invention itself. The total number of nucleotides of the capture and the detection probe that may hybridise to the nucleic acid according to the present invention should be maximal the number of nucleotides that are comprised by the nucleic acid according to the present invention. The minimal number of nucleotides (2 to 10 nucleotides) of the detection and capture probe should allow hybridisation to the 5'-end or 3'-end, respectively, of the nucleic acid according to the present invention. In order to realize high specificity and selectivity between the nucleic acid according to the present invention and other nucleic acids occurring in samples that are analyzed the total number of nucleotides of the capture and detection probe should be or maximal the number of nucleotides that are comprised by the nucleic acid according to the present invention.

[0193] Moreover the detection probe preferably carries a marker molecule or label that can be detected as previously described herein. The label or marker molecule can in principle be linked to each nucleotide of the detection probe. Preferably, the label or marker is located at the 5'-end or 3'-end of the detection probe, whereby between the nucleotides within the detection probe that are complementary to the nucleic acid according to the present invention, and the label a linker can be inserted. The linker can be formed by hydrophilic linkers of skilled in the art or by D-DNA nucleotides, modified D-DNA nucleotides, D-RNA nucleotides, modified D-RNA nucleotides, D-LNA nucleotides, PNA nucleotides, L-RNA nucleotides, L-DNA nucleotides, modified L-RNA nucleotides, modified L-DNA nucleotides and/or L-LNA nucleotides.

[0194] The detection of the nucleic acid according to the present invention can be carried out as follows:

The nucleic acid according to the present invention hybridises with one of its ends to the capture probe and with the other end to the detection probe. Afterwards unbound detection probe is removed by, e. g., one or several washing steps. The amount of bound detection probe which preferably carries a label or marker molecule, can be measured subsequently.

[0195] As preferably used herein, the terms disease and disorder shall be used in an interchangeable manner, if not indicated to the contrary.

[0196] As used herein, the term comprise is preferably not intended to limit the subject matter followed or described by such term. However, in an alternative embodiment the term comprises shall be understood in the meaning of containing and thus as limiting the subject matter followed or described by such term.

[0197] The various SEQ.ID.Nos., the chemical nature of the nucleic aicd molecules according to the present invention and the target molecules SDF-1 as used herein, the actual sequence thereof and the internal reference number is summarized in the following table.

[0198] It has to be noticed that the nucleic acids were characterized on the aptamer, i. e. D-nucleic acid level (D-RNA) with the biotinylated human D-SDF-1 (SEQ.ID. 4) or on the Spiegelmer level, i. e. L-nucleic acid (L-RNA) with the natural

configuration of SDF-1, the L- SDF-1 (human SDF-1 α, SEQ-ID. 1). The different nucleic acids share one internal reference name but one SEQ.ID for the D-RNA (Aptamer) molecule and one SEQ.ID. for the L-RNA (Spiegelmer) molecule, respectively.

5

10

15

20

25

30

35

40

45

50

55

TABLE 1 (A)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
1	L-peptide	KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNN NRQVCIDPKLKWIQEYLEKALNK	human/monkey/cat SDF-1α human/monkey/cat SDF-1
2	L-peptide	KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNN NRQVCIDPKLKWIQEYLEKALNKRFKM	human/monkey/cat SDF-1β
3	L-peptide	KPVSLSYRCPCRFFESHIARANVKHLKILNTPNCALQIVARLKNN NRQVCIDPKLKWIQEYLEKALNK	murine SDF-1α murine SDF-1
4	D-peptide	KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNN NRQVCIDPKLKWIQEYLEKALNKRFK-Biotin	biotinylated hu D-SDF-1
5	L-RNA (SPIEGELMER)	GCUGUGAAAGCAACACAUGUCAACAUGAAAGGUAGCCGCAGC	192-A10-001
6	L-RNA (SPIEGELMER)	GCUGUGAAAGUAACAUGUCAACAUGAAAGGUAACCACAGC	192-G10
7	L-RNA (SPIEGELMER)	GCUGUGAAAGUAACACGUCAACAUGAAAGGUAACCGCAGC	192-F10
8	L-RNA (SPIEGELMER)	GCUGUGAAAGUAACACGUCAACAUGAAAGGUAACCACAGC	192-B11
9	L-RNA (SPIEGELMER)	GCUGUAAAAGUAACAUGUCAACAUGAAAGGUAACCACAGC	192-C9
10	L-RNA (SPIEGELMER)	GCUGUAAAAGUAACAAGUCAACAUGAAAGGUAACUACAGC	192-E10
11	L-RNA (SPIEGELMER)	GCUGUGAAAGUAACAAGUCAACAUGAAAGGUAACCACAGC	192-C10
12	L-RNA (SPIEGELMER)	GCAGUGAAAGUAACAUGUCAACAUGAAAGGUAACCACAGC	192-D11
13	L-RNA (SPIEGELMER)	GCUGUGAAAGUAACAUGUCAACAUGAAAGGUAACCACUGC	192-G11
14	L-RNA (SPIEGELMER)	GCUAUGAAAGUAACAUGUCAACAUGAAAGGUAACCAUAGC	192-H11
15	L-RNA (SPIEGELMER)	GCUGGCGAAAGGCGACAUGUCAACAUGAAAGGUAGCCGCAGC	192-D10
16	L-RNA (SPIEGELMER)	GCUGUGAAAGCAACACAUGUCAACAUGAAAGGUAGCCACAGC	192-E9
17	L-RNA (SPIEGELMER)	GCUGUGAAAGUAACACAUGUCAACAUGAAAGGUAGCCGCAGC	192-H9

TABLE 1 (B)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
18	L-RNA (SPIEGELMER)	AGCGUGAAAGUAACACGUAAAAUGAAAGGUAACCACGCU	191-A6
19	L-RNA (SPIEGELMER)	AAAGYRACAHGUMAAX$_A$UGAAAGGUARC; X$_A$ = A or absent	Type A Formula-1
20	L-RNA (SPIEGELMER)	AAAGYRACAHGUMAAUGAAAGGUARC	Type A Formula-2
21	L-RNA (SPIEGELMER)	AAAGYRACAHGUMAAAUGAAAGGUARC	Type A Formula-3
22	L-RNA (SPIEGELMER)	AAAGYAACAHGUCAAUGAAAGGUARC	Type A Formula-4
23	L-RNA (SPIEGELMER	RSHRYR	Type A Formula-5-5'
24	L-RNA (SPIEGELMER	YRYDSY	Type A Formula-5-3'
25	L-RNA (SPIEGELMER)	CUGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCAG	192-A10-002
26	L-RNA (SPIEGELMER)	UGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCA	192-A10-003
27	L-RNA (SPIEGELMER)	GUGAAAGCAACAUGUCAAUGAAAGGUAGCCGC	192-A10-004
28	L-RNA (SPIEGELMER)	UGAAAGCAACAUGUCAAUGAAAGGUAGCCG	192-A10-005
29	L-RNA (SPIEGELMER)	GAAAGCAACAUGUCAAUGAAAGGUAGCC	192-A10-006
30	L-RNA (SPIEGELMER)	AAAGCAACAUGUCAAUGAAAGGUAGC	192-A10-007
31	L-RNA (SPIEGELMER)	GCGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCGC	192-A10-008
32	L-RNA (SPIEGELMER)	GCGCGAAAGCAACAUGUCAAUGAAAGGUAGCCGCGC	192-A10-015
33	L-RNA (SPIEGELMER)	GCGGAAAGCAACAUGUCAAUGAAAGGUAGCCCGC	192-A10-014
34	L-RNA (SPIEGELMER)	CGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCG	192-A10-016
35	L-RNA (SPIEGELMER)	GCGCAAAGCAACAUGUCAAUGAAAGGUAGCGUGC	192-A10-017
36	L-RNA (SPIEGELMER)	GUGCAAAGCAACAUGUCAAUGAAAGGUAGCGCGC	192-A10-018

TABLE 1 (C)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
37	L-RNA (SPIEGELMER)	CGCGAAAGCAACAUGUCAAUGAAAGGUAGCCGUG	192-A10-019
38	L-RNA (SPIEGELMER)	GGGCAAAGCAACAUGUCAAUGAAAGGUAGCGCCC	192-A10-020
39	L-RNA (SPIEGELMER)	GGCCAAAGCAACAUGUCAAUGAAAGGUAGCGGCC	192-A10-021
40	L-RNA (SPIEGELMER)	GCCCAAAGCAACAUGUCAAUGAAAGGUAGCGGGC	192-A10-022
41	L-RNA (SPIEGELMER)	CCCCAAAGCAACAUGUCAAUGAAAGGUAGCGGGG	192-A10-023
42	L-RNA (SPIEGELMER)	X_2BBBS; X2 = S or absent	Type A Formula-6-5'
43	L-RNA (SPIEGELMER)	SBBVX$_3$; X_3 = S or absent	Type A Formula-6-3'
44	L-RNA (SPIEGELMER)	X_1X_2NNBV; X_1 = R or absent, X_2 = S or absent	Type A Formula-7-5'
45	L-RNA (SPIEGELMER)	BNBNX$_3$X$_4$; X_3 = R or absent, X_4 = Y or absent	Type A Formula-7-3'
46	L-RNA (SPIEGELMER)	AGCGGUGGUGUGAUCUAGAUGUAGAUGUGGCUGAUCCUAGUCAGGUACGCU	193-C2-001
47	L-RNA (SPIEGELMER)	AGCGGUGGUGUGAUCUAGAUGUAGAUGUAUUGGCUGAUCCUAGUCAGGUACGCU	193-G2-001
48	L-RNA (SPIEGELMER)	AGCGGUGGUGUGAUCUAGAUGUAGAUGUAAUGGCUGAUCCUAGUCAGGUGCGCU	193-F2-001
49	L-RNA (SPIEGELMER)	GCGAGGUGGUGAUCUAGAUGUAGAUGUGGCUGAUCCUAGUCAGGUGCGC	193-G1-002
50	L-RNA (SPIEGELMER)	GCGUGGUGGUGAUCUAGAUGUAGAUGUGGCUGAUCCUAGUCAGGUGCGC	193-D2-002
51	L-RNA (SPIEGELMER)	GCAUGGUGGUGAUCUAGAUGUAAUGGCUGAUCCUAGUCAGGUGCCC	193-A1-002
52	L-RNA (SPIEGELMER)	GCGUGGUGGUGAUCUAGAUGUAAUGGCUGAUCCUAGUCAGGGACGC	193-D3-002

TABLE 1 (D)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
53	L-RNA (SPIEGELMER)	GCGUGGUGUGAUCUAGAGAUGUAGAGGCUGAUCCUAGUCAGGUACGC	193-B3-002
54	L-RNA (SPIEGELMER)	GCGUGGUGUGAUCUAGAGAUGUAAAGGCUGAUCCUAGUCAGGUACGC	193-H3-002
55	L-RNA (SPIEGELMER)	GCGUGGUGUGAUCUAGAGAUGUAGAGUGGCUGUUCCUAGUCAGGUAUGC	193-E3-002
56	L-RNA (SPIEGELMER)	GCGUGGUGUGAUCUAGAGAUGUAGAGUGGCUGAUCCUAGUUAGGUACGC	193-D1-002
57	L-RNA (SPIEGELMER)	GUGUGAUCUAGAGAUGUAGADWGGCUGWUCCUAGUYAGG	Type B Formula-1
58	L-RNA (SPIEGELMER)	GUGUGAUCUAGAGAUGUAGADUGGCUGAUCCUAGUCAGG	Type B Formula-2
59	L-RNA (SPIEGELMER)	X₁GCRWG; X₁ = A or absent	Type B Formula-3-5'
60	L-RNA (SPIEGELMER)	KRYSCX₄; X₄ = U or absent	Type B Formula-3-3'
61	L-RNA (SPIEGELMER)	GCGUGGUGUGAUCUAGAGAUGUAGUGGCUGAUCCUAGUCAGGUACGC	193-C2-002
62	L-RNA (SPIEGELMER)	CGUGGUGUGAUCUAGAGAUGUAGAGUGGCUGAUCCUAGUCAGGUACG	193-C2-003
63	L-RNA (SPIEGELMER)	GUGGUGUGAUCUAGAGAUGUAGAGUGGCUGAUCCUAGUCAGGUAC	193-C2-004
64	L-RNA (SPIEGELMER)	UGGUGUGAUCUAGAGAUGUAGAGUGGCUGAUCCUAGUCAGGUA	193-C2-005
65	L-RNA (SPIEGELMER)	GGUGUGAUCUAGAGAUGUAGAGUGGCUGAUCCUAGUCAGGU	193-C2-006
66	L-RNA (SPIEGELMER)	GUGUGAUCUAGAGAUGUAGAGUGGCUGAUCCUAGUCAGG	193-C2-007
67	L-RNA (SPIEGELMER)	GCGUGGUGUGAUCUAGAGAUGUAUUGGCUGAUCCUAGUCAGGUACGC	193-G2-012

TABLE 1 (E)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
68	L-RNA (SPIEGELMER)	GCGCGGUGUGAUCUAGAUGUAUUGGCUGAUCCUAGUCAGGCGGCGC	193-G2-013
69	L-RNA (SPIEGELMER)	GCGCGGUGUGAUCUAGAUGUAUUGGCUGAUCCUAGUCAGAGGGCGC	193-G2-014
70	L-RNA (SPIEGELMER)	GGGCGGUGUGAUCUAGAUGUAUUGGCUGAUCCUAGUCAGGGGCCC	193-G2-015
71	L-RNA (SPIEGELMER)	GGCCGGUGUGAUCUAGAUGUAUUGGCUGAUCCUAGUCAGGGGCC	193-G2-016
72	L-RNA (SPIEGELMER)	GCCCGGUGUGAUCUAGAUGUAUUGGCUGAUCCUAGUCAGGGGGC	193-G2-017
73	L-RNA (SPIEGELMER)	X_2SSBS; X_2 = G or absent	Type B Formula-4-5'
74	L-RNA (SPIEGELMER)	BVSSX$_3$; X_3 = C or absent	Type B Formula-4-3'
75	L-RNA (SPIEGELMER)	X_1GCGUG; X_1 = A or absent	Type B Formula-5-5'
76	L-RNA (SPIEGELMER)	UACGCX$_4$; X_4 = U or absent	Type B Formula-5-3'
77	L-RNA (SPIEGELMER)	X_1X_2SVNS; X_1 = A or absent, X_2 = G or absent	Type B Formula-6-5'
78	L-RNA (SPIEGELMER)	BVBSX$_3$X$_4$; X_3 = C or absent, X_4 = U or absent	Type B Formula-6-3'
79	L-RNA (SPIEGELMER)	GUGCUGCGCGGGGGUUAGGGCUAGAAGUCGGCCUGCAGCAC	197-B2
80	L-RNA (SPIEGELMER)	AGCGUGCGGAGGGUUAGGGCUAGAAGGCUAGAAGUCGGUCGACACGCU	191-D5-001
81	L-RNA (SPIEGELMER)	GUGUUGCGGAGGGUUAGGGCUAGAAGUCGGUCAGCAGCAC	197-H1
82	L-RNA (SPIEGELMER)	CGUGCGCCUUGAGAUAGGGGUUAGGGCUUAAAGUCGGCUGAUUCUCACG	190-A3-001
83	L-RNA (SPIEGELMER)	AGCGUGAAGGGGUUAGGGCUCGAAGUCGGCUGACACGCU	191-A5

TABLE 1 (F)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
84	L-RNA (SPIEGELMER)	GUGCUGCGGGGGUUAGGGCUCGAAGUCGGCCCGCAGCAC	197-H3
85	L-RNA (SPIEGELMER)	GUGUUCCCGGGGUUAGGGCUUGAAGUCGGCCGGCAGCAC	197-B1
86	L-RNA (SPIEGELMER)	GUGUUGCAGGGGUUAGGGCUUGAAGUCGGCCUGCAGCAC	197-E3
87	L-RNA (SPIEGELMER)	GUGCUGCGGGGGUUAGGGCUCAAAGUCGGCCUGCAGCAC	197-H2
88	L-RNA (SPIEGELMER)	GUGCUGCCGGGGUUAGGGCUAA-AGUCGGCCGACAGCAC	197-D1
89	L-RNA (SPIEGELMER)	GUGCUGUGGGGGUCAGGGCUAGAAGUCGGCCUGCAGCAC	197-D2
90	L-RNA (SPIEGELMER)	GGUYAGGGCUHRX$_A$AGUCGG; X$_A$ = A or absent	Type C Formula-1
91	L-RNA (SPIEGELMER)	GGUYAGGGCUHRAAGUCGG	Type C Formula-2
92	L-RNA (SPIEGELMER)	GGUYAGGGCUHRAGUCGG	Type C Formula-3
93	L-RNA (SPIEGELMER)	GGUUAGGGCUHGAAGUCGG	Type C Formula-4
94	L-RNA (SPIEGELMER)	UGAGAUAGGGGUUAGGGCUUAAAGUCGGCUGAUUCUCA	190-A3-003
95	L-RNA (SPIEGELMER)	GAGAUAGGGGUUAGGGCUUAAAGUCGGCUGAUUCUC	190-A3-004
96	L-RNA (SPIEGELMER)	GGGGUUAGGGCUUAAAGUCGGCUGAUUCU	190-A3-007
97	L-RNA (SPIEGELMER)	GCGUGGCGAGGUUAGGGCUAGAAGUCGGUCGACACGC	191-D5-002
98	L-RNA (SPIEGELMER)	CGUGGCGAGGUUAGGGCUAGAAGUCGGUCGACACG	191-D5-003
99	L-RNA (SPIEGELMER)	CGGGCGAGGUUAGGGCUAGAAGUCGGUCGACCG	191-D5-004
100	L-RNA (SPIEGELMER)	CGGGCGAGGUUAGGGCUAGAAGUCGGUCGCCCG	191-D5-005

TABLE 1 (G)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
101	L-RNA (SPIEGELMER)	CGGCGAGGUUAGGGCUAGAAGUCGGUCGCCG	191-D5-006
102	L-RNA (SPIEGELMER)	CGGGAGGUUAGGGCUAGAAGUCGGUCCCG	191-D5-007

(continued)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
103	L-RNA (SPIEGELMER)	GGGAGGUUAGGGCUAGAAGUCGGUCCC	191-D5-010
104	L-RNA (SPIEGELMER)	CCGCGGUUAGGGCUAGAAGUCGGGCGG	191-D5-017
105	L-RNA (SPIEGELMER)	CCCGGGUUAGGGCUAGAAGUCGGCGGG	191-D5-029
106	L-RNA (SPIEGELMER)	GGCGGGUUAGGGCUAGAAGUCGGCGCC	191-D5-024
107	L-RNA (SPIEGELMER)	CCCGCGGUUAGGGCUAGAAGUCGGGCGGG	191-D5-017-29a
108	L-RNA (SPIEGELMER)	GCCGCGGUUAGGGCUAGAAGUCGGGCGGC	191-D5-017-29b
109	L-RNA (SPIEGELMER)	CCCCGGGUUAGGGCUAGAAGUCGGCGGGG	191-D5-019-29a
110	L-RNA (SPIEGELMER)	CGGCGGGUUAGGGCUAGAAGUCGGCGCCG	191-D5-024-29a
111	L-RNA (SPIEGELMER)	GGGCGGGUUAGGGCUAGAAGUCGGCGCCC	191-D5-024-29b
112	L-RNA (SPIEGELMER)	UGCUGCGGGGGUUAGGGCUAGAAGUCGGCCUGCAGCA	197-B2-001
113	L-RNA (SPIEGELMER)	GCUGCGGGGGUUAGGGCUAGAAGUCGGCCUGCAGC	197-B2-002
114	L-RNA (SPIEGELMER)	CUGCGGGGGUUAGGGCUAGAAGUCGGCCUGCAG	197-B2-003
115	L-RNA (SPIEGELMER)	UGCGGGGGUUAGGGCUAGAAGUCGGCCUGCA	197-B2-004
116	L-RNA (SPIEGELMER)	GCGGGGGUUAGGGCUAGAAGUCGGCCUGC	197-B2-005

TABLE 1 (H)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
117	L-RNA (SPIEGELMER)	GCCGGGGUUAGGGCUAGAAGUCGGCCGGC	197-B2-006
118	L-RNA (SPIEGELMER)	GGCCGGGGUUAGGGCUAGAAGUCGGCCGGCC	197-B2-006-31a
119	L-RNA (SPIEGELMER)	CGCCGGGGUUAGGGCUAGAAGUCGGCCGGCG	197-B2-006-31b
120	L-RNA (SPIEGELMER)	RKSBUSNVGR	Type C Formula-5-5'
121	L-RNA (SPIEGELMER)	YYNRCASSMY	Type C Formula-5-3'
122	L-RNA (SPIEGELMER)	RKSBUGSVGR	Type C Formula-6-5'

(continued)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
123	L-RNA (SPIEGELMER)	YCNRCASSMY	Type C Formula-6-3'
124	L-RNA (SPIEGELMER)	X_SSSSV; X_S = S or absent	Type C Formula-7-5'
125	L-RNA (SPIEGELMER)	BSSSX_S; X_S = S or absent	Type C Formula-7-3'
126	L-RNA (SPIEGELMER)	SGGSV	Type C Formula-8-5'
127	L-RNA (SPIEGELMER)	YSCCS	Type C Formula-8-3'
128	L-RNA (SPIEGELMER)	GCSGG	Type C Formula-9-5'
129	L-RNA (SPIEGELMER)	CCKGC	Type C Formula-9-3'
130	L-RNA (SPIEGELMER)	SSSSR	Type C Formula-10-5'
131	L-RNA (SPIEGELMER)	YSBSS	Type C Formula-10-3'

TABLE 1 (I)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
132	L-RNA (SPIEGELMER)	5'-40 kDa-PEG-GCGUGGUGUGAUCUAGAGAUGUAUUGGCUGAUCCUAGUCAGGUACGC	193-G2-012-5'-PEG
133	L-RNA (SPIEGELMER)	5'-40 kDa-PEG-GCGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCGC	192-A10-008-5'-PEG
134	L-RNA (SPIEGELMER)	5'-40 kDa-PEG-CGGGAGGUUAGGGCUAGAAGUCGGUCCCG	191-D5-007-5'-PEG
135	L-RNA (SPIEGELMER)	5'-40 kDa-PEG-GCCGGGGGGUUAGGGCUAGAAGUCGGCCGGGC	197-B2-006-5'-PEG
136	L-RNA (SPIEGELMER)	5'-40 kDa-PEG-CGCCGGGGGUUAGGGCUAGAAGUCGGCCGGCG	197-B2-006-31b-5'PEG
137	L-RNA (SPIEGELMER)	5'-40 kDa-PEG-GCUGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCAGC	192-A10-001-5'-PEG 192-A10-001-5'-PEG40
138	L-RNA (SPIEGELMER)	UAAGGAAACUCGGUCGAUGCGGUAGCGCUGUGCAGAGCU	Control Spiegelmer
139	L-RNA (SPIEGELMER)	5'-30 kDa-PEG-GCUGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCAGC	192-A10-001-5'-PEG30
140	L-RNA (SPIEGELMER)	5'-100 kDa-HES-GCUGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCAGC	192-A10-001-5'-HES100
141	L-RNA (SPIEGELMER)	5'-130 kDa-HES-GCUGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCAGC	192-A10-001-5'-HES130
142	L-RNA (SPIEGELMER)	CGUGGUCCGUUGCGUUGUCAGGUCUAUUCGCCCCGGUGCAGGGCAUCCGCG	194-A2-001
143	L-RNA (SPIEGELMER)	GCAGUGUGACGCGGGACGUGAUAGGACAGAGCUGUAUCCCGCUCAGGUGAG	196-B12-003
144	L-RNA (SPIEGELMER)	CAACAGCAGUGUGACGCGGGACGUGAUAGGACAGAGCUGUAUCCCGCUCAG	196-B12-004

TABLE 1 (J)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
145	D-RNA (APTAMER)	GCUGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCAGC	192-A10-001
146	D-RNA (APTAMER)	GCUGUGAAAGUAACAUGUCAAUGAAAGGUAACCACAGC	192-G10
147	D-RNA (APTAMER)	GCUGUGAAAGUAACACGUCAAUGAAAGGUAACCGCAGC	192-F10
148	D-RNA (APTAMER)	GCUGUGAAAGUAACACGUCAAUGAAAGGUAACCACAGC	192-B11
149	D-RNA (APTAMER)	GCUGUAAAAGUAACAUGUCAAUGAAAGGUAACUACAGC	192-C9
150	D-RNA (APTAMER)	GCUGUAAAAGUAACAAGUCAAUGAAAGGUAACUACAGC	192-E10
151	D-RNA (APTAMER)	GCUGUGAAAGUAACAAGUCAAUGAAAGGUAACCACAGC	192-C10
152	D-RNA (APTAMER)	GCAGUGAAAGUAACAUGUCAAUGAAAGGUAACCACAGC	192-D11
153	D-RNA (APTAMER)	GCUGUGAAAGUAACAUGUCAAUGAAAGGUAACCACUGC	192-G11
154	D-RNA (APTAMER)	GCUAUGAAAGUAACAUGUCAAUGAAAGGUAACCAUAGC	192-H11
155	D-RNA (APTAMER)	GCUGCGAAAGCGACAUGUCAAUGAAAGGUAGCCGCAGC	192-D10
156	D-RNA (APTAMER)	GCUGUGAAAGCAACAUGUCAAUGAAAGGUAGCCACAGC	192-E9
157	D-RNA (APTAMER)	GCUGUGAAAGUAACAUGUCAAUGAAAGGUAGCCGCAGC	192-H9
158	D-RNA (APTAMER)	AGCGUGAAAGUAACACGUAAAAUGAAAGGUAACCACGCU	191-A6
159	D-RNA (APTAMER)	CUGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCAG	192-A10-002
160	D-RNA (APTAMER)	UGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCA	192-A10-003

TABLE 1 (K)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
161	D-RNA (APTAMER)	GUGAAAGCAACAUGUCAAUGAAAGGUAGCCGC	192-A10-004
162	D-RNA (APTAMER)	UGAAAGCAACAUGUCAAUGAAAGGUAGCCG	192-A10-005
163	D-RNA (APTAMER)	GAAAGCAACAUGUCAAUGAAAGGUAGCC	192-A10-006
164	D-RNA (APTAMER)	AAAGCAACAUGUCAAUGAAAGGUAGC	192-A10-007
165	D-RNA (APTAMER)	GCGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCGC	192-A10-008
166	D-RNA (APTAMER)	GCGCGAAAGCAACAUGUCAAUGAAAGGUAGCCGCGC	192-A10-015
167	D-RNA (APTAMER)	GCGGGAAAGCAACAUGUCAAUGAAAGGUAGCCCGC	192-A10-014
168	D-RNA (APTAMER)	CGUGAAAGCAACAUGUCAAUGAAAGGUAGCCGCG	192-A10-016
169	D-RNA (APTAMER)	GCGCAAAGCAACAUGUCAAUGAAAGGUAGCGUGC	192-A10-017
170	D-RNA (APTAMER)	GUGCAAAGCAACAUGUCAAUGAAAGGUAGCGCGC	192-A10-018
171	D-RNA (APTAMER)	CGCGAAAGCAACAUGUCAAUGAAAGGUAGCCGUG	192-A10-019
172	D-RNA (APTAMER)	GGGCAAAGCAACAUGUCAAUGAAAGGUAGCGCCC	192-A10-020
173	D-RNA (APTAMER)	GGCCAAAGCAACAUGUCAAUGAAAGGUAGCGGCC	192-A10-021
174	D-RNA (APTAMER)	GCCCAAAGCAACAUGUCAAUGAAAGGUAGCGGGC	192-A10-022
175	D-RNA (APTAMER)	CCCCAAAGCAACAUGUCAAUGAAAGGUAGCGGGG	192-A10-023
176	D-RNA (APTAMER)	AGCGUGUGUGAUCUAGAGAUGUAGUGGCUGAUCCUAGUCAGGUACGCU	193-C2-001

TABLE 1 (L)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
177	D-RNA (APTAMER)	AGCGUGGUGUGAUCUAGAUGUAUUGGCUGAUCCUAGUCAGGUACGCU	193-G2-001
178	D-RNA (APTAMER)	AGCGUGGUGUGAUCUAGAUGUAAUGGCUGAUCCUAGUCAGGUGCGCU	193-F2-001
179	D-RNA (APTAMER)	GCGAGGUGUGAUCUAGAUGUAGUGGCUGAUCCUAGUCAGGUGCGC	193-G1-002
180	D-RNA (APTAMER)	GCGUGGUGUGAUCUAGAUGUAGUGGCUGAUCCUAGUCAGGUGCGC	193-D2-002
181	D-RNA (APTAMER)	GCAUGGUGUGAUCUAGAUGUAGUGGCUGAUCCUAGUCAGGUGCCC	193-A1-002
182	D-RNA (APTAMER)	GCGUGGUGUGAUCUAGAUGUAAUGGCUGAUCCUAGUCAGGGACGC	193-D3-002
183	D-RNA (APTAMER)	GCGUGGUGUGAUCUAGAGAUGUAGAGGCUGAUCCUAGUCAGGUACGC	193-B3-002
184	D-RNA (APTAMER)	GCGUGGUGUGAUCUAGAGAUGUAAAGGCUGAUUCCUAGUCAGGUACGC	193-H3-002
185	D-RNA (APTAMER)	GCGUGGUGUGAUCUAGAGAUGUAGUGGCUGUUCCUAGUCAGGUAUGC	193-E3-002
186	D-RNA (APTAMER)	GCGUGGUGUGAUCUAGAGAUGUAGUGGCUGAUCCUAGUUAGGUACGC	193-D1-002
187	D-RNA (APTAMER)	GCGUGGUGUGAUCUAGAGAUGUAGUGGCUGAUCCUAGUCAGGUACGC	193-C2-002
188	D-RNA (APTAMER)	CGUGGGUGUGAUCUAGAGAUGUAGUGGCUGAUCCUAGUCAGGUACG	193-C2-003
189	D-RNA (APTAMER)	GUGUGGUGUGAUCUAGAGAUGUAGUGGCUGAUCCUAGUCAGGUAC	193-C2-004
190	D-RNA (APTAMER)	UGGUGUGAUCUAGAGAUGUAGUGGCUGAUCCUAGUCAGGUA	193-C2-005
191	D-RNA (APTAMER)	GGGUGUGAUCUAGAGAUGUAGUGGCUGAUCCUAGUCAGGU	193-C2-006

TABLE 1 (M)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
192	D-RNA (APTAMER)	GUGUGAUCUAGAGUAGUGGCUGAUCCUAGUCAGG	193-C2-007
193	D-RNA (APTAMER)	GCGUGGUGUGAUCUAGAGUAUUGGCUGAUCCUAGUCAGGUACGC	193-G2-012
194	D-RNA (APTAMER)	GCGCGGUGUGAUCUAGAGUAUUGGCUGAUCCUAGUCAGGCGCGC	193-G2-013
195	D-RNA (APTAMER)	GCGCGUGUGAUCUAGAGUAUUGGCUGAUCCUAGUCAGGGCGC	193-G2-014
196	D-RNA (APTAMER)	GGGCGUGUGAUCUAGAGUAUUGGCUGAUCCUAGUCAGGGCCC	193-G2-015
197	D-RNA (APTAMER)	GGCCGUGUGAUCUAGAGUAUUGGCUGAUCCUAGUCAGGGGCC	193-G2-016
198	D-RNA (APTAMER)	GCCCGUGUGAUCUAGAGUAUUGGCUGAUCCUAGUCAGGGGGC	193-G2-017
199	D-RNA (APTAMER)	GUGCUGCGGGGGGUUAGGGCUAGAAGUCGGCCUGCAGCAC	197-B2
200	D-RNA (APTAMER)	AGCGUGGCGAGGUUAGGGCUAGAAGUCGGUCGACACGCU	191-D5-001
201	D-RNA (APTAMER)	GUGUUGCGGAGGUUAGGGCUAGAAGUCGGUCAGCAGCAC	197-H1
202	D-RNA (APTAMER)	CGUGCGCUUGAGAUAGGGGUUAGGGCUUAAAGUCGGCUGAUUCUCACG	190-A3-001
203	D-RNA (APTAMER)	AGCGUGAAGGGGUUAGGGCUCGAAGUCGGCUGACACGCU	191-A5
204	D-RNA (APTAMER)	GUGCUGCGGGGGGUUAGGGCUCGAAGUCGGCCCGCAGCAC	197-H3
205	D-RNA (APTAMER)	GUGUUCCGGGGGUUAGGGCUUGAAGUCGGCCGGCAGCAC	197-B1

TABLE 1 (N)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
206	D-RNA (APTAMER)	GUGUUGCAGGGGUUAGGGCUUGAAGUCGGCCUGCAGCAC	197-E3
207	D-RNA (APTAMER)	GUGCUGCGGGGGUUAGGGCUCAAAGUCGGCCUGCAGCAC	197-H2
208	D-RNA (APTAMER)	GUGCUGCCGGGGUUAGGGCUAA-AGUCGGCCGACAGCAC	197-D1
209	D-RNA (APTAMER)	GUGCUGUGGGGGUCAGGGCUAGAAGUCGGCCUGCAGCAC	197-D2
210	D-RNA (APTAMER)	UGAGAUAGGGGUUAGGGCUUAAAGUCGGCUGAUUCUCA	190-A3-003
211	D-RNA (APTAMER)	GAGAUAGGGGUUAGGGCUUAAAGUCGGCUGAUUCUC	190-A3-004
212	D-RNA (APTAMER)	GGGGUUAGGGCUUAAAGUCGGCUGAUUCU	190-A3-007
213	D-RNA (APTAMER)	GCGUGGCGAGGUUAGGGCUAGAAGUCGGUCGACACGC	191-D5-002
214	D-RNA (APTAMER)	CGUGGCGAGGUUAGGGCUAGAAGUCGGUCGACACG	191-D5-003
215	D-RNA (APTAMER)	CGGGCGAGGUUAGGGCUAGAAGUCGGUCGACCG	191-D5-004
216	D-RNA (APTAMER)	CGGGCGAGGUUAGGGCUAGAAGUCGGUCGCCCG	191-D5-005
217	D-RNA (APTAMER)	CGGCGAGGUUAGGGCUAGAAGUCGGUCGCCG	191-D5-006
218	D-RNA (APTAMER)	CGGGAGGUUAGGGCUAGAAGUCGGUCCCG	191-D5-007
219	D-RNA (APTAMER)	GGGAGGUUAGGGCUAGAAGUCGGUCCC	191-D5-010
220	D-RNA (APTAMER)	CCGCGGUUAGGGCUAGAAGUCGGGCGG	191-D5-017
221	D-RNA (APTAMER)	CCCGGGUUAGGGCUAGAAGUCGGCGGG	191-D5-029
222	D-RNA (APTAMER)	GGCGGGUUAGGGCUAGAAGUCGGCGCC	191-D5-024
223	D-RNA (APTAMER)	CCCGCGGUUAGGGCUAGAAGUCGGGCGGG	191-D5-017-29a

TABLE 1 (O)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
224	D-RNA (APTAMER)	GCCGCGGUUAGGGCUAGAAGUCGGGCGGGC	191-D5-017-29b
225	D-RNA (APTAMER)	CCCCGGGUUAGGGCUAGAAGUCGGGCGGGG	191-D5-019-29a
226	D-RNA (APTAMER)	CGGCGGGGUUAGGGCUAGAAGUCGGGCGCCG	191-D5-024-29a
227	D-RNA (APTAMER)	GGGCGGGGUUAGGGCUAGAAGUCGGGCGCCC	191-D5-024-29b
228	D-RNA (APTAMER)	UGCUGCGGGGGGUUAGGGGCUAGAAGUCGGGCCUGCAGCA	197-B2-001
229	D-RNA (APTAMER)	GCUGCGGGGGGUUAGGGCUAGAAGUCGGGCCUGCAGC	197-B2-002
230	D-RNA (APTAMER)	CUGCGGGGGGUUAGGGGCUAGAAGUCGGGCCUGCAG	197-B2-003
231	D-RNA (APTAMER)	UGCGGGGGGUUAGGGCUAGAAGUCGGGCCUGCA	197-B2-004
232	D-RNA (APTAMER)	GCGGGGGUUAGGGCUAGAAGUCGGGCCUGC	197-B2-005
233	D-RNA (APTAMER)	GCCGGGGUUAGGGCUAGAAGUCGGGCCGGGC	197-B2-006
234	D-RNA (APTAMER)	GGCCGGGGUUAGGGCUAGAAGUCGGGCCGGCC	197-B2-006-31a
235	D-RNA (APTAMER)	CGCCGGGGUUAGGGCUAGAAGUCGGGCCGGCG	197-B2-006-31b
236	D-RNA (APTAMER)	CGUGGUCCGUUGUGUCAGGUCUAUUCGCCCCGGUGCAGGGCAUCCGCG	194-A2-001
236	D-RNA (APTAMER)	GCAGUGUGACGCGGACGCGUGAUAGGACUGAUCCCGCUCAGGUGAG	196-B12-003
238	D-RNA (APTAMER)	CAACAGCAGUGUGACGCGGACGCGUGAUAGGACAGAGCUGAUCCCGCUCAG	196-B12-004

TABLE 1 (P)

Seq.-ID	RNA/Peptide	Sequence	Internal Reference
239	L-RNA (Spiegelmer)	5'-PEG-UAAGGAAACUCGGUCUGAUGCGGUAGCGCUGUGCAGAGCU	PEGylated Control Spiegelmer
240	L-RNA (Spiegelmer)	GATCACACCACGC-(C18-PEG-spacer)-(C18-PEG-spacer)-1-NH$_2$-3'	193-G2-012-5'-PEG capture probe
241	L-RNA (Spiegelmer)	5'-NH$_2$-(C18-PEG-spacer)-(C18-PEG-spacer)-GCGUACCUGAC	193-G2-012-5'-PEG detect probe

[0199]   The present invention is further illustrated by the figures, examples and the sequence listing from which further features, embodiments and advantages may be taken, wherein

Fig. 1   shows an alignment of sequences of related RNA ligands binding to human SDF-1 indicating the sequence motif ("Type A") that is in a preferred embodiment in its entirety essential for binding to human SDF-1;

Fig. 2A   shows derivatives of RNA ligand 192-A10-001 (human SDF-1 RNA ligand of sequence motif "Type A");

Fig. 2B   shows derivatives of RNA ligand 192-A10-001 (human SDF-1 RNA ligand of sequence motif "Type A");

Fig. 3   shows an alignment of sequences of related RNA ligands binding to human SDF-1 indicating the sequence motif ("Type B") that is in a preferred embodiment in its entirety essential for binding to human SDF-1;

Fig. 4A   shows derivatives of RNA ligands 193-C2-001 and 193-G2-001 (human SDF-1 RNA ligands of sequence motif "Type B");

Fig. 4B   shows derivatives of RNA ligands 193-C2-001 and 193-G2-001 (human SDF-1 RNA ligands of sequence motif "Type B");

Fig. 5   shows an alignment of sequences of related RNA ligands binding to human SDF-1 indicating the sequence motif ("Type C") that is in a preferred embodiment in its entirety essential for binding to human SDF-1;

Fig. 6   shows derivatives of RNA ligand 190-A3-001 (human SDF-1 RNA ligand of sequence motif "Type C");

Fig. 7A   shows derivatives of RNA ligand 190-D5-001 (human SDF-1 RNA ligand of sequence motif "Type C");

Fig. 7B   shows derivatives of RNA ligand 190-D5-001 (human SDF-1 RNA ligand of sequence motif "Type C");

Fig. 8   shows derivatives of RNA ligand 197-B2 (human SDF-1 RNA ligand of sequence motif "Type C");

Fig. 9   shows further RNA ligands binding to human SDF-1;

Fig. 10   shows the human SDF-1-induced chemotaxis of Jurkat human T cell leukemia cells whereas after 3 hours migration of Jurkat human T cell leukemia cells towards various human SDF-1 concentrations a dose-response curve for human SDF-1 was obtained, represented as fluorescence signal over concentration of human SDF-1;

Fig. 11   shows the result of a binding analysis of the human SDF-1 binding aptamer 192-A10-001 to biotinylated human D-SDF-1 37°C, represented as binding of the aptamer over concentration of biotinylated human D-SDF-1;

Fig. 12   shows the efficacy of human SDF-1 binding Spiegelmer 192-A10-001 in a chemotaxis assay; cells were allowed to migrate towards human 0.3 nM SDF-1 preincubated at 37°C with various amounts of Spiegelmer 192-A10-001, represented as percentage of control over concentration of Spiegelmer 192-A10-001;

Fig. 13   shows the result of a competitive binding analysis of the human SDF-1 binding aptamers 192-A10-001, 192-F10-001, 192-C9-001, 192-E10-001, 192-C10-001, 192-D11-001, 192-G11-001, 192-H11-001, 192-D10-001, 192-E9-001 and 192-H9-001 to biotinylated human D-SDF-1 at 37°C, represented as binding of the labeled aptamer 192-A10-001 (used as reference that is displaced by the non-labeled aptamers) at 1 nM and 5 nM non-labeled aptamers 192-A10-001, 192-F10-001, 192-C9-001, 192-E10-001, 192-C10-001, 192-D11-001, 192-G11-001, 192-H11-001, 192-D10-001, 192-E9-001 and 192-H9-001;

Fig. 14   shows the result of a binding analysis of the human SDF-1 binding aptamer 192-A10-008 to biotinylated human D-SDF-1 at 37°C, represented as binding of the aptamer over concentration of biotinylated human D-SDF-1;

Fig. 15   shows a Biacore 2000 sensorgram indicating the K$_D$ value of the human SDF-1 binding Spiegelmer 192-A10-008 binding to human SDF-1 which was immobilized on a PioneerF1 sensor chip by amine coupling

procedure, represented as response (RU) over time, additionally the on-and off-rates and the K_D values of Spiegelmers 192-A10-008 and 192-A10-001 are listed;

Fig. 16   shows the efficacy of SDF-1 binding Spiegelmer 192-A10-008 in a chemotaxis assay; cells were allowed to migrate towards 0.3 nM human SDF-1 preincubated at 37°C with various amounts of Spiegelmer 192-A10-008, represented as percentage of control over concentration of Spiegelmer 192-A10-008;

Fig. 17   shows a Biacore 2000 sensorgram indicating the K_D value of Spiegelmer 193-G2-01 binding to human SDF-1 which was immobilized on a PioneerF1 sensor chip by amine coupling procedure, represented as response (RU) over time, additionally the on- and off-rates and the K_D values of Spiegelmers 193-G2-001 and 193-C2-001 are listed;

Fig. 18   shows the result of a binding analysis of the human anti-SDF-1 aptamer 193-G2-012 to biotinylated human D-SDF-1 at 37°C, represented as binding of the aptamer over concentration of biotinylated human D-SDF-1;

Fig. 19   shows the result of a competitive binding analysis of the human SDF-1 binding aptamers 190-A3-001, 190-A3-003, 190-A3-004, 190-A3-007, 191-D5-001, 191-D5-002, 191-D5-003, 191-D5-004, 191-D5-005, 191-D5-006 and 191-D5-007 to biotinylated human D-SDF-1 at 37°C, represented as binding of the labeled aptamer 190-A3-001 or 191-D5-001 (used as reference that is displaced by the non-labeled aptamers) at 500 nM, 50 nM and 10 nM non-labeled aptamers 190-A3-001, 190-A3-003, 190-A3-004, 190-A3-007, 191-D5-001, 191-D5-002, 191-D5-003, 191-D5-004, 191-D5-005, 191-D5-006 and 191-D5-007;

Fig. 20   shows the result of a binding analysis of the human SDF-1 binding aptamers 190-A3-004 and 191-D5-007 to biotinylated human D-SDF-1 37°C, represented as binding of the aptamer over concentration of biotinylated human D-SDF-1;

Fig. 21   shows a Biacore 2000 sensorgram indicating the K_D value of Spiegelmer 191-D5-007 binding to human SDF-1 which was immobilized on a PioneerF1 sensor chip by amine coupling procedure, represented as response (RU) over time, additionally the on- and off-rates and the K_D values of Spiegelmers 191-D5-001, 191-D5-007, 190-A3-003 and 197-B2 are listed;

Fig. 22   shows the efficacy of SDF-1 binding Spiegelmer 190-A3-004 in a chemotaxis assay; cells were allowed to migrate towards 0.3 nM human SDF-1 preincubated at 37°C with various amounts of Spiegelmer 190-A3-004, represented as percentage of control over concentration of Spiegelmer 190-A3-004;

Fig. 23A   shows the efficacy of SDF-1 binding Spiegelmers 193-G2-012-5'-PEG, 197-B2-006-5'-PEG, 191-D5-007-5'-PEG and 191-A10-008-5'-PEG in a chemotaxis assay; cells were allowed to migrate towards 0.3 nM human SDF-1 preincubated at 37°C with various amounts of Spiegelmers 193-G2-012-5'-PEG, 197-B2-006-5'-PEG, 191-D5-007-5'-PEG and 191-A10-008-5'-PEG, represented as percentage of control over concentration of Spiegelmers 193-G2-012-5'-PEG, 197-B2-006-5'-PEG, 191-D5-007-5'-PEG and 191-A10-008-5'-PEG;

Fig. 23B   shows the efficacy of SDF-1 binding Spiegelmers 197-B2-006-5'PEG and 197-B2-006-31b-5'-PEG in a chemotaxis assay; cells were allowed to migrate towards 0.3 nM human SDF-1 preincubated at 37°C with various amounts of Spiegelmers 197-B2-006-5'PEG and 197-B2-006-31b-5'-PEG, represented as percentage of control over concentration of Spiegelmers 197-B2-006-5'PEG and 197-B2-006-31b-5'-PEG;

Fig. 24A   shows a Biacore 2000 sensorgram indicating the K_D values of Spiegelmers 193-G2-012-5'-PEG, 191-A10-008-5'-PEG and 191-A10-001-5'-PEG binding to human SDF-1 which was immobilized on a PioneerF1 sensor chip by amine coupling procedure, represented as response (RU) over time;

Fig. 24B   shows a Biacore 2000 sensorgram indicating the K_D values of Spiegelmers 197-B2-006-5'PEG, 197-B2-006-31b-5'-PEG and 191-D5-007-5'-PEG binding to human SDF-1 which was immobilized on a PioneerF1 sensor chip by amine coupling procedure, represented as response (RU) over time;

Fig. 25A   shows the efficacy of SDF-1 binding Spiegelmers 192-A10-001, 192-A10-001-5'-HES130 and 192-A10-001-5'-HES100 in a chemotaxis assay; cells were allowed to migrate towards 0.3 nM human SDF-1 preincubated at 37°C with various amounts of Spiegelmers 192-A10-001, 192-A10-001-5'-HES130 and 192-A10-001-5'-HES100, represented as percentage of control over concentration of Spiegelmers 192-A10-001, 192-A10-001-5'-HES130 and 192-A10-001-5'-HES100;

Fig. 25B   shows the efficacy of SDF-1 binding Spiegelmers 192-A10-001, 192-A10-001-5'-PEG30 and 192-A10-001-5'-PEG40 in a chemotaxis assay; cells were allowed to migrate towards 0.3 nM human SDF-1 preincubated at 37°C with various amounts of Spiegelmers 192-A10-001, 192-A10-001-5'-PEG30 and 192-A10-001-5'-PEG40, represented as percentage of control over concentration of Spiegelmers 192-A10-001, 192-A10-001-5'-PEG30 and 192-A10-001-5'-PEG40;

Fig. 26   shows the inefficacy of a control-Spiegelmer in a chemotaxis assay; cells were allowed to migrate towards 0.3 nM human or murine SDF-1 preincubated at 37°C with various amounts of control-Spiegelmer, represented as percentage of control over concentration of control Spiegelmer;

Fig. 27   shows the murine SDF-1-induced chemotaxis of Jurkat human T cell leukemia cells whereas after 3 hours migration of Jurkat human T cell leukemia cells towards various SDF-1 concentrations a dose-response

curve for SDF-1 was obtained, represented as fluorescence signal;

Fig. 28   shows the efficacy of SDF-1 binding Spiegelmers 192-A10-001 and 191-D5-007-5'PEG in a chemotaxis assay; cells were allowed to migrate towards 0.3 nM murine SDF-1 preincubated at 37°C with various amounts of Spiegelmers 192-A10-001 and 191-D5-007-5TEG represented as percentage of control over concentration of Spiegelmers 192-A10-001 and 191-D5-007-5'PEG;

Fig. 29   shows the efficacy of SDF-1 binding Spiegelmer 192-A10-001 in a CXCR4-receptor binding assay using human [^{125}J]-SDF-1α that was preincubated at 37°C with various amounts of Spiegelmers 192-A10-001, specifically bound [^{125}J]-SDF-1α was plotted over concentration of Spiegelmer 192-A10-001; and

Fig. 30   shows the inhibition of MAP-kinase stimulation of CXCR4-expressing cells with 1 nM human SDF-1α by human SDF-1 binding Spiegelmer 192-A10-001;

Fig. 31   shows the inhibition of SDF-1 induced sprouting by human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG and by PEGylated Control Spiegelmer in aortic ring sprouting assay, whereby rings from rat aorta were embedded in collagen matrix and incubated for 6 days with SDF-1 with or without Spiegelmers (a: control; b: 10 nM SDF-1; c: 10 nM SDF-1 + 1 μM human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG; d: 10 nM SDF-1 + 1 μM PEGylated Control Spiegelmer);

Fig. 32   shows the inhibition of SDF-1 induced sprouting by human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG and by PEGylated Control Spiegelmer in aortic ring sprouting assay whereby sprouting indices are shown as mean +/- SD for 5 rings per condition (*: the value for SDF-1 is significantly different from control (Mann-Whitney-test; p= 0.009); **: the value for SDF-1 + human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG is significantly different from that for SDF-1 (Mann-Whitney-test; p= 0.028);

Fig. 33   shows the plasma level of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG and SDF-1 in rats after an intravenous bolus of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG in comparison with the SDF-1 plasma level of rat that was not treated with human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG, whereby the plasma level of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG and SDF-1 were determined over a period of 96 hours;

Example 1: Nucleic acids that bind human SDF-1

[0200]   Using biotinylated human D-SDF-1 as a target, several nucleic acids that bind to human SDF-1 could be generated the nucleotide sequences of which are depicted in Figures 1 through 9. The nucleic acids were characterized on the aptamer, i. e. D-nucleic acid level with biotinylated human D-SDF-1 or on the Spiegelmer level, i. e. L-nucleic acid with the natural configuration of SDF-1 (L- SDF-1).

[0201]   Aptamers were analyzed with biotinylated human D- SDF-1 using competitive or direct pull-down binding assays with biotinylated human D-SDF-1 (Example 4). Spiegelmers were tested with the natural configuration of SDF-1 (L-SDF-1) by surface plasmon resonance measurement using a Biacore 2000 instrument (Example 6) and a cell *culture in vitro* chemotaxis assay (Example 5).

[0202]   The nucleic acid molecules thus generated exhibit different sequence motifs, three main types are defined in Figs. 1, 2A and 2B (Type A), Figs. 3, 4A and 4B (Type B), Figs. 5, 6, 7A, 7B and 8 (Type C). For definition of nucleotide sequence motifs, the IUPAC abbreviations for ambiguous nucleotides is used:

S	strong	GorC;
W	weak	AorU;
R	purine	GorA;
Y	pyrimidine	C or U;
K	keto	G or U;
M	imino	AorC;
B	not A	C or U or G;
D	not C	A or G or U;
H	not G	A or C or U;
V	not U	A or C or G;
N	all	A or G or C or U

[0203]   If not indicated to the contrary, any nucleic acid sequence or sequence of stretches and boxes, respectively, is indicated in the 5' → 3' direction.

1.1 Type A SDF-1 binding nucleic acids

[0204] As depicted in Fig. 1 all sequences of SDF-1 binding nucleic acids of Type A comprise one core nucleotide sequence which is flanked by 5'- and 3'-terminal stretches that can hybridize to each other. However, such hybridization is not necessarily given in the molecule.

[0205] The nucleic acids were characterized on the aptamer level using direct and competitive pull-down binding assays with biotinylated human D-SDF-1 in order to rank them with respect to their binding behaviour (Example 4). Selected sequences were synthesized as Spiegelmers (Example 3) and were tested using the natural configuration of SDF-1 (L-SDF) in a cell *culture in vitro* chemotaxis assay (Example 5) and by surface plasmon resonance measurement using a Biacore 2000 instrument (Example 6).

[0206] The sequences of the defined boxes or stretches may be different between the SDF-1 binding nucleic acids of Type A which influences the binding affinity to SDF-1. Based on binding analysis of the different SDF-1 binding nucleic acids summarized as Type A SDF-1 binding nucleic acids, the core nucleotide sequence and its nucleotide sequences as described in the following are individually and more preferably in their entirety essential for binding to SDF-1:

The core nucleotide sequence of all identified sequences of Type A SDF-1 binding nucleic acids share the sequence AAAGYRACAHGUMAAX$_A$UGAAAGGUARC (Type A Formula-1), whereby X$_A$ is either absent or is 'A'. If 'A' is absent, the sequence of the core nucleotide sequence can be summarized as Type A Formula-2 (AAAGYRACAH-GMAA-UGAAAGGUARC). Type A SDF-1 binding nucleic acid 191-A6 (core nucleotide sequence: AAAGUAACAC-GUAAAAUGAAAGGUAAC) carrying the additional nucleotide 'A' within the core nucleotide sequence and still binding to SDF-1 let conclude an alternative core nucleotide sequence (AAAGYRACAHGUMAAAUGAAAGGUARC, Type A Formula-3). Exemplarily for all the other nucleic acids of Type A SDF-1 binding nucleic acids, the Type A SDF-1 binding nucleic acid 192-A10-001 was characterized for its binding affinity to human SDF-1. The equilibrium binding constant K$_D$ was determined using the pull-down binding assay (K$_D$ = 1.5 nM, Fig. 11) and by surface plasmon resonance measurement (K$_D$ = 1.0 nM, Fig. 15). The IC$_{50}$ (inhibitory concentration 50%) of 0.12 nM for 192-A10-001 was measured using a cell *culture in vitro* chemotaxis assay (Fig. 12). Consequently, all Type A SDF-1 binding nucleic acids as depicted in Fig. 1 were analyzed in a competitive pull-down binding assay vs. 192-A10-001 (Fig. 13; not all of Type A SDF-1 binding nucleic acids tested are shown in Fig. 13). The Type A SDF-1 binding nucleic acids 192-B11 and 192-C10 showed equal binding affinities as 192-A10-001 in these competition experiments. Weaker binding affinity was determined for Type A SDF-1 binding nucleic acids 192-G10, 192-F10, 192-C9, 192-E10, 192-D11, 192-G11, 192-H11 and 191-A6. The Type A SDF-1 binding nucleic acids 192-D10, 192-E9 and 192-H9 have much weaker binding affinity than 192-A10-001 (Fig. 13).

[0207] As mentioned above, the Type A SDF-1 binding nucleic acid 192-B11 and 192-C10 exhibit equal binding affinity to SDF-1 as 192-A10-001. However, they show slight differences in the nucleotide sequence of the core nucleotide sequence. Therefore the consensus sequence of the three molecules binding to SDF-1 with almost the same high affinity can be summarized by the nucleotide sequence

$$\boxed{\text{AAAGYAACAHGUCAAUGAAAGGUARC}} \text{ (Type A Formula-4)}$$

whereby the nucleotide sequence of the core nucleotide sequence of 192-A10-001 (nucleotide sequence:

$$\boxed{\text{AAAGCAACAUGUCAAUGAAAGGUAGC}}$$

represents the nucleotide sequence with the best binding affinity of Type A SDF-1 binding nucleic acids.

[0208] Five or six out of the six nucleotides of the 5'-terminal stretch of Type A SDF-1 binding nucleic acids may hybridize to the respective five or six nucleotides out of the six nucleotides of the 3'-terminal stretch Type A SDF-1 binding nucleic acids to form a terminal helix. Although these nucleotides are variable at several positions, the different nucleotides allow for hybridization of five or six out of the six nucleotides of the 5'- and 3'-terminal stretches each. The 5'-terminal and 3'-terminal stretches of Type A SDF-1 binding nucleic acids as shown in Fig. 1 can be summarized in a generic formula for the 5'-terminal stretch ('RSHRYR', Type A Formula-5-5') and for the 3'-terminal stretch ('YRYDSY', Type A Formula-5-3'). Truncated derivatives of Type A SDF-1 binding nucleic acid 192-A10-001 were analyzed in a competitive pull-down binding assay vs. the original molecule 192-A10-001 and 192-A10-008 (Fig. 2A and 2B). These experiments showed that a reduction of the six terminal nucleotides (5'end: **GCUGUG;** 3'end: **CGCAGC)** of 192-A10-001

to five nucleotides (5'end: **CUGUG**; 3'end: **CGCAG**) of the derivative 192-A10-002 could be done without reduction of binding affinity. However, the truncation to four terminal nucleotides (5'end: **UGUG**; 3'end: **CGCA**; 192-A10-003) or less (192-A10-004/ -005/ -006/ -007) led to reduced binding affinity to SDF-1 (Fig. 2A). The determined 5'-terminal and 3'-terminal stretches with a length of five and four nucleotides of the derivatives of Type A SDF-1 binding nucleic acid 192-A10-001 as shown in Figs. 2A and B can be described in a generic formula for the 5'-terminal stretch ('X_2BBBS', Type A Formula-6-5') and of the 3'-terminal stretch ('SBBVX_3'; Type A Formula-6-3'), whereby X_2 is either absent or is 'S' and X_3 is either absent or is 'S'.

[0209]   The nucleotide sequence of the 5'- and 3'-terminal stretches has an influence on the binding affinity of Type A SDF-1 binding nucleic acids. This is not only shown by the nucleic acids 192-F10 and 192-E10, but also by derivatives of 192-A10-001 (Fig. 2B;). The core nucleotide sequences of 192-F10 and 192-E10 are identical to 192-B11 and 192-C10, but comprise slight differences at the 3'-end of 5'-terminal stretch and at the 5'-end of 3'-terminal stretch resulting in reduced binding affinity.

[0210]   The substitution of 5'- and 3'-terminal nucleotides '**CUGUG**' and '**CGCAG**' of Type A SDF-1 binding nucleic acid 192-A10-002 by '**GCGCG**' and '**CGCGC**' (192-A10-015) resulted in a reduced binding affinity whereas substitutions by '**GCGUG**' and '**CGCGC**' (192-A10-008) resulted in same binding affinity as shown for 192-A10-002 (Fig. 2B, Fig. 15, Fig. 12, Fig. 16). Additionally, nine derivatives of Type A SDF-1 binding nucleic acid 192-A10-001 (192-A10-014/ -015/ -016/ -017/ -018/ -019/ -020/ -021/ -022/ -023) bearing four 5'-and 3'-terminal nucleotides respectively were tested as aptamers for their binding affinity vs. 192-A10-001 or its derivative 192-A10-008 (both have the identical binding affinity to SDF-1). All clones showed weaker, much weaker or very much weaker binding affinity to SDF-1 as 192-A10-001 (six nucleotides forming a terminal helix) or as 192-A10-008 with five terminal nucleotides, respectively (Fig. 2B). Consequently, the sequence and the number of nucleotides of the 5'- and 3'-terminal stretches are essential for an effective binding to SDF-1. As shown for Type A SDF-1 binding nucleic acids 192-A10-002 and 192-A10-08 the preferred combination of 5'- and 3'-terminal stretches are '**CUGUG**' and '**CGCAG**' (5'- and 3'-terminal stretches of Type A SDF-1 binding nucleic acid 192-A10-002) and '**GCGUG**' and '**CGCGC**' (5'- and 3'-terminal stretches of Type A SDF-1 binding nucleic acid 192-A10-008).

[0211]   However, combining the 5'-and 3'-terminal stretches of all tested Type A SDF-1 binding nucleic acids the generic formula for the 5'-terminal stretch of Type A SDF-1 binding nucleic acids is 'X_1X_2NNBV' (Type A Formula-7-5') and the generic formula for the 3'-terminal stretch of Type A SDF-1 binding nucleic acids is 'BNBNX_3X_4' (Type A Formula-7-3'), whereas

X_1 is 'R' or absent , X_2 is 'S', X_3 is 'S' and X_4 is 'Y' or absent;
or
X_1 is absent, X_2 is 'S' or absent, X_3 is 'S' or absent and X_4 is absent.

1.2 Type B SDF-1 binding nucleic acids

[0212]   As depicted in Fig. 3 all sequences of SDF-1 binding nucleic acids of Type B comprise one core nucleotide sequence which is flanked by 5'- and 3'-terminal stretches that can hybridize to each other. However, such hybridization is not necessarily given in the molecule.

[0213]   The nucleic acids were characterized on the aptamer level using direct and competitive pull-down binding assays with biotinylated human D-SDF-1 in order to rank them with respect to their binding behaviour (Example 4). Selected sequences were synthesized as Spiegelmers (Example 3) and were tested using the natural configuration of SDF-1 (L-SDF) in a cell culture *in vitro* chemotaxis assay (Example 5) and by surface plasmon resonance measurement using a Biacore 2000 instrument (Example 6).

[0214]   The sequences of the defined boxes or stretches may be different between the SDF-1 binding nucleic acids of Type B which influences the binding affinity to SDF-1. Based on binding analysis of the different SDF-1 binding nucleic acids summarized as Type B SDF-1 binding nucleic acids, the core nucleotide sequence and its nucleotide sequences as described in the following are individually and more preferably in their entirety essential for binding to SDF-1:

The core nucleotide sequence of all identified sequences of Type B SDF-1 binding nucleic acids share the sequence

GUGUGAUCUAGAUGUADWGGCUGWUCCUAGUYAGG

(Type B Formula-1).

. The Type B SDF-1 binding nucleic acids 193-G2-001, 193-C2-001 and 193-F2-001 that differ in one position of the core nucleotide sequence were analyzed in a competitive pull-down binding assay vs. the Type A SDF-1 binding nucleic acid 192-A10-001 (K_D of 1.5 nM determined in a pull-down binding assay [Fig. 11], K_D of 1.0 nM determined by surface plasmon resonance measurement [Fig. 15], IC_{50} of 0.12 nM; [Fig. 12]). Each of the three tested Type B SDF-1 binding nucleic acids showed superior binding to human SDF-1 in comparison to Type A SDF-1 binding nucleic acid 192-A10-001 whereby the binding affinity of 193-G2-001 is as good as 193-C2-001 and 193-F2-001 (Fig. 3). The data suggests that the difference in the nucleotide sequence of the core nucleotide sequence of Type B SDF-1 binding nucleic acids 193-G2-001, 193-C2-001 and 193-F2-001 has no influence on the binding affinity to SDF-1. Exemplarily the Type B SDF-1 binding nucleic acid 193-G2-001 was characterized for its binding affinity to human SDF-1. The equilibrium binding constant K_D was determined using the pull-down binding assay (K_D = 0.3 nM) and by surface plasmon resonance measurement (K_D = 0.5 nM, Fig. 17). The IC_{50} (inhibitory concentration 50%) of 0.08 nM for 193-G2-001 was measured using a cell culture *in vitro* chemotaxis assay. In contrast, the Type B SDF-1 binding nucleic acids 193-B3-002, 193-H3-002, 193-E3-002 and 193-D1-002 that differ in the sequence of the core nucleotide sequence have worse binding properties (Fig. 3). As result Type B SDF-1 binding nucleic acids with improved binding affinity to SDF-1 share a core nucleotide sequence with the sequence

$$\boxed{\text{GUGUGAUCUAGAUGUADUGGCUGAUCCUAGUCAGG}}\ \text{(Type B Formula-2).}$$

.

[0215] Four, five or six nucleotides out of the six nucleotides of the 5'-terminal stretch of Type B SDF-1 binding nucleic acids may hybridize to the respective four, five or six out of the six nucleotides of the 3'-terminal stretch of Type B SDF-1 binding nucleic acids to form a terminal helix. Although the nucleotides are variable at several positions, the different nucleotides allow the hybridization for four, five or six nucleotides out of the six nucleotides of the 5'- and 3'-terminal stretches each. The 5'-terminal and 3'-terminal stretches of Type B SDF-1 binding nucleic acids as shown in Fig. 3 can be summarized in a generic formula for the 5'-terminal stretch (Type B Formula-3-5'; 'X_1GCRWG' whereas X_1 is 'A' or absent) and of the 3'-terminal stretch (Type B Formula-3-3'; 'KRYSCX$_4$' whereas X_4 is 'U' or absent). Type B SDF-1 binding nucleic acids 193-G1-002, 193-D2-002, 193-A1-002 and 193-D3-002 have weaker binding affinities to SDF-1 although they share the identical core nucleotide sequence (Type B Formula-2) with 193-C2-001, 193-G2-001 and 193-F2-001 (Fig. 3). The unfavorable binding properties of Type B SDF-1 binding nucleic acids 193-G1-002, 193-D2-002, 193-A1-002 and 193-D3-002 may be due to the number of nucleotides and sequence of the 5'- and 3'-terminal stretches.

[0216] Truncated derivatives of the Type B SDF-1 binding nucleic acids 193-G2-001 and 193-C2-001 were analyzed in a competitive pull-down binding assay vs. 193-G2-001 and 193-G2-012, respectively (Fig. 4A and 4B). These experiments showed that a reduction of the six terminal nucleotides (5'end: **AGCGUG;** 3'end: **UACGCU**) of Type B SDF-1 binding nucleic acids 193-G2-001 and 193-C2-001 to five nucleotides (5'end: **GCGUG;** 3'end: **UACGC**) lead to molecules with similar binding affinity (193-C2-002 and 193-G2-012). The equilibrium dissociation constant K_D was determined using the pull-down binding assay (K_D = 0.3 nM, Fig. 18). A truncation to four (5'end: **CGUG;** 3'end: **UACG; 193-C2-003**) or less nucleotides (193-C2-004, 193-C2-005, 193-C2-006, 193-C2-007) resulted in a reduced binding affinity to SDF-1 which was measured by using the competition pull-down binding assay (Fig. 4A). The nucleotide sequence of the five terminal nucleotides at the 5'- and 3'-end, respectively, has an influence on the binding affinity of Type B SDF-1 binding nucleic acids. The substitution of 5'- and 3'-terminal nucleotides **'GCGUG'** and **'UACGC'** (193-C2-002, 193-G2-12) by **'GCGCG'** and **'CGCGC'** (193-G2-013) resulted in a reduced binding affinity. Additionally, the four different derivatives of Type B SDF-1 binding nucleic acid 193-G2-001 with a terminal helix with a length of four base-pairing nucleotides (193-G2-014/ -015/ -016/ -017) were tested. All of them showed reduced binding affinity to SDF-1 (Fig. 4B). Therefore the sequence and the length of the 5'- and 3'-terminal nucleotides are essential for an effective binding to SDF-1. The 5'-terminal and 3'-terminal stretches with a length of five and four nucleotides of the derivatives of Type B SDF-1 binding nucleic acids 193-C2-003 and 193-G2-012 as shown in Figs. 4A and 4B can be described in a generic formula for the 5'-terminal stretch ('X_2SSBS', Type B Formula-4-5'), whereby X_2 is either absent or is 'G', and of the 3'-terminal stretch ('BVSSX$_3$', Type B Formula-4-3'), and whereby X_3 is either absent or is 'C'. As shown for Type B SDF-1 binding nucleic acids 193-G2-001 and 193-C2-01 and their derivatives 193-G2-012 and 193-C2-002 the preferred combination of 5'- and 3'-terminal stretches are 'X_1GCGUG' (5'-terminal stretch; Type B Formula 5-5') and 'UACGCX$_4$' (3'-terminal stretch; Type B Formula 5-3'), whereas X_1 is either 'A' or absent and X_4 is 'U' or absent.

[0217] However, combining the 5'- and 3'-terminal stretches of all tested Type B SDF-1 binding nucleic acids the generic formula for the 5'-terminal stretch of Type B SDF-1 binding nucleic acids is 'X_1X_2SVNS' (Type B Formula-6-5') and the generic formula for the 3'-terminal stretch Type B SDF-1 binding nucleic acids is 'BVBSX$_3X_4$' (Type B Formula-6-3'), whereas

X_1 is 'A' or absent, X_2 is 'G', X_3 is 'C' and X_4 is 'U' or absent;
or X_1 is absent, X_2 is 'G' or absent, X_3 is 'C' or absent and X_4 is absent;

1.3 Type C SDF 1 binding nucleic acids

[0218] As depicted in Fig. 5 all sequences of SDF-1 binding nucleic acids of Type C comprise one core nucleotide sequence which is flanked by 5'- and 3'-terminal stretches that can hybridize to each other. However, such hybridization is not necessarily given in the molecule.

[0219] The nucleic acids were characterized on the aptamer level using direct and competitive pull-down binding assays with biotinylated human D-SDF-1 in order to rank them with respect to their binding behaviour (Example 4). Selected sequences were synthesized as Spiegelmers (Example 3) and were tested using the natural configuration of SDF-1 (L-SDF) in a cell culture *in vitro* chemotaxis assay (Example 5) and by surface plasmon resonance measurement using a Biacore 2000 instrument (Example 6).

[0220] The sequences of the defined boxes or stretches may be different between the SDF-1 binding nucleic acids of Type C which influences the binding affinity to SDF-1. Based on binding analysis of the different SDF-1 binding nucleic acids summarized as Type C SDF-1 binding nucleic acids, the core nucleotide sequence and its nucleotide sequence as described in the following are individually and more preferably in their entirety essential for binding to SDF-1:

The core nucleotide sequence of all identified sequences of Type C SDF-1 binding nucleic acids share the sequence

$$\boxed{\text{GGUYAGGGCUHRX}_\text{A}\text{AGUCGG}} \text{ (Type C Formula-1)}$$

, whereby X_A is either absent or is 'A'. With the exception of Type C SDF-1 binding nucleic acid 197-D1 the core nucleotide sequence of all identified sequences of Type C SDF-1 binding nucleic acids share the nucleotide sequence

$$\boxed{\text{GGUYAGGGCUHRAAGUCGG}} \text{ (Type C Formula-2)}$$

. Type C SDF-1 binding nucleic acid 197-D1 (core nucleotide sequence:

$$\boxed{\text{GGUUAGGGCUAA-AGUCGG}}$$

) missing one nucleotide 'A' within the core nucleotide sequence and still binding to SDF-1 let conclude an alternative core nucleotide sequence (

$$\boxed{\text{GGUYAGGGCUHR-AGUCGG}},$$

, Type C Formula-3). Initially, all Type C SDF-1 binding nucleic acids as depicted in Fig. 5 were analyzed in a competitive pull-down binding assay vs. Type A SDF-1 binding nucleic acid 192-A10-001 (K_D = 1.5 nM determined by pull-down assay and by surface plasmon resonance measurements; IC_{50} = 0.12 nM). The Type C SDF-1 binding nucleic acids 191-D5-001, 197-B2, 190-A3-001, 197-H1, 197-H3 and 197-E3 showed weaker binding affinities than 192-A10-001 in competition experiments. Much weaker binding affinity was determined for 191-A5, 197-B1, 197-D1, 197-H2 and 197-D2 (Fig. 5). The molecules or derivatives thereof were further characterized by further competitive pull-down binding assays, plasmon resonance measurements and an *in vitro* chemotaxis assay. The Type C SDF-1 binding nucleic acid 191-D5-001 was characterized for its binding affinity to human SDF-1 whereas the equilibrium binding constant K_D was determined by surface plasmon resonance measurement (K_D = 0.8 nM, Fig. 21). The IC_{50} (inhibitory concentration 50%) of 0.2 nM for 191-D5-001 was measured using a cell-culture *in vitro* chemotaxis assay. The binding affinity of Type C SDF-1 binding nucleic acid 197-B2 for human SDF-1 was determined by surface plasmon resonance measurement (K_D = 0.9 nM), its IC_{50} (inhibitory concentration 50%) of 0.2 nM was analyzed in a cell-culture *in vitro* chemotaxis assay. These data indicates that Type C SDF-1 binding nucleic acids 191-D5-001 and 197-B2 have the similar binding affinity to SDF-1 (Fig. 5 and 8).

[0221] Type C SDF-1 binding nucleic acid 190-A3-001 (48 nt) comprises a 5'-terminal stretch of 17 nucleotides and a 3'-terminal stretch of 12 nucleotides whereby on the one hand the four nucleotides at the 5'-end of the 5'-terminal stretch and the four nucleotides at the 3'-end of the 3'-terminal stretch may hybridize to each other to form a terminal helix. Alternatively the nucleotides **'UGAGA'** in the 5'-terminal stretch may hybridize to the nucleotides **'UCUCA'** in the 3'-terminal stretch to form a terminal helix. A reduction to eight nucleotides of the 5'-terminal stretch (**'GAGAUAGG'**) and to nine nucleotides of the 3'-terminal stretch (**'CUGAUUCUC'**) of molecule 190-A3-001 (whereby six out of the eight/nine nucleotides of the 5'- and 3'-terminal stretch can hybridize to each other) does not have an influence on the binding affinity to SDF-1 (190-A3-004; Fig. 6 and Fig. 19). The equilibrium binding constant K_D od 190-A3-004 was determined using the pull-down binding assay (K_D = 4.6 nM, Fig. 20) and by surface plasmon resonance measurement (K_D = 4.7 nM). The IC_{50} (inhibitory concentration 50%) of 0.1 nM for 190-A3-004 was measured using a cell-culture *in vitro* chemotaxis assay (Fig. 22). However, the truncation to two nucleotides at the 5'-terminal stretch leads to a very strong reduction of binding affinity (190-A3-007; Fig. 6 and Fig. 19).

[0222] The Type C SDF-1 binding nucleic acids 191-D5-001, 197-B2 and 197-H1 (core nucleotide sequence:

GGUUAGGGCUAGAAGUCGG)

), 197-H3/191-A5 (core nucleotide sequence:

GGUUAGGGCUCGAAGUCGG)

) and 197-E3/197-B1 (core nucleotide sequence:

GGUUAGGGCUUGAAGUCGG)

) share an almost identical core nucleotide sequence (Type C formula-4; nucleotide sequence:

GGUUAGGGCUHGAAGUCGG

). 191-D5-001, 197-B2 and 197-H1 do not share a similar 5'- and 3'-terminal stretch (197-H3 and 197-E3 have the identical 5'- and 3'-terminal stretch as 197-B2). However, the respective ten (197-B2, 197-E3, 197-H3) or nine out of the ten (191-D5-001, 197-H1) nucleotides of the 5'-terminal stretch may hybridize to the respective ten (197-B2, 197-E3, 197-H3) or nine out of the ten (191-D5-001, 197-H1) nucleotides of the 3'-terminal stretch (Fig. 5). Thus, the 5'-terminal stretch of Type C SDF-1 binding nucleic acids 197-B2, 191-D5-001, 197-H1, 197-E3 and 197-H3 as mentioned above plus 191-A5, 197-B1, 197-H2, 197-D1 and 197-D2 comprise a common generic nucleotide sequence of 'RKS-BUSNVGR' (Type C Formula-5-5'). The 3'-terminal stretch of Type C SDF-1 binding nucleic acids 197-B2, 191-D5-001, 197-H1, 197-E3, and 197-H3 as mentioned above plus 191-A5, 197-B1, 197-H2, 197-D1 and 197-D2 comprise a common generic nucleotide sequence of 'YYNRCASSMY' (Type C Formula-5-3'), whereby the 5' and the 3'-terminal stretches of Type C SDF-1 binding nucleic acids 197-B2, 191-D5-001, 197-H1, 197-E3 and 197-H3 are preferred. These preferred 5'-and 3'-terminal stretches of Type C SDF-1 binding nucleic acids 197-B2, 191-D5-001, 197-H1, 197-E3 and 197-H3 can be summarized in the generic formula 'RKSBUGSVGR' (Type C Formula-6-5'; 5'-terminal stretch) and 'YCNRCAS-SMY' (Type C Formula-6-3'; 3'-terminal stretch).

[0223] Truncated derivatives of Type C SDF-1 binding nucleic acid 191-D5-001 were constructed and tested in a competitive pull-down binding assay vs. the original molecule 191-D5-001 (Fig. 7A, Fig. 7B and Fig. 19). At first the length of the 5'- and 3'-terminal stretches were shortened from ten nucleotides (191-D5-001) each to seven nucleotides each (191-D5-004) as depicted in Fig. 7A whereby nine out of the ten (191-D5-001) or six out of the seven nucleotides (191-D5-004) of the 5'-terminal stretch and of the 3'-terminal stretch, respectively can hybridize to each other. The reduction to seven nucleotides of the 5'- and 3'-terminal stretch respectively (whereas six out of the seven nucleotides can hybridize to each other) led to reduced binding affinity to SDF-1 (191-D5-004). The terminal stretches of Type C SDF-1 binding nucleic acid 191-D5-004 were modified whereby the non-pairing nucleotide 'A' within the 3'-terminal stretch of 191-D5-004 was substituted by a 'C' (191-D5-005). This modification led to an improvement of binding. This

derivative, Type C SDF-1 binding nucleic acid 191-D5-005, showed similar binding to SDF-1 as 191-D5-001. Further truncation of the 5'- and 3'-terminal stretch to five nucleotides respectively led to a molecule with a length of total 29 nucleotides (191-D5-007). Because of the similarities of 191-D5-001 and of the Type C SDF-1 binding nucleic acids 197-B2, 191-D5-001, 197-H1, 191-A5, 197-H3, 197-B1, 197-E3, 197-D1, 197-H2 and 197-D2 and because of the data

5   shown for 191-D5-007 it may assume that the 5'-and 3'-terminal stretch can in principle be truncated down to five nucleotides whereby the nucleotide sequence 'CGGGA' for 5'-terminal stretch and 'UCCCG' for the 3'-terminal stretch was successfully tested (Type C SDF-1 binding nucleic acid 191-D5-007). Type C SDF-1 binding nucleic acid 191-D5-007 surprisingly binds somewhat better to SDF-1 than 191-D5-001 (determined on aptamer level using the competition binding assay). The equilibrium binding constant K_D of 191-D5-007 was determined using the pull-down binding assay

10   (K_D = 2.2 nM, Fig. 20) and by surface plasmon resonance measurement (K_D = 0.8 nM, Fig. 21). The IC_{50} (inhibitory concentration 50%) of 0.1 nM for 191-D5-007 was measured using a cell-culture *in vitro* chemotaxis assay. Further truncation of both terminal stretches to four nucleotides (191-D5-010, Fig.7A).

[0224]   Further derivatives of Type C SDF-1 binding nucleic acid 191-D5-001 (191-D5-017/ -024/ - 029) bearing 5'- and 3'-terminal stretches of respectively four nucleotides also showed reduced binding affinity to SDF-1 in the competition

15   pull-down binding assay vs. 191-D5-007 (Fig. 7B). Alternative 5'- and 3'-terminal stretches with a length of respectively five nucleotides were additionally tested, too (191-D5-017-29a, 191-D5-017-29b, 191-D5-019-29a, 191-D5-024-29a, 191-D5-024-29b). The generic formula of these derivatives for the 5'-terminal stretch is 'X$_s$SSSV' (Type C Formula-7-5') and for the 3'-stretch is 'BSSSX$_s$' Type C Formula-7-3'), whereby X$_s$ is absent or ,S'. Two out of the five tested variants showed identical binding affinity to SDF-1 as 191-D5-007 (191-D5-024-29a, 191-D5-024-29b; Fig. 7B). The sequences

20   of the 5'-terminal and 3'-terminal stretches of 191-D5-001-derivatives that show the best binding affinity to SDF-1 and comprise a 5'-terminal and 3'-terminal stretch of five nucleotides respectively (191-D5-007, 191-D5-024-29a, 191-D5-024-29b) can be summarized in a generic formula (5'-terminal stretch: 'SGGSR', Type C Formula-8-5'; 3'-terminal stretch: , YSCCS', Type C Formula-8-3').

[0225]   Truncated derivatives of Type C SDF-1 binding nucleic acid 197-B2 were analyzed in a competitive pull-down

25   binding assay vs. the original molecule 197-B2 and 191-D5-007 (Fig. 8). Using the competitive pull-down binding assay vs. 191-D5-007 it was shown that 197-B2 has the same binding affinity to SDF-1 as 191-D5-007. The 5'- and 3'-terminal stretches were shortened without loss of binding affinity from ten nucleotides (197-B2) each to five nucleotides each (197-B2-005) whereby the nucleotides of the 5'-terminal stretch and of the 3'-terminal stretch can completely hybridize to each other. If the 5'-terminal ('**GCGGG**') and 3'-terminal ('**CCUGC**') stretch of 197-B2-005 was substituted by '**GCCGG**'

30   (5'-terminal stretch) and by '**CCGGC**' (3'-terminal stretch) of 197-B2-006, the binding affinity to SDF-1 fully persisted. Because 197-B2 and 191-D5-001 (and their derivatives) share the identical core nucleotide sequence (

35

GGUUAGGGCUAGAAGUCGG

) and several derivatives of 191-D5 with 5'- and 3'-terminal stretches with a length of respectively four nucleotides were tested, a further truncation of the 5'- and 3'-terminal stretch was omitted. Two further derivatives were designed that comprise six nucleotides at the 5'- and 3'-end (5'- and 3'-terminal stretches) respectively. The binding affinity to SDF-1

40   of both molecules (197-B2-006-31a and 197-B2-006-31b) is the same as shown for 191-D5-007 and 197-B2-006 (Fig. 8). The sequences of the 5'-terminal and 3'-terminal stretches of 197-B2 derivatives that show the best binding affinity to SDF-1 and comprise a 5'-terminal and 3'-terminal stretch of five nucleotides respectively can be summarized in a generic formula (5'-terminal stretch: 'GCSGG', Type C Formula-9-5'; 3'-terminal stretch: ,CCKGC', Type C Formula-9-3').

[0226]   Combining the preferred 5'- and 3'-stretches of truncated derivatives of Type C SDF-1 binding nucleic acids

45   191-D5-001 (5'-terminal stretch: 'SGGSR', Type C Formula-8-5'; 3'-terminal stretch: ,YSCCS', Type C Formula-8-3') and 197-B2 (5'-terminal stretch: 'GCSGG', Type C Formula-9-5'; 3'-terminal stretch: ,CCKGC', Type C Formula-9-3') the common preferred generic formula for the 5'-terminal and the 3'-terminal stretch is 'SSSSR' (5'-terminal stretch, Type C Formula-10-5') and 'YSBSS' (3'-terminal stretch: Type C Formula-10-3').

50   *1.4 Further SDF-1 binding nucleic acids*

[0227]   Additionally, further three SDF-1 binding nucleic acids that do not share the SDF-1 binding motifs of 'Type A', 'Type B' and 'Type C' were identified. There were analyzed as aptamers using the pull-down binding assay (Fig. 9).

[0228]   It is to be understood that any of the sequences shown in Figs. 1 through 9 are nucleic acids according to the

55   present invention, including those truncated forms thereof but also including those extended forms thereof under the proviso, however, that the thus truncated and extended, respectively, nucleic acid molecules are still capable of binding to the target.

Example 2: 40kda-PEG and other Modification of SDF-binding Spiegelmers

[0229] In order to prolong the Spiegelmer's plasma residence time *in vivo,* the Spiegelmers 193-G2-012, 192-A10-008, 191-D5-007, 197-B2-006 and 197-B2-006-31b were covalently coupled to a 40 kDa polyethylene glycol (PEG) moiety at the 5'-end as described in chapter 3 (PEGylated-clones: 193-G2-012-5'-PEG, 192-A10-008-5'PEG, 191-DS-007-5'PEG, 197-B2-006-5'PEG and 197-B2-006-31b-5'PEG).

[0230] The PEGylated Spiegelmer molecules were analyzed in a cell culture *in vitro* TAX-assay (Chapter 5) and by plasmon resonance measurements using a Biacore (Chapter 6). All 40 kDa-PEG-modified Spiegelmers are still able to inhibit SDF-1 induced chemotaxis and to bind to SDF-1 in low nanomolar range (Fig. 23A, 23B, 24A and Fig. 24B).

[0231] Additionally, SDF-binding Spiegelmer 192-A10-001 was modified with 40kDa-PEG, 30 kDa-PEG, 100kDa-HES or 130 kDa-HES (PEGylated-clones: 192-A10-001-5'PEG40, 192-A10-001-5'PEG30, 192-A10-001-5'HES100, 192-A10-001-5'HES130; coupling procedure in chapter 3). As depicted in Fig. 25A and Fig. 25B neither a PEG-moiety or a HES-moiety has an influence on Spiegelmers potency to inhibit SDF-1 induced chemotaxis.

Example 3: Synthesis and derivatization of Aptamers and Spiegelmers

3.1 SMALL SCALE SYNTHESIS

[0232] Aptamers and Spiegelmers were produced by solid-phase synthesis with an ABI 394 synthesizer (Applied Biosystems, Foster City, CA, USA) using 2'TBDMS RNA phosphoramidite chemistry (Damha and Ogilvie, 1993). rA(N-Bz)-, rC(Ac)-, rG(N-ibu)-, and rU- phosphoramidites in the D- and L-configuration were purchased from ChemGenes, Wilmington, MA. Aptamers and Spiegelmers were purified by gel electrophoresis.

3.2 LARGE SCALE SYNTHESIS PLUS MODIFICATION

[0233] The Spiegelmers were produced by solid-phase synthesis with an ÄktaPilot100 synthesizer (Amersham Biosciences; General Electric Healthcare, Freiburg) using 2'TBDMS RNA phosphoramidite chemistry (Damha and Ogilvie, 1993). L-rA(N-Bz)-, L-rC(Ac)-, L-rG(N-ibu)-, and L-rU- phosphoramidites were purchased from ChemGenes (Wilmington, MA, USA). The 5'-amino-modifier was purchased from American International Chemicals Inc. (Framingham, MA, USA). Synthesis of the Spiegelmers was started on L-riboG; L-riboC, L-riboA, L-riboU respectively modified CPG pore size 1000 Å (Link Technology, Glasgow, UK). For coupling (15 min per cycle), 0.3 M benzylthiotetrazole (American International Chemicals Inc., Framingham, MA, USA) in acetonitrile, and 3.5 equivalents of the respective 0.2 M phosphoramidite solution in acetonitrile was used. An oxidation-capping cycle was used. Further standard solvents and reagents for oligonucleotide synthesis were purchased from Biosolve (Valkenswaard, NL). The Spiegelmers were synthesized DMT-ON; after deprotection, it was purified via preparative RP-HPLC (Wincott F. *et al.*, 1995) using Source15RPC medium (Amersham). The 5'DMT-group was removed with 80% acetic acid (90 min at RT). Subsequently, aqueous 2 M NaOAc solution was added and the Spiegelmer was desalted by tangential-flow filtration using a 5 K regenerated cellulose membrane (Millipore, Bedford, MA).

3.3 PEGYLATION

[0234] In order to prolong the Spiegelmer's plasma residence time *in vivo,* the Spiegelmers were covalently coupled to a 40 kDa polyethylene glycol (PEG) moiety at the 5'-end.

[0235] For PEGylation (for technical details of the method for PEGylation see European patent application EP 1 306 382), the purified 5'-amino modified Spiegelmerd were dissolved in a mixture of H_2O (2.5 ml), DMF (5 ml), and buffer A (5 ml; prepared by mixing citric acid • H_2O [7 g], boric acid [3.54 g], phosphoric acid [2.26 ml], and 1 M NaOH [343 ml] and adding water to a final volume of 1 l; pH = 8.4 was adjusted with 1 M HCl).

[0236] The pH of the Spiegelmer solution was brought to 8.4 with 1 M NaOH. Then, 40 kDa PEG-NHS ester (Nektar Therapeutics, Huntsville, AL) was added at 37°C every 30 min in six portions of 0.25 equivalents until a maximal yield of 75 to 85% was reached. The pH of the reaction mixture was kept at 8 - 8.5 with 1 M NaOH during addition of the PEG-NHS ester.

[0237] The reaction mixture was blended with 4 ml urea solution (8 M), , and 4 ml buffer B (0.1 M triethylammonium acetate in H_2O) and heated to 95°C for 15 min. The PEGylated Spiegelmer was then purified by RP-HPLC with Source 15RPC medium (Amersham), using an acetonitrile gradient (buffer B; buffer C: 0.1 M triethylammonium acetate in acetonitrile). Excess PEG eluted at 5% buffer C, PEGylated Spiegelmer at 10 - 15% buffer C. Product fractions with a purity of >95% (as assessed by HPLC) were combined and mixed with 40 ml 3 M NaOAC. The PEGylated Spiegelmer was desalted by tangential-flow filtration (5 K regenerated cellulose membrane, Millipore, Bedford MA).

3.4 HESylation

[0238] In order to prolong the Spiegelmer's plasma residence time *in vivo,* the Spiegelmers were covalently coupled to <u>H</u>ydroxyl <u>E</u>thyl <u>S</u>tarch (HES) of various molecular weights of >130 kDa and substitution degree >0.5. The 5'-end of the Spiegelmer is the preferred site for conjugation.

[0239] For HESylation (for technical details of the method for Hesylation of nucleic acids see German Offenlegungsschrift DE 101 12 825 A1, and for D/L-nucleic acids PCT WO 02/080979 A2), the purified 5'-amino modified Spiegelmer was dissolved in sodium bicarbonate (0.3M, 1 ml) and the pH is adjusted to 8.5.

[0240] In respect to the Spiegelmer, a 5-fold excess of the free HES acid (3.3 mmol, Supramol, Rosbach, Germany) and di(N-succinimidyl) carbonate (3.3 mmol) were added to N,N-dimethylformamide (1 ml) to yield a solution of the activated N-hydroxysuccimide ester of HES. To dissolve all reactants the mixture was stirred briefly at 60°C, cooled to 25 °C and then stirred for 1.5 h at 25 °C. The solution of Spiegelmer was added to the solution of activated HES, and the resulting mixture was stirred at 25°C and pH 8.5. The reaction was monitored by analytical IEX-HPLC. Typically the conjugation proceeded to >75 % within 1hr.

[0241] For IEX-HPLC purification via Source 15Q medium (GE, Freiburg, Germany) the reaction mixture was blended with a 10fold-quantity of buffer A (1mM EDTA, 25mM Tris, 10 mM NaClO4 in water/acetonitrile 9:1, pH 4). Excess HES elutes at 5% buffer A (1mM EDTA, 25mM Tris, 500 mM NaClO4 in water/acetonitrile 9:1, pH 4), whereas the HES-Spiegelmer conjugate elutes at 20-30% buffer B. Product fractions with a purity of >95% (as assessed by HPLC) were combined and desalted by tangential-flow filtration (5 K regenerated cellulose membrane, Millipore, Bedford MA).

Example 4: Determination of binding constants (Pull-down binding assay)

4.1 Direct pull-down binding assay

[0242] The affinity of aptamers to biotinlayted human D-SDF-1 was measured in a pull-down binding assay format at 37°C. Aptamers were 5'-phosphate labeled by T4 polynucleotide kinase (Invitrogen, Karlsruhe, Germany) using [γ-^{32}P]-labeled ATP (Hartmann Analytic, Braunschweig, Germany). The specific radioactivity of labeled aptamers was 200,000 - 800,000 cpm/pmol. Aptamers were incubated after de- and renaturation at 10, 20, 30 or 40 pM concentration at 37°C in selection buffer (20 mM Tris-HCl pH 7.4; 137 mM NaCl; 5 mM KCl; 1 mM MgCl$_2$; 1 mM CaCl$_2$; 0.1% [w/vol] Tween-20) together with varying amounts of biotinlayted human D-SDF-1 for 4 - 12 hours in order to reach equilibrium at low concentrations. Selection buffer was supplemented with 10 μg/ml human serum albumin (Sigma-Aldrich, Steinheim, Germany), and 10 μg/ml yeast RNA (Ambion, Austin, USA) in order to prevent adsorption of binding partners with surfaces of used plasticware or the immobilization matrix. The concentration range of biotinlayted human D-SDF-1 was set from 8 pM to 100 nM; total reaction volume was 1 ml. Peptide and peptide-aptamer complexes were immobilized on 1.5 μl Streptavidin Ultralink Plus particles (Pierce Biotechnology, Rockford, USA) which had been preequilibrated with selection buffer and resuspended in a total volume of 6 μl. Particles were kept in suspension for 30 min at the respective temperature in a thermomixer. Immobilized radioactivity was quantitated in a scintillation counter after detaching the supernatant and appropriate washing. The percentage of binding was plotted against the concentration of biotinlayted human D-SDF-1 and dissociation constants were obtained by using software algorithms (GRAFIT; Erithacus Software; Surrey U.K.) assuming a 1:1 stoichiometry.

4.2 Competitive pull-down binding assay

[0243] In order to compare different D-SDF-1 binding aptamers, a competitive ranking assay was performed. For this purpose the most affine aptamer available was radioactively labeled (see above) and served as reference. After de- and renaturation it was incubated at 37°C with biotinlayted human D-SDF-1 in 1 ml selection buffer at conditions that resulted in around 5 - 10 % binding to the peptide after immobilization and washing on NeutrAvidin agarose or Streptavidin Ultralink Plus (both from Pierce) without competition. An excess of de- and renatured non-labeled D-RNA aptamer variants was added to different concentrations (e.g. 2, 10, and 50 nM) with the labeled reference aptamer to parallel binding reactions. The aptamers to be tested competed with the reference aptamer for target binding, thus decreasing the binding signal in dependence of their binding characteristics. The aptamer that was found most active in this assay could then serve as a new reference for comparative analysis of further aptamer variants.

Example 5: Analysis of the inhibition of SDF-1-induced chemotaxis by SDF-1-binding Spiegelmers

[0244] Jurkat human T cell leukemia cells (obtained from DSMZ, Braunschweig) were cultivated at 37°C and 5% CO$_2$ in RPMI 1640 medium with Glutamax (Invitrogen, Karlsruhe, Germany) which contains 10% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin (Invitrogen, Karlsruhe, Germany). One day before the experiment, cells

were seeded in a new flask with a density of 0.3 x 10^6/ml (9 x 10^6/30 ml) in standard medium (Invitrogen, Karlsruhe, Germany).

[0245] For the experiment, cells were centrifuged (5min at 300g), resuspended, counted and washed once with 15 ml HBH (Hanks balanced salt solution containing 1 mg/ml bovine serum albumin and 20 mM HEPES; Invitrogen, Karlsruhe, Germany). Then the cells were resuspended at 3 x 10^6/ml or 1.33 x 10^6/ml, depending on the type of filter plate used. Cells were then allowed to migrate through the porous membranes of the filter plates for several hours towards a solution containing SDF-1 and various amounts of Spiegelmer. Either Transwell plates and inserts with porous Polycarbonate membrane, 5 μm pore size (Corning; 3421) or MultiScreen MIC plates (Millipore, MAMIC5S10) were used.

5.1 Protocol for Transwell plates

[0246] The stimulation solutions (SDF-1 + various concentrations of Spiegelmer) were made up in 600 μl HBH in the lower compartments of the Transwell plates and incubated for 20 - 30 min. All conditions were made up at least twice. The inserts were transferred to the wells containing the stimulation solutions and 100 μl of a cell suspension with 3 x 10^6/ml were added to the inserts (3 x 10^5 cells/well). The cells were then allowed to migrate for 3 h at 37°C.

[0247] Thereafter, the inserts were removed and 60 μl resazurin (Sigma, Deisenhofen, Germany) working solution (440 μM in PBS; Biochrom, Berlin, Germany) were added to the wells (also to calibration wells). The plates were then incubated at 37°C for 2.5 to 3 h. After incubation, 200μl of each well were transferred to a black 96 well plate. Measurement of the fluorescence signals was done at 544 nm (excitation) and 590 nm (emission) in a Fluostar Optima multidetection plate reader (BMG, Offenburg, Germany).

5.2 Protocol for Millipore MultiScreen plates

[0248] The stimulation solutions (SDF-1 + various concentrations of Spiegelmer) were made up as 10X solutions in a 0.2 ml low profile 96-tube plate. 135 μl HBH were pipetted into the lower compartments of the *MultiScreen* plate and 15 μl of the stimulation solutions were added. All conditions were made up as triplicates. After 20 to 30 min the filter plate was inserted into the plate containing the stimulation solutions and 75 μl of a cell suspension with 1.33 x 10^6/ml were added to the wells of the filter plate (1 x 10^5 cells/well). The cells were then allowed to migrate for 3 h at 37°C.

[0249] Thereafter, the insert plate is removed and 20 μl resazurin working solution (440 μM in PBS) are added to the lower wells. The plates were then incubated at 37°C for 2.5 to 3 h.

After incubation, 100μl of each well were transferred to a black 96 well plate. Measurement of the fluorescence signals was performed as described above.

5.3 Evaluation

[0250] For evaluation, fluorescence values were corrected for background fluorescence (no cells in well). Then the difference between experimental conditions with and without SDF-1 was calculated. The value for the sample without Spiegelmer (SDF-1 only) was set 100% and the values for the samples with Spiegelmer were calculated as per cent of this. For a dose-response curve the per cent-values were plotted against Spiegelmer concentration and the IC$_{50}$-value (concentration of Spiegelmer at which 50% of the activity without Spiegelmer is present) was determined graphically from the resulting curve.

5.4 Results

5.4.1 Dose dependent stimulation of Jurkat cells by human SDF-1

[0251] Human SDF-1 was found to stimulate migration of Jurkat cells in an dose dependent manner, with half-maximal stimulation at about 0.3 nM (Fig. 11).

5.4.2 Dose dependent inhibition of human SDF-1 induced chemotaxis by SDF-1 binding Spiegelmers

[0252] When cells were allowed to migrate towards a solution containing human SDF-1 plus increasing concentrations of SDF-1 binding Spiegelmers, dose-dependent inhibition was observed. The respective IC50s of the tested Spiegelmers are specified in Example 1. When an unspecific Control Spiegelmer was used instead of SDF-1 binding Spiegelmers, no inhibitory effect was observed up to 1 μM (Fig. 26).

5.4.3 Dose dependant inhibition of mouse SDF-1 induced chemotaxis by SDF-1 binding Spiegelmers

[0253] SDF-1 is well conserved across species: SDF-1 from mouse differs from human SDF-1α in one amino acid (isoleucin at position 18 instead of valine). Murine SDF-1 can stimulate chemotaxis of Jurkat cells (Fig. 27) and this action was found to be inhibited by Spiegelmers 192-A10-001 and 191-D5-007-5'-PEG with the same potency as in the case of human SDF-1 (Fig. 28).

Example 6: Binding Analysis by Surface Plasmon Resonance Measurement

[0254] The Biacore 2000 instrument (Biacore AB, Uppsala, Sweden) was used to analyze binding of Spiegelmers to human SDF-1α. When coupling of SDF-1α was to be achieved via amine groups, SDF-1α was dialyzed against water for 1 - 2 h (Millipore VSWP mixed cellulose esters; pore size, 0.025 μm) to remove interfering amines. CM4 sensor chips (Biacore AB, Uppsala, Sweden) were activated before protein coupling by a 35-μl injection of a 1:1 dilution of 0.4 M NHS and 0.1 M EDC at a flow of 5 μl/min. Chemokine was then injected in concentrations of 0.1 - 1.5 μg/ml at a flow of 2 μl/min until the instrument's response was in the range of 1000 - 2000 RU (relative units). Unreacted NHS esters were deactivated by injection of 35 μl ethanolamine hydrochloride solution (pH 8.5) at a flow of 5 μl/min. The sensor chip was primed twice with binding buffer and equilibrated at 10 μl/min for 1 - 2 hours until the baseline appeared stable. For all proteins, kinetic parameters and dissociation constants were evaluated by a series of Spiegelmer injections at concentrations of 1000, 500, 250, 125, 62.5, 31.25, and 0 nM in selection buffer (Tris-HCl, 20 mM; NaCl, 137 mM; KCl, 5 mM; CaCl$_2$, 1 mM; MgCl$_2$, 1 mM; Tween20, 0.1% [w/v]; pH 7.4). In all experiments, the analysis was performed at 37°C using the Kinject command defining an association time of 180 and a dissociation time of 360 seconds at a flow of 10 μl/min. Data analysis and calculation of dissociation constants (K$_D$) was done with the BIAevaluation 3.0 software (BIACORE AB, Uppsala, Sweden) using the Langmuir 1:1 stochiometric fitting algorithm.

Example 7: Inhibition of [^{125}J]-DF-1-binding to CXCR4 expressing cells by SDF-1-binding Spiegelmers

7.1 Method

[0255] A cDNA clone coding for human CXCR4-receptor (NM_003467.2) was purchased from OriGene Technologies (Rockville, MD) and cloned into the pCR3.1-vector (Invitrogen, Karlsruhe, Germany). The resulting vector was transfected into CHO-K1 cells (DSMZ, Braunschweig, Germany) using Lipofectamin 2000 (Invitrogen) and stable expressing cell lines were selected by treatment with geneticin. Expression of receptors was verified by RT-PCR.
[0256] For binding assays CXCR4-expressing cells were seeded into polylysine-coated 24-well plates at a cell density of 1 x 10^5 cells/well and cultivated overnight at 37°C and 5% CO$_2$ in CHO-Ultra medium (Cambrex, Verviers, Belgium) containing 50 units/ml penicillin, 50 μg/ml streptomycin and 0.5 mg/ml geneticin.
[0257] For the binding experiment, the medium was removed and the cells were washed once with Hanks balanced salt solution, additionally containing 20 mM HEPES, 1 mg/ml bovine serum albumin, 0.1 mg/ml bacitracin (HBB). Then the cells were incubated in 0.2 ml HBB for 1 h at room temperature together with 50 pM [^{125}J]-SDF-1 (PerkinElmer, Rodgau, Germany) and varying concentrations of Spiegelmer.
[0258] Non-specific binding was determined by adding unlabeled human SDF-1 (R & D Systems, Wiesbaden, Germany) to a final concentration of 0.5uM to several wells.
[0259] After the incubation period the supernatant was removed and the wells were washed 3 times with ice-cold HBB. Thereafter the cells were lysed with 0.1 ml 0.1 M NaOH. Lysates were transfered into szintillation vials and after addition of 4 ml Unisafe 1 Liquid Szintillation cocktail (Zinsser, Frankfurt, Germany) were counted in a Beckman LS6500 szintillation counter.
[0260] Since the values for non-specific binding (binding in the presence of high amont of unlabeled SDF-1) were somewhat higher than the values for total binding in the presence of high concentrations (500 pM) of Spiegelmer, the difference between maximal binding ("max") and binding in the presence of 500 pM Spiegelmer was used for calculation of IC$_{50}$-values.

7.2 Results

[0261] Plotting bound [^{125}J]-SDF-1 against Spiegelmer concentration revealed that binding of SDF-1 could be blocked by Spiegelmer 192-A10-001 with an IC$_{50}$ of about 60 pM (Fig. 29).

mM Glutamin. The rings were oriented such that the trimmed edges were perpendicular to the bottom of the well. The collagen was allowed to solidify by incubating the plates for at least one hour at 37°C. Thereafter 1 ml MCDB131-medium with additions (SDF-1 and Spiegelmers) was added per well. Rings were then incubated at 37°C for six to seven days. As control for sprouting the experiments were additionally done with VEGF (Vascular endothelial growth factor).

[0269] Sprouting was documented by taking pictures with a digital camera. In some cases rings were fixed by addition of 1 ml 10% paraformaldehyde and stored at 2-8°C for further documentation. Pictures were analysed with the Scion Image image processing software. After calibration with the help of a picture taken from a stage micrometer, a line was drawn in a distance of 0.33 mm from one edge of a ring. A plot histogram along this line was generated by the software, histograms were printed and peaks (representing sprouts crossing the line) were counted. This number was taken as sprouting index. 4 to 5 rings per condition were evaluated. Statistical analysis was performed with WinSTAT for Excel.

Results

[0270] It could be demonstrated that SDF-1 induces sprouting and that this effect could be blocked with human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG No blockage of SDF-1 induced sprouting was observed by the non-functional PEGylated Control Spiegelmer (Figs. 31 and 32).

Example 10: Plasma level of SDF-1 and human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG administered to rats as single intravenous bolus of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG

[0271] To test whether the human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG is functional *in vivo,* human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG was administered into rats as an intravenous bolus and the plasma level of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG and of SDF-1 were determined. As control the SDF-1 plasma levels of untreated rats were determined.

Animals, administration and sample collection

[0272] Human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG was dissolved in PBS to a final concentration of 0.5 mg/ml and sterile filtered. Male Sprague Dawley rats (weight approximately 300 g) were administered with 1.0 mg/kg human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG as single intravenous bolus. Blood samples were collected at several time points (as shown in Fig. 33) to follow the plasma clearance of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG.

Sandwich hybridisation assay for quantification of Spiegelmer

[0273] The amount of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG in the samples was quantified by a sandwich hybridisation assay. The principle of the sandwich hybridisation assay is quite similiar to a commonly used ELISA (Enzyme-linked Immunosorbent Assay): immobilization and detection of the Spiegelmer. The detection is based on the hybridisation of a biotinylated detect probe to one end of the Spiegelmer. The remaining single-stranded end of the Spiegelmer mediates immobilization of the complex upon hybridisation to an immobilized capture probe. After un-bound complexes have been removed, the detect probe hybridised to the Spiegelmer is finally detected by a streptavidin/alkaline phosphatase conjugate converting a chemiluminescence substrate. Such an sandwich hybridisation assay was also applied to detection and quantification of an RNA aptamer as described by Drolet *et al.* (Drolet et. al, 2000).

Hybridisation plate preparation

[0274] The 193-G2-012 capture probe (Seq.ID.:240) was immobilized to white DNA-BIND 96well plates (Corning Costar, Wiesbaden, Germany) at 100 nM in 0.5 M sodium phosphate, 1 mM EDTA, pH 8.5 over night at 4°C. Wells were washed twice and blocked with 0.5% w/v BSA in 0.25 M sodium phosphate, 0.5 mM EDTA, pH 8.5 for 2 h at 25°C, washed again and stored at room temperature until use. Prior to hybridisation, washed twice with wash buffer (3xSSC, 0.5% [w/v] sodium dodecyl sarcosinate, pH 7.0; in advance a 20x stock [3 M NaCl, 0,3 M Na$_3$Citrate] is prepared without sodium lauroylsarcosine and diluted accordingly).

Sample preparation

[0275] All samples were assayed in duplicates. Plasma samples were thawed on ice, vortexed and spun down briefly in a cooled tabletop centrifuge. Tissue homogenates were thawed at RT and centrifuged 5 min at maximum speed and RT. Samples were diluted with hybridisation buffer (40 nM 193-G2-012 detection probe [Seq.ID.241] in wash buffer) at

RT according to the following scheme:

1:10	10 μl sample	+ 90 μl hybridisation buffer
1:100	20 μl 1:10	+ 180 μl hybridisation buffer

[0276] All sample dilutions were assayed. Human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG standard was serial diluted to a 12-point calibration curve spanning the 0.001-40 nM range. Calibration standard was identical to that of the in-study samples.

<u>Hybridisation and detection</u>

[0277] Samples were heated for 5 min at 95°C and cooled to room temperature. Spiegelmer/detection probe complexes were annealed to immobilized capture probes for 45 min at 25°C at 500 rpm on a shaker. Unbound Spiegelmers were removed by washing twice with wash buffer and 1× TBST (20 mM Tris-Cl, 137 mM NaCl, 0.1% Tween 20, pH 7.5), respectively. Hybridized complexes were detected by streptavidin alkaline phosphatase diluted 1:5000 in 1× TBST for 1 h at 25°C at 500 rpm on a shaker. To remove unbound conjugate, wells were washed again with 1× TBST. Wells were finally filled with 100 ml CSDP substrate (Applied Biosystems, Darmstadt, Germany) and incubated for 45 min at 25°C. Chemiluminescence was measured on a FLUOstar Optima microplate reader (BMG Labtechnologies, Offenburg, Germany).

Data analysis

[0278] The following assayed sample dilutions were used for quantitative data analysis:

rat EDTA plasma   1:100

[0279] The data obtained from the vehicle group (no Spiegelmer was administered) was subtracted as background signal.

ELISA for quantification of Spiegelmer

[0280] The amount of SDF-1 present in the plasma samples was quantitated with an in vitro enzyme-linked immuno-sorbent assay which employs an antibody specific for human SDF-1α coated on a 96-well plate (Human SDF-1α ELISA kit; RayBiotech, Norcross GA, USA). The assay was performed according to the instructions of the vendor.

Results

[0281] As shown in Fig. 33 the regular plasma level of SDF-1 in untreated rats is in the low picomolar range (approximately 50 pM). By contrast the plasma level of rats that were treated with human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG looks different: Within the first eight hours after administration of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG the SDF-1 plasma level increased to approximately 700 pM. Between 12 and 72 hours the SDF-1 plasma level decreased down to approximately 50 pM again. This time course of SDF-1 plasma level can be directly correlated with the plasma level of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG. Because of renal elimination of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG, the plasma level of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG decreased from approximately 1100 nM to below 50 nM within 72 hours. However, human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG (MW appproximately 54000 Da) was not eliminated out of the body within an hour as can be seen for non-PEGylated Spiegelmers (approximately 15000 Da) or other molecules with a molecular mass below the filtration limit of the kidney like SDF-1. The endogenous SDF-1 was bound by human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG forming SDF-1- Spiegelmer-complexes whereby the elimination and/or degradation of SDF-1 was retarded what as consequence led to elevated SDF-1 plasma levels within the first eight hours. Due to proceeding elimination of human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG over the time- whereby the elimination rate is much slower than for much smaller molecules like SDF-1 - the plasma level of the complexes formed by human SDF-1 binding Spiegelmer 193-G2-012-5'-PEG and SDF-1 decreased (Fig. 33).

References

[0282] The complete bibliographic data of the documents recited herein are, if not indicated to the contrary, as follows.

Aiuti, A., I. J. Webb, et al. (1997). "The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood." J Exp Med 185(1): 111-20.

Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990), Basic local alignment search tool. J Mol Biol. 215(3):403-10.

Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25(17):3389-402.

Ambati, J., A. Anand, et al. (2003). An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med. 9: 1390-7.

Arya, S. K., C. C. Ginsberg, et al. (1999). "In vitro phenotype of SDF1 gene mutant that delays the onset of human immunodeficiency virus disease in vivo." J Hum Virol 2(3): 133-8.

Auerbach et al. (2003) Angiogenesis assays: a critical overview. Clin.Chem. 49: 32-40.

Baggiolini, M. (1998). "Chemokines and leukocyte traffic." Nature 392(6676): 565-8.

Baggiolini, M., B. Dewald, et al. (1994). "Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines." Adv Immunol 55: 97-179.

Balabanian, K., B. Lagane, et al. (2005). "WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12." Blood 105(6): 2449-57.

Balabanian, K., J. Couderc, et al. (2003). "Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus." J Immunol 170(6): 3392-400.

Balkwill, F. (2004). "Cancer and the chemokine network." Nat Rev Cancer 4(7): 540-50.

Bazan, J. F., K. B. Bacon, et al. (1997). "A new class of membrane-bound chemokine with a CX3C motif." Nature 385(6617): 640-4.

Bertolini, F., C. Dell'Agnola, et al. (2002). "CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma." Cancer Res 62(11): 3106-12.

Bleul, C. C., J. L. Schultze, et al. (1998). "B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement." J Exp Med 187(5): 753-62.

Bleul, C. C., M. Farzan, et al. (1996). "The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry." Nature 382(6594): 829-33.

Brooks, H. L., Jr., S. Caballero, Jr., et al. (2004). "Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone." Arch Ophthalmol 122(12): 1801-7.

Buckley, C. D., N. Amft, et al. (2000). "Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium." J Immunol 165(6): 3423-9.

Burger, J. A., N. Tsukada, et al. (2000). "Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1." Blood 96(8): 2655-63.

Butler, J. M., S. M. Guthrie, et al. (2005). "SDF-1 is both necessary and sufficient to promote proliferative retinopathy." J Clin Invest 115(1): 86-93.

Cabioglu, N., A. Sahin, et al. (2005). "Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow." Clin Exp Metastasis 22(1): 39-46.

Corcione, A., L. Ottonello, et al. (2000). "Stromal cell-derived factor-1 as a chemoattractant for follicular center lymphoma B cells." J Natl Cancer Inst 92(8): 628-35.

Crump, M. P., J. H. Gong, et al. (1997). "Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1." Embo J 16(23): 6996-7007.

D'Apuzzo, M., A. Rolink, et al. (1997). "The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4." Eur J Immunol 27(7): 1788-93.

De Klerck, B., L. Geboes, et al. (2005). "Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis." Arthritis Res Ther 7(6): R1208-20.

Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf JL, Gill SC, Bendele RA (2000). Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 17:1503

Eaton, B. E., L. Gold, et al. (1997). "Post-SELEX combinatorial optimization of aptamers." Bioorg Med Chem 5(6): 1087-96.

Fedyk, E. R., D. Jones, et al. (2001). "Expression of stromal-derived factor-1 is decreased by IL-1 and TNF and in dermal wound healing." J Immunol 166(9): 5749-54.

Fong, D. S., L. P. Aiello, et al. (2004). "Diabetic retinopathy." Diabetes Care 27(10): 2540-53.

Geminder, H., O. Sagi-Assif, et al. (2001). "A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma." J Immunol 167(8): 4747-57.

Godessart, N. (2005). "Chemokine receptors: attractive targets for drug discovery." Ann N Y Acad Sci 1051: 647-57.

Grassi, F., S. Cristino, et al. (2004). "CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients." J Cell Physiol 199(2): 244-51.

Grunewald, M., I. Avraham, et al. (2006). "VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells." Cell 124(1): 175-89.

Guleng, B., K. Tateishi, et al. (2005). "Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner." Cancer Res 65(13): 5864-71.

Gulino, A. V., D. Moratto, et al. (2004). "Altered leukocyte response to CXCL12 in patients with warts hypogamma-globulinemia, infections, myelokathexis (WHIM) syndrome." Blood 104(2): 444-52.

Hartmann, T. N., M. Burger, et al. (2004). "The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer." J Biol Regul Homeost Agents 18(2): 126-30.

Hwang, J. H., H. K. Chung, et al. (2003). "CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells." J Clin Endocrinol Metab 88(1): 408-16.

Jiang, W., P. Zhou, et al. (1994). "Molecular cloning of TPAR1, a gene whose expression is repressed by the tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA)." Exp Cell Res 215(2): 284-93.

Jose, P. J., D. A. Griffiths-Johnson, et al. (1994). "Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation." J Exp Med 179(3): 881-7.

Juarez, J. and L. Bendall (2004). "SDF-1 and CXCR4 in normal and malignant hematopoiesis." Histol Histopathol 19(1): 299-309.

Kanbe, K., K. Takagishi, et al. (2002). "Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4." Arthritis Rheum 46(1): 130-7.

Kang, H., G. Watkins, et al. (2005). "Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer." Breast Cancer Res 7(4): R402-10.

Kawai, T., U. Choi, et al. (2005). "Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome." Exp Hematol 33(4): 460-8.

Koshiba, T., R. Hosotani, et al. (2000). "Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression." Clin Cancer Res 6(9): 3530-5.

Krumbholz, M., D. Theil, et al. (2006). "Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment." Brain 129: 200-211.

Kryczek, I., A. Lange, et al. (2005). "CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers." Cancer Res 65(2): 465-72.

Kucia, M., R. Reca, et al. (2005). "Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis." Stem Cells 23(7): 879-94.

Kusser, W. (2000). "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution." J Biotechnol 74(1): 27-38.

Lapteva, N., A. G. Yang, et al. (2005). "CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo." Cancer Gene Ther 12(1): 84-9.

M.J. Damha, K.K. Ogilvie, Methods in Molecular Biology, Vol. 20 Protocols for oligonucleotides and analogs, ed. S. Agrawal, p. 81-114, Humana Press Inc. 1993

Ma, Q., D. Jones, et al. (1998). "Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice." Proc Natl Acad Sci U S A 95(16): 9448-53.

Marechal, V., F. Arenzana-Seisdedos, et al. (1999). "Opposite effects of SDF-1 on human immunodeficiency virus type 1 replication." J Virol 73(5): 3608-15.

Matthys, P., S. Hatse, et al. (2001). "AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice." J Immunol 167(8): 4686-92.

McGinnis S, Madden TL (2004). BLAST: at the core of a powerful and diverse set of sequence analysis tools. Nucleic Acids Res. 32(Web Server issue):W20-5.

Meleth, A. D., E. Agron, et al. (2005). "Serum inflammatory markers in diabetic retinopathy." Invest Ophthalmol Vis Sci 46(11): 4295-301.

Menu, E., K. Asosingh, et al. (2006). "The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model." Haematologica.

Miller, M. D. and M. S. Krangel (1992). "Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines." Crit Rev Immunol 12(1-2): 17-46.

Moser, B., M. Wolf, et al. (2004). "Chemokines: multiple levels of leukocyte migration control." Trends Immunol 25(2): 75-84.

Muller, A., B. Homey, et al. (2001). "Involvement of chemokine receptors in breast cancer metastasis." Nature 410(6824): 50-6.

Murdoch, C. (2000). "CXCR4: chemokine receptor extraordinaire." Immunol Rev 177: 175-84.

Murphy, P. M., M. Baggiolini, et al. (2000). "International union of pharmacology. XXII. Nomenclature for chemokine receptors." Pharmacol Rev 52(1): 145-76.

Nagasawa, T., H. Kikutani, et al. (1994). "Molecular cloning and structure of a pre-B-cell growth-stimulating factor." Proc Natl Acad Sci U S A 91(6): 2305-9.

Nagasawa, T., S. Hirota, et al. (1996). "Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1." Nature 382(6592): 635-8.

Needleman & Wunsch (1970), A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol. 48(3):443-53.

Oppenheim, J. J., C. O. Zachariae, et al. (1991). "Properties of the novel proinflammatory supergene "intercrine" cytokine family." Annu Rev Immunol 9: 617-48.

Orimo, A., P. B. Gupta, et al. (2005). "Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion." Cell 121(3): 335-48.

Pearson & Lipman (1988), Improved tools for biological sequence comparison. Proc. Nat'l. Acad. Sci. USA 85: 2444

Perissinotto, E., G. Cavalloni, et al. (2005). "Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression." Clin Cancer Res 11(2 Pt 1): 490-7.

Phillips, R. J., M. D. Burdick, et al. (2003). "The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases." Am J Respir Crit Care Med 167(12): 1676-86.

Ponath, P. D., S. Qin, et al. (1996). "Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils." J Clin Invest 97(3): 604-12.

Rubin, J. B., A. L. Kung, et al. (2003). "A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors." Proc Natl Acad Sci USA 100(23): 13513-8.

Salcedo et al. (1999) Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells. In vivo neovascularization induced by stromal-derived factor-1a. Am.J.Pathol. 154:1125-1135.

Salcedo, R. and J. J. Oppenheim (2003). "Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses." Microcirculation 10(3-4): 359-70.

Salcedo, R., K. Wasserman, et al. (1999). "Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha." Am J Pathol 154(4): 1125-35.

Salvucci, O., L. Yao, et al. (2002). "Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1." Blood 99(8): 2703-11.

Saur, D., B. Seidler, et al. (2005). "CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer." Gastroenterology 129(4): 1237-50.

Schall, T. J. and K. B. Bacon (1994). "Chemokines, leukocyte trafficking, and inflammation." Curr Opin Immunol 6(6): 865-73.

Scotton, C. J., J. L. Wilson, et al. (2002). "Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer." Cancer Res 62(20): 5930-8.

Sengupta, N., S. Caballero, et al. (2005). "Preventing stem cell incorporation into choroidal neovascularization by targeting homing and attachment factors." Invest Ophthalmol Vis Sci 46(1): 343-8.

Shirozu, M., T. Nakano, et al. (1995). "Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene." Genomics 28(3): 495-500.

Smith & Waterman (1981), Adv. Appl. Math. 2: 482

Soriano, A., C. Martinez, et al. (2002). "Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression." J Infect Dis 186(7): 922-31.

Springer, T. A. (1995). "Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration." Annu Rev Physiol 57: 827-72.

Sun, Y. X., A. Schneider, et al. (2005). "Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo." J Bone Miner Res 20(2): 318-29.

Takenaga, M., H. Tamamura, et al. (2004). "A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma." Biochem Biophys Res Commun 320(1): 226-32.

Tamamura, H., M. Fujisawa, et al. (2004). "Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent." FEBS Lett 569(1-3): 99-104.

Tashiro, K., H. Tada, et al. (1993). "Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins." Science 261(5121): 600-3.

Venkatesan, N., S. J. Kim, et al. (2003). "Novel phosphoramidite building blocks in synthesis and applications toward modified oligonucleotides." Curr Med Chem 10(19): 1973-91.

Wang, J., E. Guan, et al. (2001). "Role of tyrosine phosphorylation in ligand-independent sequestration of CXCR4 in human primary monocytes-macrophages." J Biol Chem 276(52): 49236-43.

Wang, N., Q. L. Wu, et al. (2005). "Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma: pattern of expression and correlation with clinical outcome." J Transl Med 3: 26.

Wincott F, DiRenzo A, Shaffer C, Grimm S, Tracz D, Workman C, Sweedler D, Gonzalez C, Scaringe S, Usman N (1995). Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res. 23(14):2677-84

Yamaguchi, J., K. F. Kusano, et al. (2003). "Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization." Circulation 107(9): 1322-8.

Yasumoto, K., K. Koizumi, et al. (2006). "Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer." Cancer Res 66(4): 2181-7.

Zeelenberg, I. S., L. Ruuls-Van Stalle, et al. (2001). "Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a T cell hybridoma." J Clin Invest 108(2): 269-77.

Zeelenberg, I. S., L. Ruuls-Van Stalle, et al. (2003). "The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases." Cancer Res 63(13): 3833-9.

Zhou, Y., P. H. Larsen, et al. (2002). "CXCR4 is a major chemokine receptor on glioma cells and mediates their survival." J Biol Chem 277(51): 49481-7.

Zou, Y. R., A. H. Kottmann, et al. (1998). "Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development." Nature 393(6685): 595-9.

SEQUENCE LISTING

[0283]

5   <110> NOXXON Pharma AG

       <120> SDF-1 binding nucleic acids

       <130> N10052 PCT
10
       <160> 241

       <170> PatentIn version 3.1

15   <210> 1
       <211> 68
       <212> PRT
       <213> Homo sapiens

20   <400> 1

            Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
            1   5   10   15

25
            His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
                        20   25   30

30
            Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
                    35   40   45

            Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
                50   55   60
35

            Ala Leu Asn Lys
            65

40   <210> 2
       <211> 72
       <212> PRT
       <213> Homo sapiens

45   <400> 2

50

55

59

```
        Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
        1               5               10              15

        His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
                    20              25              30

        Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
            35              40                  45

        Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
            50              55              60

        Ala Leu Asn Lys Arg Phe Lys Met


                            65              70
```

```
<210> 3
<211> 68
<212> PRT
<213> Mus musculus

<400> 3
```

```
        Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
        1               5               10              15

        His Ile Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
                    20              25              30

        Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
            35              40                  45

        Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
            50              55              60

        Ala Leu Asn Lys
        65
```

```
<210> 4
<211> 71
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)..(71)
<223> D-peptide

<220>
<221> misc_feature
```

EP 2 041 282 B1

<222> (71)..(71)
<223> biotinylated

<400> 4

Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
1   5   10   15

His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
            20   25   30

Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
        35   40   45

Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
    50   55   60

Ala Leu Asn Lys Arg Phe Lys
65   70

<210> 5
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

<400> 5
gcugugaaag caacauguca augaaaggua gccgcagc   38

<210> 6
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

<400> 6
gcugugaaag uaacauguca augaaaggua accacagc   38

<210> 7
<211> 38
<212> RNA

<213> Artificial sequence

<220>
<223> synthetic

5

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

10

<400> 7
gcgugaaag uaacacguca augaaaggua accgcagc   38

<210> 8
15   <211> 38
<212> RNA
<213> Artificial sequence

<220>
20   <223> synthetic

<220>
<221> L-RNA
<222> (1)..(38)
25   <223>

<220>
<221> misc_feature
<222> (1)..(38)
30   <223> L-RNA

<400> 8
gcgugaaag uaacacguca augaaaggua accacagc   38

35   <210> 9
<211> 38
<212> RNA
<213> Artificial sequence

40   <220>
<223> synthetic

<220>
<221> L-RNA
45   <222> (1)..(38)
<223>

<220>
<221> misc_feature
50   <222> (1)..(38)
<223> L-RNA

<400> 9
gcguaaaag uaacauguca augaaaggua acuacagc   38

55

<210> 10
<211> 38
<212> RNA

<213> Artificial

<220>
<221> L-RNA
<222> (1)..(38)
<223>

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

<400> 10
gcguaaaag uaacaaguca augaaaggua acuacagc   38

<210> 11
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> L-RNA
<222> (1)..(38)
<223>

<400> 11
gcugugaaag uaacaaguca augaaaggua accacagc   38

<210> 12
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

<400> 12
gcagugaaag uaacauguca augaaaggua accacagc   38

<210> 13
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> L-RNA
<222> (1)..(38)

<223>

<400> 13
gcugugaaag uaacauguca augaaaggua accacugc   38

<210> 14
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

<400> 14
gcuaugaaag uaacauguca augaaaggua accauagc   38

<210> 15
<211> 38
<212> RNA
<213> Artificial Sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

<400> 15
gcugcgaaag cgacauguca augaaaggua gccgcagc   38

<210> 16
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> L-RNA
<222> (1)..(38)
<223>

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

<400> 16
gcugugaaag caacauguca augaaaggua gccacagc   38

<210> 17
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

<400> 17
gcugugaaag uaacauguca augaaaggua gccgcagc   38

<210> 18
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

<400> 18
agcgugaaag uaacacguaa aaugaaaggu aaccacgcu   39

<210> 19
<211> 27
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(27)
<223> L-RNA

<220>
<221> misc_feature
<222> (16)..(16)
<223> A or absent

<400> 19
aaagyracah gumaaaugaa agguarc   27

<210> 20
<211> 26
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(26)
<223> L-RNA

<400> 20
aaagyracah gumaaugaaa gguarc   26

<210> 21
<211> 27
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(27)
<223> L-RNA

<400> 21
aaagyracah gumaaaugaa agguarc   27

<210> 22
<211> 26
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(26)
<223> L-RNA

<400> 22
aaagyaacah gucaaugaaa gguarc   26

<210> 23
<211> 6
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(6)
<223> L-RNA

<400> 23
rshryr   6

<210> 24
<211> 6
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(6)
<223> L-RNA

<400> 24
yrydsy   6

<210> 25
<211> 36
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(36)
<223> L-RNA

<400> 25
cugugaaagc aacaugucaa ugaaagguag ccgcag   36

<210> 26
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(34)
<223> L-RNA

<400> 26
ugugaaagca acaugucaau gaaagguagc cgca   34

<210> 27
<211> 32
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature

<222> (1)..(32)
<223> L-RNA

<400> 27
gugaaagcaa caugucaaug aaagguagcc gc   32

<210> 28
<211> 30
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1). (30)
<223> L-RNA

<400> 28
ugaaagcaac augucaauga aagguagccg   30

<210> 29
<211> 28
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> L-RNA
<222> (1)..(28)
<223>

<400> 29
gaaagcaaca ugucaaugaa agguagcc   28

<210> 30
<211> 26
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(26)
<223> L-RNA

<400> 30
aaagcaacau gucaaugaaa gguagc   26

<210> 31
<211> 36
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(36)
<223> L-RNA

<400> 31
gcgugaaagc aacaugucaa ugaaagguag ccgcgc   36

<210> 32
<211> 36
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(36)
<223> L-RNA

<400> 32
gcgcgaaagc aacaugucaa ugaaagguag ccgcgc   36

<210> 33
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(34)
<223> L-RNA

<400> 33
gcggaaagca acaugucaau gaaagguagc ccgc   34

<210> 34
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(34)
<223> L-RNA

<400> 34
cgugaaagca acaugucaau gaaagguagc cgcg   34

<210> 35
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(34)
<223> L-RNA

<400> 35
gcgcaaagca acaugucaau gaaagguagc gugc   34

<210> 36
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(34)
<223> L-RNA

<400> 36
gugcaaagca acaugucaau gaaagguagc gcgc   34

<210> 37
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(34)
<223> L-RNA

<400> 37
cgcgaaagca acaugucaau gaaagguagc cgug   34

<210> 38
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature

<222> (1)..(34)
<223> L-RNA

<400> 38
gggcaaagca acaugucaau gaaagguagc gccc   34

<210> 39
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(34)
<223> L-RNA

<400> 39
ggccaaagca acaugucaau gaaagguagc ggcc   34

<210> 40
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(34)
<223> L-RNA

<400> 40
gcccaaagca acaugucaau gaaagguagc gggc   34

<210> 41
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(34)
<223> L-RNA

<400> 41
ccccaaagca acaugucaau gaaagguagc gggg   34

<210> 42
<211> 5
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
5   <221> misc_feature
<222> (1)..(5)
<223> L-RNA

<220>
10   <221> misc_feature
<222> (1)..(1)
<223> s or absent

<400> 42
15   sbbbs 5

<210> 43
<211> 5
<212> RNA
20   <213> Artificial sequence

<220>
<223> synthetic

25   <220>
<221> misc_feature
<222> (1)..(5)
<223> L-RNA

30   <220>
<221> misc_feature
<222> (5)..(5)
<223> s or absent

35   <400> 43
sbbvs   5

<210> 44
<211> 6
40   <212> RNA
<213> Artificial sequence

<220>
<223> synthetic
45
<220>
<221> misc_feature
<222> (3)..(3)
<223> nucleotide = a, g, c or u
50
<220>
<221> misc_feature
<222> (4)..(4)
<223> nucleotide = a, g, c or u
55
<220>
<221> misc_feature
<222> (1)..(6)

<223> L-RNA

<220>
<221> misc_feature
<222> (1)..(1)
<223> R or absent

<220>
<221> misc_feature
<222> (2)..(2)
<223> s or absent

<400> 44
rsnnbv   6

<210> 45
<211> 6
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(6)
<223> L-RNA

<220>
<221> misc_feature
<222> (2)..(2)
<223> nucleotide = a, g, c or u

<220>
<221> misc_feature
<222> (4)..(4)
<223> nucleotide = a, g, c or u

<220>
<221> misc_feature
<222> (5)..(5)
<223> R or absent

<220>
<221> misc_feature
<222> (6)..(6)
<223> y or absent

<400> 45
bnbnry 6

<210> 46
<211> 47
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(47)
<223> L-RNA

5

<400> 46
agcguggugu gaucuagaug uaguggcuga uccuagucag guacgcu   47

<210> 47
10   <211> 47
<212> RNA
<213> Artificial sequence

<220>
15   <223> synthetic

<220>
<221> misc_feature
<222> (1)..(47)
20   <223> L-RNA

<400> 47
agcguggugu gaucuagaug uauuggcuga uccuagucag guacgcu   47

25   <210> 48
<211> 47
<212> RNA
<213> Artificial sequence

30   <220>
<223> synthetic

<220>
<221> misc_feature
35   <222> (1)..(47)
<223> L-RNA

<400> 48
agcguggugu gaucuagaug uaauggcuga uccuagucag gugcgcu   47
40
<210> 49
<211> 45
<212> RNA
<213> Artificial sequence
45
<220>
<223> synthetic

<220>
50   <221> misc_feature
<222> (1)..(45)
<223> L-RNA

<400> 49
55   gcgaggugug aucuagaugu aguggcugau ccuagucagg ugcgc   45

<210> 50
<211> 45

<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(45)
<223> L-RNA

<400> 50
gcguggugug aucuagaugu aguggcugau ccuagucagg ugcgc   45

<210> 51
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(45)
<223> L-RNA

<400> 51
gcauggugug aucuagaugu aguggcugau ccuagucagg ugccc   45

<210> 52
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(45)
<223> L-RNA

<400> 52
gcguggugug aucuagaugu aauggcugau ccuagucagg gacgc   45

<210> 53
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(45)
<223> L-RNA

<400> 53
gcguggugug aucuagaugu agaggcugau ccuagucagg uacgc   45

5

<210> 54
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

10

<220>
<221> misc_feature
<222> (1)..(45)
<223> L-RNA

15

<400> 54
gcguggugug aucuagaugu aaaggcugau ccuagucagg uacgc   45

20

<210> 55
<211> 45
<212> RNA
<213> Artificial sequence

25

<220>
<223> synthetic

<220>
<221> L-RNA
<222> (11..(45)
<223>

30

<220>
<221> misc_feature
<222> (1)..(45)
<223> L-RNA

35

<400> 55
gcguggugug aucuagaugu aguggcuguu ccuagucagg uaugc   45

40

<210> 56
<211> 45
<212> RNA
<213> Artificial sequence

45

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(45)
<223> L-RNA

50

<400> 56
gcguggugug aucuagaugu aguggcugau ccuaguuagg uacgc   45

55

<210> 57
<211> 35

<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(35)
<223> L-RNA

<400> 57
gugugaucua gauguadwgg cugwuccuag uyagg   35

<210> 58
<211> 35
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(35)
<223> L-RNA

<400> 58
gugugaucua gauguadugg cugauccuag ucagg   35

<210> 59
<211> 6
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(6)
<223> L-RNA

<220>
<221> misc_feature
<222> (1)..(1)
<223> A or absent

<400> 59
agcrwg 6

<210> 60
<211> 6
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(6)
<223> L-RNA

<220>
<221> misc_feature
<222> (6)..(6)
<223> U or absent

<400> 60
kryscu   6

<210> 61
<211> 45
<212> RNA
<213> Artificial Sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(45)
<223> L-RNA

<400> 61
gcguggugug aucuagaugu aguggcugau ccuagucagg uacgc   45

<210> 62
<211> 43
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(43)
<223> L-RNA

<400> 62
cgugguguga ucuagaugua guggcugauc cuagucaggu acg   43

<210> 63
<211> 41
<212> RNA
<213> Artificial Sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(41)
<223> L-RNA

<400> 63
guggugugau cuagauguag uggcugaucc uagucaggua c   41

<210> 64
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> L-RNA
<222> (1)..(39)
<223>

<220>
<221> misc_feature
<222> (1)..(39)
<223> L-RNA

<400> 64
uggugugauc uagauguagu ggcugauccu agucaggua   39

<210> 65
<211> 37
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(37)
<223> L-RNA

<400> 65
ggugugaucu agauguagug gcugauccua gucaggu   37

<210> 66
<211> 35
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(35)
<223> L-RNA

<400> 66
gugugaucua gauguagugg cugauccuag ucagg   35

<210> 67
<211> 45

<212> RNA
<213> Artificial sequence

<220>
5   <223> synthetic

<220>
<221> misc_feature
<222> (1)..(45)
10   <223> L-RNA

<400> 67
gcguggugug aucuagaugu auuggcugau ccuagucagg uacgc   45

15   <210> 68
<211> 45
<212> RNA
<213> Artificial sequence

20   <220>
<223> synthetic

<220>
<221> misc_feature
25   <222> (1)..(45)
<223> L-RNA

<400> 68
gcgcggugug aucuagaugu auuggcugau ccuagucagg cgcgc   45
30
<210> 69
<211> 43
<212> RNA
<213> Artificial sequence
35
<220>
<223> synthetic

<220>
40   <221> misc_feature
<222> (1)..(43)
<223> L-RNA

<400> 69
45   gcgcguguga ucuagaugua uuggcugauc cuagucaggg cgc   43

<210> 70
<211> 43
<212> RNA
50   <213> Artificial sequence

<220>
<223> synthetic

55   <220>
<221> misc_feature
<222> (1)..(43)
<223> L-RNA

<400> 70
gggcguguga ucuagaugua uuggcugauc cuagucaggg ccc   43

<210> 71
<211> 43
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(43)
<223> L-RNA

<400> 71
ggccguguga ucuagaugua uuggcugauc cuagucaggg gcc   43

<210> 72
<211> 43
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(43)
<223> L-RNA

<400> 72
gcccguguga ucuagaugua uuggcugauc cuagucaggg ggc   43

<210> 73
<211> 5
<212> RNA
<213> Artificial Sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(5)
<223> L-RNA

<220>
<221> misc_feature
<222> (1)..(1)
<223> G or absent

<400> 73
gssbs 5

<210> 74
<211> 5

<212> RNA
<213> Artificial sequence

5

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(5)

10

<223> L-RNA

<220>
<221> misc_feature
<222> (5)..(5)

15

<223> C or absent

<400> 74
bvssc 5

20

<210> 75
<211> 6
<212> RNA
<213> Artificial sequence

25

<220>
<223> synthetic

<220>
<221> misc_feature

30

<222> (1)..(6)
<223> L-RNA

<220>
<221> misc_feature

35

<222> (1)..(1)
<223> A or absent

<400> 75
agcgug   6

40

<210> 76
<211> 6
<212> RNA
<213> Artificial sequence

45

<220>
<223> synthetic

<220>

50

<221> misc_feature
<222> (1)..(6)
<223> L-RNA

<220>

55

<221> misc_feature
<222> (6)..(6)
<223> U or absent

<400> 76
uacgcu   6

<210> 77
<211> 6
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(6)
<223> L-RNA

<220>
<221> misc_feature
<222> (1)..(1)
<223> A or absent

<220>
<221> misc_feature
<222> (2)..(2)
<223> G or absent

<220>
<221> misc_feature
<222> (5)..(5)
<223> nucleotide = a, g, c or u

<400> 77
agsvns   6

<210> 78
<211> 6
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(6)
<223> L-RNA

<220>
<221> misc_feature
<222> (5)..(5)
<223> C or absent

<220>
<221> misc_feature
<222> (6)..(6)
<223> U or absent

<400> 78

bvbscu   6

```
<210> 79
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(39)
<223> L-RNA

<400> 79
gugcugcggg gguuagggcu agaagucggc cugcagcac        39

<210> 80
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(39)
<223> L-RNA

<400> 80
agcguggcga gguuagggcu agaagucggu cgacacgcu        39

<210> 81
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(39)
<223> L-RNA

<400> 81
guguugcgga gguuagggcu agaagucggu cagcagcac        39

<210> 82
<211> 48
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic
```

<220>
<221> L-RNA
<222> (1)..(48)
<223>

<400> 82
cgugcgcuug agauaggggu uagggcuuaa agucggcuga uucucacg   48

<210> 83
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(39)
<223> L-RNA

<400> 83
agcgugaagg gguuagggcu cgaagucggc ugacacgcu   39

<210> 84
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> L-RNA
<222> (1)..(39)
<223>

<400> 84
gugcugcggg gguuagggcu cgaagucggc ccgcagcac   39

<210> 85
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(39)
<223> L-RNA

<400> 85
guguucccgg gguuagggcu ugaagucggc cggcagcac   39

<210> 86
<211> 39

<212> RNA
<213> Artificial sequence

<220>
5 <223> synthetic

<220>
<221> misc_feature
<222> (1)..(39)
10 <223> L-RNA

<400> 86
guguugcagg gguuagggcu ugaagucggc cugcagcac   39

15 <210> 87
<211> 39
<212> RNA
<213> Artificial sequence

20 <220>
<223> synthetic

<220>
<221> misc_feature
25 <222> (1)..(39)
<223> L-RNA

<400> 87
gugcugcggg gguuagggcu caaagucggc cugcagcac   39
30
<210> 88
<211> 38
<212> RNA
<213> Artificial sequence
35
<220>
<223> synthetic

<220>
40 <221> misc_feature
<222> (1)..(38)
<223> L-RNA

<400> 88
45 gugcugccgg gguuagggcu aaagucggcc gacagcac   38

<210> 89
<211> 39
<212> RNA
50 <213> Artificial sequence

<220>
<223> synthetic

55 <220>
<221> misc_feature
<222> (1)..(39)
<223> L-RNA

<400> 89
gugcuguggg ggucagggcu agaagucggc cugcagcac 39

<210> 90
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(19)
<223> L-RNA

<220>
<221> misc_feature
<222> (13)..(13)
<223> A or absent

<220>
<221> misc_feature
<222> (13)..(13)
<223> A or absent

<400> 90
gguyagggcu hraagucgg 19

<210> 91
<211> 19
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(19)
<223> L-RNA

<400> 91
gguyagggcu hraagucgg 19

<210> 92
<211> 18
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(18)
<223> L-RNA

<400> 92
gguyagggcu hragucgg   18

<210> 93
<211> 19
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(19)
<223> L-RNA

<400> 93
gguuagggcu hgaagucgg   19

<210> 94
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

<400> 94
ugagauaggg guuagggcuu aaagucggcu gauucuca   38

<210> 95
<211> 36
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(36)
<223> L-RNA

<400> 95
gagauagggg uuagggcuua aagucggcug auucuc   36

<210> 96
<211> 29
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(29)
<223> L-RNA

5

<400> 96
gggguuaggg cuuaaagucg gcugauucu   29

<210> 97
10   <211> 37
<212> RNA
<213> Artificial sequence

<220>
15   <223> synthetic

<220>
<221> misc_feature
<222> (1)..(37)
20   <223> L-RNA

<400> 97
gcguggcgag guuagggcua gaagucgguc gacacgc   37

25   <210> 98
<211> 35
<212> RNA
<213> Artificial sequence

30   <220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(35)
35   <223> L-RNA

<400> 98
cguggcgagg uuagggcuag aagucggucg acacg   35
40

<210> 99
<211> 33
<212> RNA
<213> Artificial sequence
45

<220>
<223> synthetic

<220>
50   <221> misc_feature
<222> (1)..(33)
<223> L-RNA

<400> 99
55   cgggcgaggu uagggcuaga agucggucga ccg   33

<210> 100
<211> 32

89

<212> RNA
<213> artificial sequence

<220>
5   <223> synthetic

<220>
<221> misc_feature
<222> (1)..(32)
10   <223> L-RNA

<400> 100
gggcgagguu agggcuagaa gucggucgcc cg   32

15   <210> 101
<211> 31
<212> RNA
<213> Artificial sequence

20   <220>
<223> synthetic

<220>
<221> misc_feature
25   <222> (1)..(31)
<223> L-RNA

<400> 101
cggcgagguu agggcuagaa gucggucgcc g   31
30
<210> 102
<211> 29
<212> RNA
<213> Artificial sequence
35
<220>
<223> synthetic

<220>
40   <221> misc_feature
<222> (1)..(29)
<223> L-RNA

<400> 102
45   cgggagguua gggcuagaag ucgguccg   29

<210> 103
<211> 27
<212> RNA
50   <213> Artificial sequence

<220>
<223> synthetic

55   <220>
<221> misc_feature
<222> (1).. (27)
<223> L-RNA

<400> 103
gggagguuag ggcuagaagu cgguccc   27

<210> 104
<211> 27
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(27)
<223> L-RNA

<400> 104
ccgcgguuag ggcuagaagu cgggcgg   27

<210> 105
<211> 27
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(27)
<223> L-RNA

<400> 105
cccggguuag ggcuagaagu cggcggg   27

<210> 106
<211> 27
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(27)
<223> L-RNA

<400> 106
ggcggguuag ggcuagaagu cggcgcc   27

<210> 107
<211> 29
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

5

<220>
<221> misc_feature
<222> (1)..(29)
<223> L-RNA

<400> 107
cccgcgguua gggcuagaag ucgggcggg   29

10

<210> 108
<211> 29
<212> RNA
<213> Artificial sequence

15

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(29)
<223> L-RNA

20

<400> 108
gccgcgguua gggcuagaag ucgggcggc   29

25

<210> 109
<211> 29
<212> RNA
<213> Artificial sequence

30

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(29)
<223> L-RNA

35

<400> 109
ccccggguua gggcuagaag ucggcgggg   29

40

<210> 110
<211> 29
<212> RNA
<213> Artificial sequence

45

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(29)
<223> L-RNA

50

<400> 110
cggcggguua gggcuagaag ucggcgccg   29

55

<210> 111
<211> 29

<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(29)
<223> L-RNA

<400> 111
gggcggguua gggcuagaag ucggcgccc   29

<210> 112
<211> 37
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(37)
<223> L-RNA

<400> 112
ugcugcgggg guuagggcua gaagucggcc ugcagca   37

<210> 113
<211> 35
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(35)
<223> L-RNA

<400> 113
gcugcggggg uuagggcuag aagucggccu gcagc   35

<210> 114
<211> 33
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(33)
<223> L-RNA

<400> 114
cugcgggggu uagggcuaga agucggccug cag   33

5

<210> 115
<211> 31
<212> RNA
<213> Artificial sequence

<220>
10   <223> synthetic

<220>
<221> misc_feature
<222> (1)..(31)
15   <223> L-RNA

<400> 115
ugcgggggguu agggcuagaa gucggccugc a   31

20   <210> 116
<211> 29
<212> RNA
<213> Artificial sequence

25   <220>
<223> synthetic

<220>
<221> L-RNA
<222> (1)..(29)
30   <223>

<400> 116
gcgggggguua gggcuagaag ucggccugc   29

35

<210> 117
<211> 29
<212> RNA
<213> Artificial sequence

40

<220>
<223> synthetic

<220>
45   <221> misc_feature
<222> (1)..(29)
<223> L-RNA

<400> 117
50   gccggggguua gggcuagaag ucggccggc   29

<210> 118
<211> 31
<212> RNA
55   <213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(31)
<223> L-RNA

5

<400> 118
ggccgggguu agggcuagaa gucggccggc c   31

<210> 119
10   <211> 31
<212> RNA
<213> Artificial sequence

<220>
15   <223> synthetic

<220>
<221> misc_feature
<222> (1)..(31)
20   <223> L-RNA

<400> 119
cgccgggguu agggcuagaa gucggccggc g   31

25   <210> 120
<211> 10
<212> RNA
<213> Artificial sequence

30   <220>
<223> synthetic

<220>
<221> misc_feature
35   <222> (1)..(10)
<223> L-RNA

<220>
<221> misc_feature
40   <222> (7)..(7)
<223> nucleotide = a, g, c or u

<400> 120
rksbusnvgr   10
45

<210> 121
<211> 10
<212> RNA
<213> Artificial sequence
50

<220>
<223> synthetic

<220>
55   <221> misc_feature
<222> (1)..(10)
<223> L-RNA

<220>
<221> misc_feature
<222> (3)..(3)
<223> n is any nucleotide

5

<220>
<221> misc_feature
<222> (3)..(3)
<223> nucleotide = a, g, c or u

10

<400> 121
yynrcassmy 10

<210> 122
15   <211> 10
<212> RNA
<213> Artificial sequence

<220>
20   <223> synthetic

<220>
<221> misc_feature
<222> (1)..(10)
25   <223> L-RNA

<400> 122
rksbugsvgr 10

30   <210> 123
<211> 10
<212> RNA
<213> Artificial sequence

35   <220>
<223> synthetic

<220>
<221> misc_feature
40   <222> (1)..(10)
<223> L-RNA

<220>
<221> misc_feature
45   <222> (3)..(3)
<223> n is any nucleotide

<220>
<221> misc_feature
50   <222> (3)..(3)
<223> nucleotide = a, g, c or u

<400> 123
ycnrcassmy   10
55

<210> 124
<211> 5
<212> RNA

<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(5)
<223> L-RNA

<220>
<221> S or absent
<222> (1)..(1)
<223>

<220>
<221> misc_feature
<222> (1)..(1)
<223> S or absent

<400> 124
ssssv 5

<210> 125
<211> 5
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(5)
<223> L-RNA

<220>
<221> misc_feature
<222> (5)..(5)
<223> S or absent

<400> 125
bssss   5

<210> 126
<211> 5
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(5)
<223> L-RNA

<400> 126

sggsv   5

<210> 127
<211> 5
<212> RNA
<213> Artificial Sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(5)
<223> L-RNA

<400> 127
ysccs   5

<210> 128
<211> 5
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(5)
<223> L-RNA

<400> 128
gcsgg   5

<210> 129
<211> 5
<212> RNA
<213> Artificial

<220>
<221> misc_feature
<222> (1)..(5)
<223> L-RNA

<400> 129
cckgc 5

<210> 130
<211> 5
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(5)

<223> L-RNA

<400> 130
sssssr 5

<210> 131
<211> 5
<212> RNA
<213> artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(5)
<223> L-RNA

<400> 131
ysbss 5

<210> 132
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(45)
<223> L-RNA

<220>
<221> misc_feature
<222> (1)..(1)
<223> 40 kDa-PEG

<400> 132
gcguggugug aucuagaugu auuggcugau ccuagucagg uacgc   45

<210> 133
<211> 36
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(36)
<223> L-RNA

<220>
<221> misc_feature
<222> (1)..(1)

<223> 40 kDa-PEG

<400> 133
gcgugaaagc aacaugucaa ugaaagguag ccgcgc   36

<210> 134
<211> 29
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(29)
<223> L-RNA

<220>
<221> misc_feature
<222> (1)..(1)
<223> 40 kDa-PEG

<400> 134
cgggagguua gggcuagaag ucgguccg   29

<210> 135
<211> 29
<212> RNA
<213> Artificial

<220>
<221> misc_feature
<222> (1)..(29)
<223> L-RNA

<220>
<221> 40 kDa-PEG
<222> (1)..(1)
<223>

<220>
<221> misc_feature
<222> (1)..(1)
<223> 40 kDa-PEG

<400> 135
gccgggguua gggcuagaag ucggccggc   29

<210> 136
<211> 31
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>

<221> L-RNA
<222> (1)..(31)
<223>

5   <220>
<221> 40 kDa-PEG
<222> (1)..(1)
<223>

10   <220>
<221> misc_feature
<222> (1)..(1)
<223> 40 kDa-PEG

15   <400> 136
cgccggggu agggcuagaa gucggccggc g   31

<210> 137
<211> 38
20   <212> RNA
<213> Artificial sequence

<220>
<223> synthetic
25
<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA
30
<220>
<221> 40 kDa-PEG-
<222> (1)..(1)
<223>
35
<220>
<221> misc_feature
<222> (1)..(1)
<223> 40 kDa-PEG-
40
<400> 137
gcugugaaag caacauguca augaaaggua gccgcagc   38

<210> 138
45   <211> 40
<212> RNA
<213> Artificial sequence

<220>
50   <223> synthetic

<220>
<221> misc_feature
<222> (1)..(40)
55   <223> L-RNA

<400> 138
uaaggaaacu cggucugaug cgguagcgcu gugcagagcu   40

<210> 139
<211> 38
<212> RNA
<213> Artificial

5

<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

10

<220>
<221> misc_feature
<222> (1)..(1)
<223> 30 kDa-PEG

15

<400> 139
gcugugaaag caacauguca augaaaggua gccgcagc   38

<210> 140
<211> 38
20
<212> RNA
<213> Artificial

<220>
25
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

<220>
30
<221> misc_feature
<222> (1)..(1)
<223> 100 kDa-HES

<400> 140
35
gcugugaaag caacauguca augaaaggua gccgcagc   38

<210> 141
<211> 38
<212> RNA
40
<213> Artificial sequence

<220>
<223> synthetic

45
<220>
<221> misc_feature
<222> (1)..(38)
<223> L-RNA

50
<220>
<221> misc_feature
<222> (1)..(1)
<223> 130 kDa-HES

55
<400> 141
gcugugaaag caacauguca augaaaggua gccgcagc   38

<210> 142

<211> 48
<212> RNA
<213> Artificial sequence

5 <220>
<223> synthetic

<220>
<221> misc_feature
10 <222> (1)..(48)
<223> L-RNA

<400> 142
cgugguccgu ugugucaggu cuauucgccc cggugcaggg cauccgcg   48

15 <210> 143
<211> 49
<212> RNA
<213> Artificial sequence

20 <220>
<223> synthetic

<220>
<221> misc_feature
25 <222> (1)..(49)
<223> L-RNA

<400> 143
30 gcagugugac gcggacguga uaggacagag cugaucccgc ucaggugag   49

<210> 144
<211> 49
<212> RNA
35 <213> Artificial sequence

<220>
<223> synthetic

40 <220>
<221> misc_feature
<222> (1)..(99)
<223> L-RNA

45 <400> 144
caacagcagu gugacgcgga cgugauagga cagagcugau cccgcucag   49

<210> 145
<211> 38
50 <212> RNA
<213> Artificial sequence

<220>
<223> synthetic
55
<400> 145
gcugugaaag caacauguca augaaaggua gccgcagc   38

<210> 146
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 146
gcugugaaag uaacauguca augaaaggua accacagc   38

<210> 147
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 147
gcugugaaag uaacacguca augaaaggua accgcagc   38

<210> 148
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 148
gcugugaaag uaacacguca augaaaggua accacagc   38

<210> 149
<211> 38
<212> RNA
<213> artificial sequence

<220>
<223> synthetic

<400> 149
gcuguaaaag uaacauguca augaaaggua acuacagc   38

<210> 150
<211> 38
<212> RNA
<213> artificial sequence

<220>
<223> synthetic

<400> 150
gcuguaaaag uaacaaguca augaaaggua acuacagc   38

<210> 151
<211> 38
<212> RNA

<213> artificial sequence

<220>
<223> synthetic

<400> 151
gcugugaaag uaacaaguca augaaaggua accacagc   38

<210> 152
<211> 38
<212> RNA
<213> artificial sequence

<220>
<223> synthetic

<400> 152
gcagugaaag uaacauguca augaaaggua accacagc   38

<210> 153
<211> 38
<212> RNA
<213> artificial sequence

<220>
<223> synthetic

<400> 153
gcugugaaag uaacauguca augaaaggua accacugc   38

<210> 154
<211> 38
<212> RNA
<213> artificial sequence

<220>
<223> synthetic

<400> 154
gcuaugaaag uaacauguca augaaaggua accauagc   38

<210> 155
<211> 38
<212> RNA
<213> artificial sequence

<220>
<223> synthetic

<400> 155
gcugcgaaag cgacauguca augaaaggua gccgcagc   38

<210> 156
<211> 38
<212> RNA
<213> artificial sequence

<220>

<223> synthetic

<400> 156
gcugugaaag caacauguca augaaaggua gccacagc   38

<210> 157
<211> 38
<212> RNA
<213> artificial sequence

<220>
<223> synthetic

<220>
<221> synthetic
<222> (1)..(38)
<223>

<400> 157
gcugugaaag uaacauguca augaaaggua gccgcagc   38

<210> 158
<211> 39
<212> RNA
<213> artificial sequence

<220>
<223> synthetic

<400> 158
agcgugaaag uaacacguaa aaugaaaggu aaccacgcu   39

<210> 159
<211> 36
<212> RNA
<213> artificial sequence

<220>
<223> synthetic

<400> 159
cugugaaagc aacaugucaa ugaaagguag ccgcag   36

<210> 160
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 160
ugugaaagca acaugucaau gaaagguagc cgca   34

<210> 161
<211> 32
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 161
gugaaagcaa caugucaaug aaagguagcc gc   32

<210> 162
<211> 30
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 162
ugaaagcaac augucaauga aagguagccg   30

<210> 163
<211> 28
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 163
gaaagcaaca ugucaaugaa agguagcc   28

<210> 164
<211> 26
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 164
aaagcaacau gucaaugaaa gguagc   26

<210> 165
<211> 36
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 165
gcgugaaagc aacaugucaa ugaaagguag ccgcgc   36

<210> 166
<211> 36
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 166
gcgcgaaagc aacaugucaa ugaaagguag ccgcgc   36

<210> 167
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 167
gcggaaagca acaugucaau gaaagguagc ccgc   34

<210> 168
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 168
cgugaaagca acaugucaau gaaagguagc cgcg   34

<210> 169
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 169
gcgcaaagca acaugucaau gaaagguagc gugc   34

<210> 170
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 170
gugcaaagca acaugucaau gaaagguagc gcgc   34

<210> 171
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 171
cgcgaaagca acaugucaau gaaagguagc cgug   34

<210> 172
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 172
gggcaaagca acaugucaau gaaaggguagc gccc   34

<210> 173
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 173
ggccaaagca acaugucaau gaaaggguagc ggcc   34

<210> 174
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 174
gcccaaagca acaugucaau gaaaggguagc gggc   34

<210> 175
<211> 34
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 175
ccccaaagca acaugucaau gaaaggguagc gggg   34

<210> 176
<211> 47
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 176
agcguggugu gaucuagaug uaguggcuga uccuagucag guacgcu   47

<210> 177
<211> 47
<212> RNA

<213> Artificial sequence

<220>
<223> synthetic

<400> 177
agcguggugu gaucuagaug uauuggcuga uccuagucag guacgcu   47

<210> 178
<211> 47
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 178
agcguggugu gaucuagaug uaauggcuga uccuagucag gugcgcu   47

<210> 179
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 179
gcgaggugug aucuagaugu aguggcugau ccuagucagg ugcgc   45

<210> 180
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 180
gcguggugug aucuagaugu aguggcugau ccuagucagg ugcgc   45

<210> 181
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 181
gcauggugug aucuagaugu aguggcugau ccuagucagg ugccc   45

<210> 182
<211> 45
<212> RNA
<213> Artificial sequence

<220>

<223> synthetic

<400> 182
gcguggugug aucuagaugu aauggcugau ccuagucagg gacgc   45

<210> 183
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 183
gcguggugug aucuagaugu agaggcugau ccuagucagg uacgc   45

<210> 184
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 184
gcguggugug aucuagaugu aaaggcugau ccuagucagg uacgc   45

<210> 185
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 185
gcguggugug aucuagaugu aguggcuguu ccuagucagg uaugc   45

<210> 186
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 186
gcguggugug aucuagaugu aguggcugau ccuaguuagg uacgc   45

<210> 187
<211> 45
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 187

gcguggugug aucuagaugu aguggcugau ccuagucagg uacgc   45

<210> 188
<211> 43
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 188
cguggguguga ucuagaugua guggcugauc cuagucaggu acg   43

<210> 189
<211> 41
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 189
guggugugau cuagauguag uggcugaucc uagucaggua c   41

<210> 190
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 190
uggugugauc uagauguagu ggcugauccu agucaggua   39

<210> 191
<211> 37
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 191
ggugugaucu agauguagug gcugauccua gucaggu   37

<210> 192
<211> 35
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 192
gugugaucua gauguagugg cugauccuag ucagg   35

<210> 193

<211> 45
<212> RNA
<213> Artificial sequence

5

<220>
<223> synthetic

<400> 193
gcguggugug aucuagaugu auuggcugau ccuagucagg uacgc   45

10

<210> 194
<211> 45
<212> RNA
<213> Artificial sequence

15

<220>
<223> synthetic

<400> 194

20

gcgcggugug aucuagaugu auuggcugau ccuagucagg cgcgc   45

<210> 195
<211> 43
<212> RNA

25

<213> Artificial sequence

<220>
<223> synthetic

30

<400> 195
gcgcguguga ucuagaugua uuggcugauc cuagucaggg cgc   43

<210> 196
<211> 43

35

<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

40

<400> 196
gggcguguga ucuagaugua uuggcugauc cuagucaggg ccc   43

<210> 197

45

<211> 43
<212> RNA
<213> Artificial sequence

<220>

50

<223> synthetic

<400> 197
ggccguguga ucuagaugua uuggcugauc cuagucaggg gcc   43

55

<210> 198
<211> 43
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 198
gcccguguga ucuagaugua uuggcugauc cuagucaggg ggc   43

<210> 199
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 199
gugcugcggg gguuagggcu agaagucggc cugcagcac   39

<210> 200
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 200
agcguggcga gguuagggcu agaagucggu cgacacgcu   39

<210> 201
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 201
guguugcgga gguuagggcu agaagucggu cagcagcac   39

<210> 202
<211> 48
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 202
cgugcgcuug agauaggggu uagggcuuaa agucggcuga uucucacg   48

<210> 203
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 203
agcgugaagg gguuagggcu cgaagucggc ugacacgcu   39

<210> 204
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 204
gugcugcggg gguuagggcu cgaagucggc ccgcagcac   39

<210> 205
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 205
guguucccgg gguuagggcu ugaagucggc cggcagcac   39

<210> 206
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 206
guguugcagg gguuagggcu ugaagucggc cugcagcac   39

<210> 207
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 207
gugcugcggg gguuagggcu caaagucggc cugcagcac   39

<210> 208
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 208
gugcugccgg gguuagggcu aaagucggcc gacagcac   38

<210> 209
<211> 39
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 209
gugcuguggg ggucagggcu agaagucggc cugcagcac   39

<210> 210
<211> 38
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 210
ugagauaggg guuagggcuu aaagucggcu gauucuca   38

<210> 211
<211> 36
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 211
gagauagggg uuagggcuua aagucggcug auucuc   36

<210> 212
<211> 29
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 212
gggguuaggg cuuaaagucg gcugauucu   29

<210> 213
<211> 37
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 213
gcguggcgag guuagggcua gaagucgguc gacacgc   37

<210> 214
<211> 35
<212> RNA

<213> Artificial sequence

<220>
<223> synthetic

<400> 214
cguggcgagg uuagggcuag aagucggucg acacg   35

<210> 215
<211> 33
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 215
cgggcgaggu uagggcuaga agucggucga ccg   33

<210> 216
<211> 33
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 216
cgggcgaggu uagggcuaga agucggucgc ccg   33

<210> 217
<211> 31
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 217
cggcgagguu agggcuagaa gucggucgcc g   31

<210> 218
<211> 29
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 218
cgggagguua gggcuagaag ucggucccg   29

<210> 219
<211> 27
<212> RNA
<213> Artificial sequence

<220>

<223> synthetic

<400> 219
gggaggguuag ggcuagaagu cgguccc 27

<210> 220
<211> 27
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 220
ccgcgguuag ggcuagaagu cgggcgg   27

<210> 221
<211> 27
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 221
cccggguuag ggcuagaagu cggcggg 27

<210> 222
<211> 27
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 222
ggcggguuag ggcuagaagu cggcgcc   27

<210> 223
<211> 29
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 223
cccgcgguua gggcuagaag ucgggcggg   29

<210> 224
<211> 29
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 224

gccgcgguua gggcuagaag ucgggcggc   29

<210> 225
<211> 29
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 225
ccccgdgguua gggcuagaag ucggcgggg   29

<210> 226
<211> 29
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 226
cggcgdgguua gggcuagaag ucggcgccg   29

<210> 227
<211> 29
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 227
gggcgdgguua gggcuagaag ucggcgccc   29

<210> 228
<211> 37
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 228
ugcugcgggg guuagggcua gaagucggcc ugcagca   37

<210> 229
<211> 35
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 229
gcugcggggg uuagggcuag aagucggccu gcagc   35

<210> 230

EP 2 041 282 B1

<211> 33
<212> RNA
<213> Artificial sequence

5   <220>
<223> synthetic

<400> 230
cugcgggggu uagggcuaga agucggccug cag   33
10

<210> 231
<211> 31
<212> RNA
<213> Artificial sequence
15

<220>
<223> synthetic

<400> 231
20   ugcggggguu agggcuagaa gucggccugc a   31

<210> 232
<211> 29
<212> RNA
25   <213> Artificial sequence

<220>
<223> synthetic

30   <400> 232
gcggggguua gggcuagaag ucggccugc   29

<210> 233
<211> 29
35   <212> RNA
<213> Artificial sequence

<220>
<223> synthetic
40

<400> 233
gccgggguua gggcuagaag ucggccggc   29

<210> 234
45   <211> 31
<212> RNA
<213> Artificial sequence

<220>
50   <223> synthetic

<400> 234
ggccgggguu agggcuagaa gucggccggc c   31

55   <210> 235
<211> 31
<212> RNA
<213> Artificial sequence

120

<220>
<223> synthetic

<400> 235
cgccgggguu agggcuagaa gucggccggc g   31

<210> 236
<211> 48
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 236
cgugguccgu ugugucaggu cuauucgccc cggugcaggg cauccgcg   48

<210> 237
<211> 49
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 237
gcagugugac gcggacguga uaggacagag cugaucccgc ucaggugag   49

<210> 238
<211> 49
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<400> 238
caacagcagu gugacgcgga cgugauagga cagagcugau cccgcucag   49

<210> 239
<211> 40
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(40)
<223> L-RNA

<220>
<221> misc_feature
<222> (1)..(1)
<223> pegylated

<400> 239

uaaggaaacu cggucugaug cgguagcgcu gugcagagcu   40

<210> 240
<211> 13
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(13)
<223> L-RNA

<220>
<221> misc_feature
<222> (3)..(3)
<223> u represents a t

<220>
<221> misc_feature
<222> (13)..(13)
<223> attached to -(C18-PEG-spacer)-(C18-PEG-spacer)-1-NH2

<400> 240
gaucacacca cgc   13

<210> 241
<211> 11
<212> RNA
<213> Artificial sequence

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (1)..(11)
<223> L-RNA

<220>
<221> misc_feature
<222> (1)..(1)
<223> attached to 5'-NH2-(C18-PEG-spacer)-(C18-PEG-spacer)-

<400> 241
gcguaccuga c   11

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 02101350 A **[0032]**
- EP 1306382 A **[0126] [0235]**
- DE 12004006249 **[0127]**
- WO 2005074993 A **[0128] [0129]**
- EP 0211950 W **[0128] [0129] [0130]**
- US 6011020 A **[0159]**
- DE 10112825 A1 **[0239]**
- WO 02080979 A2 **[0239]**

Non-patent literature cited in the description

- **AIUTI, A. ; I. J. WEBB et al.** The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. *J Exp Med,* 1997, vol. 185 (1), 111-20 **[0282]**
- **ALTSCHUL SF ; GISH W ; MILLER W ; MYERS EW ; LIPMAN DJ.** Basic local alignment search tool. *J Mol Biol.,* 1990, vol. 215 (3), 403-10 **[0282]**
- **ALTSCHUL SF ; MADDEN TL ; SCHAFFER AA ; ZHANG J ; ZHANG Z ; MILLER W ; LIPMAN DJ.** Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.,* 1997, vol. 25 (17), 3389-402 **[0282]**
- **AMBATI, J. ; A. ANAND et al.** An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. *Nat Med.,* 2003, vol. 9, 1390-7 **[0282]**
- **ARYA, S. K. ; C. C. GINSBERG et al.** In vitro phenotype of SDF1 gene mutant that delays the onset of human immunodeficiency virus disease in vivo. *J Hum Virol,* 1999, vol. 2 (3), 133-8 **[0282]**
- **AUERBACH et al.** Angiogenesis assays: a critical overview. *Clin.Chem.,* 2003, vol. 49, 32-40 **[0282]**
- **BAGGIOLINI, M.** Chemokines and leukocyte traffic. *Nature,* 1998, vol. 392 (6676), 565-8 **[0282]**
- **BAGGIOLINI, M. ; B. DEWALD et al.** Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. *Adv Immunol,* 1994, vol. 55, 97-179 **[0282]**
- **BALABANIAN, K. ; B. LAGANE et al.** WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. *Blood,* 2005, vol. 105 (6), 2449-57 **[0282]**
- **BALABANIAN, K. ; J. COUDERC et al.** Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. *J Immunol,* 2003, vol. 170 (6), 3392-400 **[0282]**
- **BALKWILL, F.** Cancer and the chemokine network. *Nat Rev Cancer,* 2004, vol. 4 (7), 540-50 **[0282]**
- **BAZAN, J. F. ; K. B. BACON et al.** A new class of membrane-bound chemokine with a CX3C motif. *Nature,* 1997, vol. 385 (6617), 640-4 **[0282]**
- **BERTOLINI, F. ; C. DELL'AGNOLA et al.** CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. *Cancer Res,* 2002, vol. 62 (11), 3106-12 **[0282]**
- **BLEUL, C. C. ; J. L. SCHULTZE et al.** B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement. *J Exp Med,* 1998, vol. 187 (5), 753-62 **[0282]**
- **BLEUL, C. C. ; M. FARZAN et al.** The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature,* 1996, vol. 382 (6594), 829-33 **[0282]**
- **BROOKS, H. L., JR. ; S. CABALLERO, JR. et al.** Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. *Arch Ophthalmol,* 2004, vol. 122 (12), 1801-7 **[0282]**
- **BUCKLEY, C. D. ; N. AMFT et al.** Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. *J Immunol,* 2000, vol. 165 (6), 3423-9 **[0282]**
- **BURGER, J. A. ; N. TSUKADA et al.** Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. *Blood,* 2000, vol. 96 (8), 2655-63 **[0282]**
- **BUTLER, J. M. ; S. M. GUTHRIE et al.** SDF-1 is both necessary and sufficient to promote proliferative retinopathy. *J Clin Invest,* 2005, vol. 115 (1), 86-93 **[0282]**
- **CABIOGLU, N. ; A. SAHIN et al.** Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. *Clin Exp Metastasis,* 2005, vol. 22 (1), 39-46 **[0282]**

• **CORCIONE, A. ; L. OTTONELLO et al.** Stromal cell-derived factor-1 as a chemoattractant for follicular center lymphoma B cells. *J Natl Cancer Inst,* 2000, vol. 92 (8), 628-35 **[0282]**

• **CRUMP, M. P ; J. H. GONG et al.** Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. *Embo J,* 1997, vol. 16 (23), 6996-7007 **[0282]**

• **D'APUZZO, M. ; A. ROLINK et al.** The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. *Eur J Immunol,* 1997, vol. 27 (7), 1788-93 **[0282]**

• **DE KLERCK, B. ; L. GEBOES et al.** Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. *Arthritis Res Ther,* 2005, vol. 7 (6), R1208-20 **[0282]**

• **DROLET DW ; NELSON J ; TUCKER CE ; ZACK PM ; NIXON K ; BOLIN R ; JUDKINS MB ; FARMER JA ; WOLF JL ; GILL SC.** Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. *Pharm. Res.,* 2000, vol. 17, 1503 **[0282]**

• **EATON, B. E. ; L. GOLD et al.** Post-SELEX combinatorial optimization of aptamers. *Bioorg Med Chem,* 1997, vol. 5 (6), 1087-96 **[0282]**

• **FEDYK, E. R. ; D. JONES et al.** Expression of stromal-derived factor-1 is decreased by IL-1 and TNF and in dermal wound healing. *J Immunol,* 2001, vol. 166 (9), 5749-54 **[0282]**

• **FONG, D. S. ; L. P. AIELLO et al.** Diabetic retinopathy. *Diabetes Care,* 2004, vol. 27 (10), 2540-53 **[0282]**

• **GEMINDER, H. ; O. SAGI-ASSIF et al.** A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. *J Immunol,* 2001, vol. 167 (8), 4747-57 **[0282]**

• **GODESSART, N.** Chemokine receptors: attractive targets for drug discovery. *Ann N Y Acad Sci,* 2005, vol. 1051, 647-57 **[0282]**

• **GRASSI, F. ; S. CRISTINO et al.** CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. *J Cell Physiol,* 2004, vol. 199 (2), 244-51 **[0282]**

• **GRUNEWALD, M. ; I. AVRAHAM et al.** VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. *Cell,* 2006, vol. 124 (1), 175-89 **[0282]**

• **GULENG, B. ; K. TATEISHI et al.** Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. *Cancer Res,* 2005, vol. 65 (13), 5864-71 **[0282]**

• **GULINO, A. V. ; D. MORATTO et al.** Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. *Blood,* 2004, vol. 104 (2), 444-52 **[0282]**

• **HARTMANN, T. N. ; M. BURGER et al.** The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer. *J Biol Regul Homeost Agents,* 2004, vol. 18 (2), 126-30 **[0282]**

• **HWANG, J. H. ; H. K. CHUNG et al.** CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. *J Clin Endocrinol Metab,* 2003, vol. 88 (1), 408-16 **[0282]**

• **JIANG, W. ; P. ZHOU et al.** Molecular cloning of TPAR1, a gene whose expression is repressed by the tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA). *Exp Cell Res,* 1994, vol. 215 (2), 284-93 **[0282]**

• **JOSE, P. J. ; D. A. GRIFFITHS-JOHNSON et al.** Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. *J Exp Med,* 1994, vol. 179 (3), 881-7 **[0282]**

• **JUAREZ, J. ; L. BENDALL.** SDF-1 and CXCR4 in normal and malignant hematopoiesis. *Histol Histopathol,* 2004, vol. 19 (1), 299-309 **[0282]**

• **KANBE, K. ; K. TAKAGISHI et al.** Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4. *Arthritis Rheum,* 2002, vol. 46 (1), 130-7 **[0282]**

• **KANG, H. ; G. WATKINS et al.** Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. *Breast Cancer Res,* 2005, vol. 7 (4), R402-10 **[0282]**

• **KAWAI, T. ; U. CHOI et al.** Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome. *Exp Hematol,* 2005, vol. 33 (4), 460-8 **[0282]**

• **KOSHIBA, T. ; R. HOSOTANI et al.** Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. *Clin Cancer Res,* 2000, vol. 6 (9), 3530-5 **[0282]**

• **KRUMBHOLZ, M. ; D. THEIL et al.** Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. *Brain,* 2006, vol. 129, 200-211 **[0282]**

• **KRYCZEK, I. ; A. LANGE et al.** CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. *Cancer Res,* 2005, vol. 65 (2), 465-72 **[0282]**

• **KUCIA, M. ; R. RECA et al.** Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. *Stem Cells,* 2005, vol. 23 (7), 879-94 **[0282]**

- KUSSER, W. Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution. *J Biotechnol,* 2000, vol. 74 (1), 27-38 **[0282]**
- LAPTEVA, N. ; A. G. YANG et al. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. *Cancer Gene Ther,* 2005, vol. 12 (1), 84-9 **[0282]**
- Methods in Molecular Biology. **M.J. DAMHA ; K.K. OGILVIE.** Protocols for oligonucleotides and analogs. Humana Press Inc, 1993, vol. 20, 81-114 **[0282]**
- MA, Q. ; D. JONES et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. *Proc Natl Acad Sci U S A,* 1998, vol. 95 (16), 9448-53 **[0282]**
- MARECHAL, V. ; F. ARENZANA-SEISDEDOS et al. Opposite effects of SDF-1 on human immunodeficiency virus type 1 replication. *J Virol,* 1999, vol. 73 (5), 3608-15 **[0282]**
- MATTHYS, P. ; S. HATSE et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. *J Immunol,* 2001, vol. 167 (8), 4686-92 **[0282]**
- MCGINNIS S ; MADDEN TL. BLAST: at the core of a powerful and diverse set of sequence analysis tools. *Nucleic Acids Res.,* 2004, vol. 32, 20-5 **[0282]**
- MELETH, A. D. ; E. AGRON et al. Serum inflammatory markers in diabetic retinopathy. *Invest Ophthalmol Vis Sci,* 2005, vol. 46 (11), 4295-301 **[0282]**
- MENU, E. ; K. ASOSINGH et al. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. *Haematologica,* 2006 **[0282]**
- MILLER, M. D. ; M. S. KRANGEL. Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. *Crit Rev Immunol,* 1992, vol. 12 (1-2), 17-46 **[0282]**
- MOSER, B. ; M. WOLF et al. Chemokines: multiple levels of leukocyte migration control. *Trends Immunol,* 2004, vol. 25 (2), 75-84 **[0282]**
- MULLER, A. ; B. HOMEY et al. Involvement of chemokine receptors in breast cancer metastasis. *Nature,* 2001, vol. 410 (6824), 50-6 **[0282]**
- MURDOCH, C. CXCR4: chemokine receptor extraordinaire. *Immunol Rev,* 2000, vol. 177, 175-84 **[0282]**
- MURPHY, P. M. ; M. BAGGIOLINI et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacol Rev,* 2000, vol. 52 (1), 145-76 **[0282]**
- NAGASAWA, T. ; H. KIKUTANI et al. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. *Proc Natl Acad Sci U S A,* 1994, vol. 91 (6), 2305-9 **[0282]**
- NAGASAWA, T. ; S. HIROTA et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature,* 1996, vol. 382 (6592), 635-8 **[0282]**

- NEEDLEMAN ; WUNSCH. A general method applicable to the search for similarities in the amino acid sequence of two proteins. *J Mol Biol.,* 1970, vol. 48 (3), 443-53 **[0282]**
- OPPENHEIM, J. J. ; C. O. ZACHARIAE et al. Properties of the novel proinflammatory supergene "intercrine" cytokine family. *Annu Rev Immunol,* 1991, vol. 9, 617-48 **[0282]**
- ORIMO, A. ; P. B. GUPTA et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell,* 2005, vol. 121 (3), 335-48 **[0282]**
- PEARSON ; LIPMAN. Improved tools for biological sequence comparison. *Proc. Nat'l. Acad. Sci. USA,* 1988, vol. 85, 2444 **[0282]**
- PERISSINOTTO, E. ; G. CAVALLONI et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. *Clin Cancer Res,* 2005, vol. 11 (2), 490-7 **[0282]**
- PHILLIPS, R. J. ; M. D. BURDICK et al. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. *Am J Respir Crit Care Med,* 2003, vol. 167 (12), 1676-86 **[0282]**
- PONATH, P. D. ; S. QIN et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. *J Clin Invest,* 1996, vol. 97 (3), 604-12 **[0282]**
- RUBIN, J. B. ; A. L. KUNG et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. *Proc Natl Acad Sci USA,* 2003, vol. 100 (23), 13513-8 **[0282]**
- SALCEDO et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells. In vivo neovascularization induced by stromal-derived factor-1a. *Am.J.Pathol.,* 1999, vol. 154, 1125-1135 **[0282]**
- SALCEDO, R. ; J. J. OPPENHEIM. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. *Microcirculation,* 2003, vol. 10 (3-4), 359-70 **[0282]**
- SALCEDO, R. ; K. WASSERMAN et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. *Am J Pathol,* 1999, vol. 154 (4), 1125-35 **[0282]**
- SALVUCCI, O. ; L. YAO et al. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. *Blood,* 2002, vol. 99 (8), 2703-11 **[0282]**
- SAUR, D. ; B. SEIDLER et al. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. *Gastroenterology,* 2005, vol. 129 (4), 1237-50 **[0282]**

• SCHALL, T. J. ; K. B. BACON. Chemokines, leukocyte trafficking, and inflammation. *Curr Opin Immunol*, 1994, vol. 6 (6), 865-73 **[0282]**

• SCOTTON, C. J. ; J. L. WILSON et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. *Cancer Res*, 2002, vol. 62 (20), 5930-8 **[0282]**

• SENGUPTA, N. ; S. CABALLERO et al. Preventing stem cell incorporation into choroidal neovascularization by targeting homing and attachment factors. *Invest Ophthalmol Vis Sci*, 2005, vol. 46 (1), 343-8 **[0282]**

• SHIROZU, M. ; T. NAKANO et al. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. *Genomics*, 1995, vol. 28 (3), 495-500 **[0282]**

• SMITH ; WATERMAN. *Adv. Appl. Math.*, 1981, vol. 2, 482 **[0282]**

• SORIANO, A. ; C. MARTINEZ et al. Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. *J Infect Dis*, 2002, vol. 186 (7), 922-31 **[0282]**

• SPRINGER, T. A. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. *Annu Rev Physiol*, 1995, vol. 57, 827-72 **[0282]**

• SUN, Y. X. ; A. SCHNEIDER et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. *J Bone Miner Res*, 2005, vol. 20 (2), 318-29 **[0282]**

• TAKENAGA, M. ; H. TAMAMURA et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. *Biochem Biophys Res Commun*, 2004, vol. 320 (1), 226-32 **[0282]**

• TAMAMURA, H. ; M. FUJISAWA et al. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. *FEBS Lett*, 2004, vol. 569 (1-3), 99-104 **[0282]**

• TASHIRO, K. ; H. TADA et al. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. *Science*, 1993, vol. 261 (5121), 600-3 **[0282]**

• VENKATESAN, N. ; S. J. KIM et al. Novel phosphoramidite building blocks in synthesis and applications toward modified oligonucleotides. *Curr Med Chem*, 2003, vol. 10 (19), 1973-91 **[0282]**

• WANG, J. ; E. GUAN et al. Role of tyrosine phosphorylation in ligand-independent sequestration of CXCR4 in human primary monocytes-macrophages. *J Biol Chem*, 2001, vol. 276 (52), 49236-43 **[0282]**

• WANG, N. ; Q. L. WU et al. Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma: pattern of expression and correlation with clinical outcome. *J Transl Med*, 2005, vol. 3, 26 **[0282]**

• WINCOTT F ; DIRENZO A ; SHAFFER C ; GRIMM S ; TRACZ D ; WORKMAN C ; SWEEDLER D ; GONZALEZ C ; SCARINGE S ; USMAN N. Synthesis, deprotection, analysis and purification of RNA and ribozymes. *Nucleic Acids Res.*, 1995, vol. 23 (14), 2677-84 **[0282]**

• YAMAGUCHI, J. ; K. F. KUSANO et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. *Circulation*, 2003, vol. 107 (9), 1322-8 **[0282]**

• YASUMOTO, K. ; K. KOIZUMI et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. *Cancer Res*, 2006, vol. 66 (4), 2181-7 **[0282]**

• ZEELENBERG, I. S. ; L. RUULS-VAN STALLE et al. Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a T cell hybridoma. *J Clin Invest*, 2001, vol. 108 (2), 269-77 **[0282]**

• ZEELENBERG, I. S. ; L. RUULS-VAN STALLE et al. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. *Cancer Res*, 2003, vol. 63 (13), 3833-9 **[0282]**

• ZHOU, Y. ; P. H. LARSEN et al. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. *J Biol Chem*, 2002, vol. 277 (51), 49481-7 **[0282]**

• ZOU, Y. R. ; A. H. KOTTMANN et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. *Nature*, 1998, vol. 393 (6685), 595-9 **[0282]**

PATENTKRAV

1. Nukleinsyremolekyle, som binder til SDF-1, omfattende i 5'->3' retningen en første strækning af nukleotider, en kernenukleotidsekvens og en anden strækning af nukleo-

5   tider, eller en anden strækning af nukleotider, en kernenukleotidsekvens og en første strækning af nukleotider,

hvor længden af nukleinsyremolekylet er 20 til 50 nukleotider,

hvor nukleinsyremolekylet er valgt fra gruppen bestående af type A nukleinsyremolekyler, type B nukleinsyremolekyler, type C nukleinsyremolekyler og nukleinsyremole-

10   kyler med en nukleinsyresekvens i overensstemmelse med enhver af SEQ.ID.No. 142, SEQ.ID.No. 143 og SEQ.ID.No. 144;

hvor type A nukleinsyremolekylerne omfatter følgende kernenukleotidsekvens:

    5' AAAGYRACAHGUMAAX$_A$UGAAAGGUARC 3' (SEQ.ID. 19)

15

hvor X$_A$ er enten fraværende eller er A, og

hvor den første strækning af nukleotider af type A nukleinsyremolekylerne omfatter en nukleotidsekvens af 5' X$_1$X$_2$NNBV 3' (SEQ.ID.No. 44) og den anden strækning af nukleotider af type A nukleinsyremolekylerne omfatter en nukleotidsekvens af 5'

20   BNBNX$_3$X$_4$ 3' (SEQ.ID.No. 45),

hvor X$_1$ er enten fraværende eller R, X$_2$ er S, X$_3$ er S og X$_4$ er enten fraværende eller Y,

eller

X$_1$ er fraværende, X$_2$ er enten fraværende eller S, X$_3$ er enten fraværende eller S og X$_4$

25   er fraværende;

hvor type B nukleinsyremolekylerne omfatter følgende kernenukleotidsekvens:

    5' GUGUGAUCUAGAUGUADWGGCUGWUCCUAGUYAGG 3'
    (SEQ.ID.No. 57), og

30

hvor den første strækning af nukleotider af type B nukleinsyremolekylerne omfatter en nukleotidsekvens af 5' X$_1$X$_2$SVNS 3' (SEQ.ID.No. 77) og den anden strækning af nukleotider af type B nukleinsyremolekylerne omfatter en nukleotidsekvens af 5' BVBSX$_3$X$_4$ 3' (SEQ.ID.No. 78), hvor

35   X$_1$ er enten fraværende eller er A, X$_2$ er G, X$_3$ er C og X$_4$ er enten fraværende eller er U,

eller

X_1 er fraværende, X_2 er enten fraværende eller er G, X_3 er enten fraværende eller er C

og X_4 er fraværende;

hvor type C nukleinsyremolekylerne omfatter en kernenukleotidsekvens af

5

GGUYAGGGCUHRX$_A$AGUCGG (SEQ.ID.No.90),

hvor X_A er enten fraværende eller er A, og

hvor den første strækning af nukleotider i type C nukleinsyremolekylerne omfatter en

10   nukleotidsekvens af 5' RKSBUSNVGR 3' (SEQ.ID.No. 120) og den anden strækning

af nukleotider af type C nukleinsyremolekylerne omfatter en nukleotidsekvens af

5' YYNRCASSMY 3' (SEQ.ID.No. 121),

eller

hvor den første strækning af nukleotider af type C nukleinsyremolekylerne omfatter en

15   nukleotidsekvens af 5' XsSSSV 3' (SEQ.ID.No. 124) og den anden strækning af

nukleotider af type C nukleinsyremolekylerne omfatter en nukleotidsekvens af

5' BSSSXs 3' (SEQ.ID.No. 125), hvor X_s er enten fraværende eller er S,

eller

hvor den første strækning af nukleotider af type C nukleinsyremolekylerne omfatter en

20   nukleotidsekvens af 5' UGAGAUAGG 3' og den anden strækning af nukleotider af type

C nukleinsyremolekylerne omfatter a nukleotidsekvens af 5' CUGAUUCUCA 3',

eller

hvor den første strækning af nukleotider af type C nukleinsyremolekylerne omfatter en

nukleotidsekvens af 5' GAGAUAGG 3' og den anden strækning af nukleotider af type

25   C nukleinsyremolekylerne omfatter en nukleotidsekvens af 5' CUGAUUCUC 3'.

2. Nukleinsyremolekyle ifølge krav 1, hvor type A nukleinsyremolekylerne omfatter en

kernenukleotidsekvens valgt fra gruppen omfattende

30   5' AAAGYRACAHGUMAAUGAAAGGUARC 3' (SEQ.ID.No. 20),

5' AAAGYRACAHGUMAAAUGAAAGGUARC 3' (SEQ.ID.No. 21), og

5' AAAGYAACAHGUCAAUGAAAGGUARC 3' (SEQ.ID.No. 22),

fortrinsvis omfatter kernenukleotidsekvensen

5' AAAGYAACAHGUCAAUGAAAGGUARC 3' (SEQ. ID. No. 22).

35

2

3. Nukleinsyremolekyle ifølge ethvert af kravene 1 til 2, hvor den første og anden strækning af nukleotider af type A nukleinsyremolekylerne eventuelt hybridiserer med hinanden, hvorved der efter hybridisering er dannet en dobbelt-strenget struktur.

5   4. Nukleinsyremolekyle ifølge krav 3, hvor den dobbelt-strengede struktur består af fire til seks basepar, fortrinsvis fem basepar.

5. Nukleinsyremolekyle ifølge ethvert af kravene 1 til 4, hvor den første strækning af nukleotider af type A nukleinsyremolekylerne omfatter en nukleotidsekvens af

10   5' X_2BBBS 3' (SEQ.ID.No. 42) og den anden strækning af nukleotider af type A nukleinsyremolekylerne omfatter en nukleotidsekvens af 5' SBBVX_3 3' (SEQ.ID.No. 43),
hvor X_2 er enten fraværende eller er S og X_3 er enten fraværende eller er S;
fortrinsvis omfatter den første strækning af nukleotider af type A nukleinsyremole-

15   kylerne en nukleotidsekvens af 5' CUGUG 3' og den anden strækning af nukleotider af type A nukleinsyremolekylerne omfatter en nukleotidsekvens af 5' CGCAG 3';
eller den første strækning af nukleotider af type A nukleinsyremolekylerne omfatter en nukleotidsekvens af 5' GCGUG 3' og den anden strækning af nukleotider af type A nukleinsyremolekylerne omfatter en nukleotidsekvens af 5' CGCGC 3'.

20

6. Nukleinsyremolekyle ifølge ethvert af kravene 1 til 5, hvor type A nukleinsyremole-kylet har en nukleinsyresekvens i overensstemmelse med enhver af SEQ.ID.No. 5 til 18, 25 til 41, 133, 137 og 139 til 141.

25   7. Nukleinsyremolekyle ifølge krav 1, hvor type B nukleinsyremolekylerne omfatter en kernenukleotidsekvens af GUGUGAUCUAGAUGUADUGGCUGAUCCUAGUCAGG (SEQ.ID.No. 58).

8. Nukleinsyremolekyle ifølge ethvert af kravene 1 og 7, hvor den første og anden

30   strækning af nukleotider af type B nukleinsyremolekylerne eventuelt hybridiserer med hinanden, hvorved der efter hybridisering er dannet en dobbeltstrenget kultur.

9. Nukleinsyremolekyle ifølge krav 8, hvor den dobbelt-strengede struktur består af fire til seks basepar, fortrinsvis fem basepar.

35

10. Nukleinsyremolekyle ifølge ethvert af kravene 1 og 7 til 9, hvor den første stræk-
ning af nukleotider i type B nukleinsyremolekylerne omfatter en nukleotidsekvens af 5'
X$_2$SSBS 3' (SEQ.ID.No. 73) og den anden strækning af nukleotider af type B nuklein-
syremolekylerne omfatter en nukleotidsekvens af 5' BVSSX$_3$ 3' (SEQ.ID.No. 74),

5   hvor X$_2$ er enten fraværende eller G, og X$_3$ er enten fraværende eller C,
fortrinsvis omfatter den første strækning af nukleotider af type B nukleinsyremole-
kylerne en nukleotidsekvens af 5' GCGUG 3' og den anden strækning af nukleotider af
type B nukleinsyremolekylerne omfatter en nukleotidsekvens af 5' UACGC 3'.

10   **11.** Nukleinsyremolekyle ifølge ethvert af kravene 1 og 7 til 10, hvor type B nuklein-
syremolekylet har en nukleinsyresekvens i overensstemmelse med enhver af
SEQ.ID.Nos. 46 til 56, 61 til 72 og 132.

12. Nukleinsyremolekyle ifølge krav 1, hvor type C nukleinsyremolekylerne omfatter en
15   kernenukleotidsekvens valgt fra gruppen omfattende

5' GGUYAGGGCUHRAAGUCGG 3' (SEQ.ID.No. 91),
5' GGUYAGGGCUHRAGUCGG 3' (SEQ.ID.No. 92), og
5' GGUUAGGGCUHGAAGUCGG 3' (SEQ.ID.No. 93),
20   fortrinsvis omfatter kernenukleotidsekvensen
5' GGUUAGGGCUHGAAGUCGG 3' (SEQ. ID. No. 93).

13. Nukleinsyremolekyle ifølge ethvert af kravene 1 og 12, hvor i det mindste en del af
den første strækning og i det mindste en del af den anden strækning af nukleotider af
25   type C nukleinsyremolekylerne eventuelt hybridiserer med hinanden, hvorved der efter
hybridisering er dannet en dobbeltstrenget struktur.

14. Nukleinsyremolekyle ifølge krav 13, hvor den dobbelt-strengede struktur omfatter 4
til 10 basepar, fortrinsvis 4 til 6 basepar, mere foretrukket 5 basepar.
30
15. Nukleinsyremolekyle ifølge ethvert af kravene 1 og 12 til 14, hvor den første
strækning af nukleotider af type C nukleinsyremolekylerne omfatter en nukleotid-
sekvens af 5' RKSBUGSVGR 3' (SEQ.ID.No. 122) og den anden strækning af
nukleotider af type C nukleinsyremolekylerne omfatter en nukleotidsekvens af
35   5' YCNRCASSMY 3' (SEQ.ID.No. 123).

16. Nukleinsyremolekyle ifølge ethvert af kravene 1 og 12 til 14, hvor den første strækning af nukleotider i type C nukleinsyremolekylerne omfatter en nukleotidsekvens af 5' SSSSR 3' (SEQ.ID.No. 130) og den anden strækning af nukleotider af type C nukleinsyremolekylerne omfatter en nukleotidsekvens af 5' YSBSS 3' (SEQ.ID.No.

5   131).

17. Nukleinsyremolekyle ifølge ethvert af kravene 1 og 12 til 16, hvor type C nuklein-syremolekylet har en nukleinsyresekvens i overensstemmelse med enhver af SEQ.ID.No'. 79 til 89, 94 til 119 og 134 til 136.

10

18. Nukleinsyremolekyle ifølge krav 1, hvor nukleinsyremolekylet har en nukleinsyre-sekvens i overensstemmelse med enhver af SEQ.ID.Nos. 142 til 144.

19. Nukleinsyremolekyle ifølge ethvert af kravene 1 til 18, hvor nukleinsyremolekylet er

15   en antagonist for SDF-1.

20. Nukleinsyremolekyle ifølge ethvert af kravene 1 til 19, hvor nukleinsyremolekylet er en antagonist for SDF-1 receptorsystemet, hvor fortrinsvis SDF-1 receptoren for SDF-1 receptorsystemet er CXCR4 receptoren.

20

21. Nukleinsyremolekyle ifølge ethvert af kravene 1 til 20, hvor SDF-1 er en human SDF-1, hvor fortrinsvis SDF-1 omfatter en aminosyresekvens i overensstemmelse med SEQ ID No. 1.

25   22. Nukleinsyremolekyle ifølge ethvert af kravene 1 til 21, hvor nukleinsyremolekylet omfatter en modifikation, fortrinsvis er modifikationen valgt fra gruppen omfattende en HES gruppe og en PEG gruppe.

23. Nukleinsyremolekyle ifølge ethvert af kravene 1 til 22, hvor nukleotiderne i nuklein-

30   syremolekylet er L-nukleotider, fortrinsvis nukleotiderne af sekvenserne i overensstem-melse med enhver af SEQ.ID.No. 19, 20, 21, 22, 57, 58, 90, 91, 92 og 93.

24. Nukleinsyremolekyle ifølge ethvert af kravene 1 til 23 til anvendelse ved en frem-gangsmåde til behandling af en sygdom.

35

25. Farmaceutisk sammensætning omfattende et nukleinsyremolekyle ifølge ethvert af kravene 1 til 24 og eventuelt en yderligere bestanddel, hvor den yderligere bestanddel er valgt fra gruppen omfattende farmaceutisk acceptable excipienser og farmaceutisk aktive agenser.

5

26. Anvendelse af et nukleinsyremolekyle ifølge ethvert af kravene 1 til 24 til frem- stillingen af et lægemiddel.

27. Nukleinsyremolekyle til anvendelse ifølge krav 24, hvor sygdommen er medieret af

10   SDF-1, fortrinsvis er en sådan sygdom eller lidelse valgt fra gruppen omfattende bagsiden-af-øjesygdomme som diabetisk retinopati og alders-relateret makular- degeneration; brystcancer, ovariecancer, prostatacancer, pankreascancer, thyroidcancer, nasopharynxcancer, koloncancer, lungecancer og mavecancer; osteosarcoma; melanoma; glioma; medullo- og neuroblastoma; leukæmi; WHIM

15   syndrom; immunologiske defektsyndromer; pathologisk neovaskularisation; inflammation; multipel sclerose; rheumatoid arthritis / osteoarthritis og nephritis.

28. Nukleinsyremolekyle ifølge ethvert af kravene 1 til 23, hvor nukleinsyremolekylet er til anvendelse ved hæmning af angiogenese, neovaskularisation, inflammation og

20   metastase.

29. Anvendelse af et nukleinsyremolekyle ifølge ethvert af kravene 1 til 24 til frem- stillingen af et diagnostisk middel.

25   30. Anvendelse ifølge krav 29, hvor det diagnostiske middel er til diagnose af en sygdom, hvor sygdommen er medieret af SDF-1, fortrinsvis er en sådan sygdom valgt fra gruppen omfattende bagsiden-af-øjesygdomme som diabetisk retinopati og alders- relateret makulardegeneration; brystcancer, ovariecancer, prostatacancer, pankreascancer, thyroidcancer, nasopharynxcancer, koloncancer, lungecancer og

30   mavecancer; osteosarcoma; melanoma; glioma; medullo- og neuroblastoma; leukæmi; WHIM syndrom; immunologiske defektsyndromer; pathologisk neovaskularisation; inflammation; multipel sclerose; rheumatoid arthritis / osteoarthritis og nephritis.

31. Anvendelse ifølge krav 29, hvor det diagnostiske middel er til diagnose af angio-

35   genese, neovaskularisation, inflammation og/eller metastase.

32. Kompleks omfattende SDF-1 og et nukleinsyremolekyle ifølge ethvert af kravene 1 til 24, hvor komplekset fortrinsvis er et krystallinsk kompleks.

33. Anvendelse af et nukleinsyremolekyle ifølge ethvert af kravene 1 til 24 til detektion

5   af SDF-1.

34. Sæt til detektion af SDF-1, omfattende et nukleinsyremolekyle ifølge ethvert af kravene 1 til 24.

10